RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Patent application
Compounds targeting ROCK activity are developed to treat neurodegenerative diseases by inhibiting ROCK, offering therapeutic benefits across various neurological conditions.
Patent Information
- Application Number
- JP2021577261
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-28
- Filing Date
- 2020-06-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-06-26
AI Technical Summary
There is an unmet need for new drugs to treat neurodegenerative diseases, particularly Huntington's disease and Alzheimer's disease.
Development of compounds that inhibit ROCK (rho-kinase) through specific chemical structures, including Formula I compounds, their deuterated analogs, pharmaceutically acceptable salts, solvates, prodrugs, and stereoisomers, which can be administered to treat conditions mediated by ROCK activity.
These compounds effectively inhibit ROCK activity, providing therapeutic benefits in treating a wide range of conditions including Huntington's disease, spinal cord and brain injuries, Parkinson's disease, Alzheimer's disease, and other neurological disorders by reducing disease progression and improving symptoms.
Smart Images

Figure 0007593956000001 
Figure 0007593956000002 
Figure 0007593956000003
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED PATENT APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 868,793, filed June 28, 2019, which is incorporated by reference in its entirety.
[0002] Provided herein are certain inhibitors of ROCK (rho-kinase or rho-associated kinase), their compositions, and methods of their use. [Background technology]
[0003] Rho-kinase ("ROCK") is a protein that is a potent and widespread biochemical modulator involved in multiple biological processes. In humans, ROCK is a member of the AGC family of serine / threonine kinases and has two distinct isoforms, ROCK1 and ROCK2, that are ubiquitously expressed across tissues. ROCK1 and ROCK2 have central roles in numerous cellular functions, including smooth muscle cell contraction, cytokinesis, cell proliferation, cell adhesion and cell migration, indicating that they may have a wide range of therapeutic applications. These include, among others, cardiovascular disease, pulmonary disease, eye disease, erectile dysfunction, cancer, gastrointestinal disease, fibrotic disease, neurodegenerative disease, neurological injury, chronic and neuropathic pain, and diabetes.
[0004] ROCK signaling components have been reported to be elevated in brain and blood cell components from Huntington's disease (HD) patients. Accordingly, identification of a primary and secondary set of proteins interacting with huntingtin (HTT) led to the identification of Rho GTPase signaling components acting as modifiers of mutant HTT (mHTT) toxicity. In addition, sequential network interaction filtering applied across known and novel HTT interactors identified ROCK1 as an HTT interactor, suggesting that altered levels of ROCK in HD may play a role in disease pathogenesis. Increased expression of the ROCK downstream protein profilin or treatment of polyglutamine fragment (in the case of mutated HTT)-expressing cell cultures with ROCK inhibitors leads to a reduction in mHTT aggregation.
[0005] ROCK plays a role in other neurological diseases and injuries. ROCK protein levels and activation of its signaling pathway are promoted in the brains of patients with mild cognitive impairment and Alzheimer's disease. Accordingly, reducing ROCK1 expression through RNAi treatment in primary cortical neurons reduced amyloid-β levels. Summary of the Invention [Problem to be solved by the invention]
[0006] For example, there is an unmet need for new drugs to treat neurodegenerative diseases, particularly HD, Parkinson's disease and Alzheimer's. [Means for solving the problem]
[0007] The present invention relates to compounds useful for inhibiting ROCK. Some embodiments have the formula I:
[0008] [ka] [In formula: Ring B is a 6- to 10-membered aryl or 6- to 10-membered heteroaryl ring, and is selected from the group consisting of 1 to 5 R 4 is optionally replaced by; X is -O- or -N(R 3 )-and; R 1 is H or optionally substituted C 1~3 is alkyl; R 2 , oxo, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, C 1~3 Hydroxyalkyl or C 1~3 is alkoxy; or The Two R's 2 together with the carbon atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; R 3 is H or C 1~3 is alkyl; or R 2 and R 3 together with the atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; Each R 4 Independently, halo, C 1~3 Alkyl, C 1~3 Alkoxy or C 1~3 haloalkoxy; or The Two R's 4 together with the atoms to which they are attached, are joined together to form a heterocycloalkyl ring, wherein the heterocycloalkyl ring is selected from the group consisting of 1 to 3 halo or C 1~3 optionally substituted with alkyl; n is 0, 1 or 2. or a deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers thereof.
[0009] Also provided are additional compounds as described herein. In some embodiments, a compound selected from Table 1, or a pharma- ceutically acceptable salt thereof, is provided.
[0010] Also provided is a pharmaceutical composition comprising a compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and a pharma- ceutically acceptable carrier.
[0011] Also provided is a process for preparing a pharmaceutical composition comprising mixing a compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and a pharma- ceutically acceptable carrier.
[0012] Also provided is a method of treating or preventing a condition or disorder mediated by at least one isoform of ROCK in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound described herein or a deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof.
[0013] Also provided is a method of treating or preventing a condition or disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound as described herein or a deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof, wherein the condition or disorder is selected from Huntington's disease (HD), spinal cord and / or brain injury, chronic pulmonary hypertension, Parkinson's disease, amyotrophic lateral sclerosis, cerebral cavernous malformation, cardiovascular disease, Alzheimer's disease (AD), glaucoma, multiple sclerosis (MS), corneal lesions, diabetes, chronic and / or neuropathic pain, stroke, ischemia, retinopathy, spinal muscular atrophy (SMA), erectile dysfunction, nephropathy (non-hypertensive), hypertensive nephropathy, hypertension (elevated blood pressure), optic nerve lesions, hepatic fibrosis, lupus, post-transplant liver failure, encephalomyelitis, epilepsy, and glioblastoma.
[0014] In some embodiments, a compound selected from those in Table 1 or a deuterated analog, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof is provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] definition The following description describes exemplary embodiments of the present technology. However, it should be recognized that such description is not intended as a limitation on the scope of the invention, but rather is provided as a description of exemplary embodiments.
[0016] As used herein, the following words, statements and symbols are generally intended to have the meanings set forth below, except to the extent that the context in which they are used herein indicates otherwise.
[0017] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(O)NH2 is attached through a carbon atom.
[0018] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes examples where the event or circumstance does occur and examples where it does not occur. An "optionally substituted" group is one that may be unsubstituted with the group shown or defined. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined below. Those skilled in the art will understand that with respect to any group that contains one or more substituents, it is not intended that such groups introduce any substitution or substitution pattern that is sterically impractical, synthetically infeasible, and / or inherently unstable.
[0019] "Alkyl" includes straight and branched chains having a designated number of carbon atoms, typically 1 to 20 carbon atoms, such as 1 to 8 carbon atoms, for example 1 to 6 carbon atoms. For example, C1-C6 alkyl includes both straight and branched chain alkyls of 1 to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and the like. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be included, so for example, "butyl" includes n-butyl, sec-butyl, isobutyl, and t-butyl, and "propyl" is meant to include n-propyl and isopropyl.
[0020] Alkylene is another subset of alkyl, referring to the same residues as alkyl but with two points of attachment. An alkylene group will usually have 2 to 20 carbon atoms, such as 2 to 8 carbon atoms, for example 2 to 6 carbon atoms. For example, C1 alkylene is a methylene group. The term "alkylene" includes straight and branched chain diradicals having the indicated number of carbon atoms, usually 1 to 20 carbon atoms, for example 1 to 8 carbon atoms, for example 1 to 6 carbon atoms or 1 to 4 carbon atoms. Examples of C1 to C4 alkylene include methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 1,3-propylene, 1,1-butylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 2-methyl-1,2-propylene, and 2-methyl-1,3-propylene.
[0021] "Alkoxy" means an alkyl group of the indicated number of carbon atoms attached through an oxygen bridge, e.g., methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, etc. An alkoxy group will typically have 1 to 6 carbon atoms attached through an oxygen bridge.
[0022] "Aryl" refers to an aromatic carbocyclic ring having the indicated number of carbon atoms, e.g., 6-12 or 6-10 carbon atoms. An aryl group may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). In some instances, both rings of a polycyclic aryl group are aromatic (e.g., naphthyl). In other instances, a polycyclic aryl group may contain a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) fused to an aromatic ring, provided that the polycyclic aryl group is attached to the parent structure through an atom in the aromatic ring. Thus, a 1,2,3,4-tetrahydronaphthalen-5-yl group (wherein the moiety is attached to the parent structure through an aromatic carbon atom) is considered an aryl group, while a 1,2,3,4-tetrahydronaphthalen-1-yl group (wherein the moiety is attached to the parent structure through a non-aromatic carbon atom) is not considered an aryl group. Similarly, 1,2,3,4-tetrahydroquinolin-8-yl group (the moiety is attached to the parent structure via an aromatic carbon atom) is considered an aryl group, while 1,2,3,4-tetrahydroquinolin-1-yl group (the moiety is attached to the parent structure via a non-aromatic nitrogen atom) is not considered an aryl group. However, the term "aryl" does not encompass or overlap with "heteroaryl" as defined herein, regardless of the point of attachment (e.g., both quinolin-5-yl and quinolin-2-yl are heteroaryl groups). In some examples, aryl is phenyl or naphthyl. In certain examples, aryl is phenyl.
[0023] Divalent radicals formed from substituted benzene derivatives and having free valences at ring atoms are named substituted phenylene radicals. Divalent radicals derived from monovalent polycyclic hydrocarbon radicals by removing one hydrogen atom from the carbon atom having a free valence, whose names end in "-yl", are named by adding "-ydene" to the name of the corresponding monovalent radical, e.g., a naphthyl group with two points of attachment is called naphthylidene.
[0024] "Cycloalkyl" refers to a partially unsaturated non-aromatic or fully saturated carbocyclic ring having the indicated number of carbon atoms, e.g., 3-10 or 3-8 or 3-6 ring carbon atoms. Cycloalkyl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, and cyclohexyl, as well as bridged spirocyclic and caged ring groups (e.g., norbornane, bicyclo[2.2.2]octane). In addition, one ring of a polycyclic cycloalkyl group may be aromatic, provided that the polycyclic cycloalkyl group is attached to the parent structure through a non-aromatic carbon. For example, the group 1,2,3,4-tetrahydronaphthalen-1-yl (the moiety is attached to the parent structure through a non-aromatic carbon atom) is a cycloalkyl group, while 1,2,3,4-tetrahydronaphthalen-5-yl (the moiety is attached to the parent structure through an aromatic carbon atom) is not considered a cycloalkyl group; it is considered an aryl group. A cycloalkyl may be a "cycloalkenyl," which is a cycloalkyl that contains at least one unit of unsaturation.
[0025] The term "halo" includes fluoro, chloro, bromo, and iodo, and the term "halogen" includes fluorine, chlorine, bromine, and iodine.
[0026] The term "haloalkyl" refers to a C alkyl group substituted with halogen, from one to full substitution. 1~6 Alkyl groups are fully substituted C 1~6 Haloalkyl is a group of formula C n L 2n+1 where L is a halogen and "n" is 1, 2, 3 or 4; if more than one halogen is present, they may be the same or different and are selected from the group consisting of F, Cl, Br and I, e.g., F. 1~4Examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like.
[0027] The term "hydroxyalkyl" refers to an alkyl group, as defined herein, where the alkyl is substituted with 1, 2, 3 or 4 hydroxy groups, one hydroxy group for each carbon atom. Examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl, 3-hydroxypropyl, 2-hydroxy-sec-butyl, 3,4-dihydroxybutyl, and the like.
[0028] The term "haloalkoxy" means a haloalkyl attached directly to an oxygen atom. Examples include, but are not limited to, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, and the like.
[0029] "Heteroaryl" refers to an aromatic ring (e.g., 5-12 membered, or 5-10 membered heteroaryl) containing the indicated number of atoms, composed of one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) selected from N, O, and S, with the remaining ring atoms being carbon. Heteroaryl groups do not contain adjacent S and O atoms. In some embodiments, the total number of S and O atoms in a heteroaryl group does not exceed 2. In some embodiments, the total number of S and O atoms in a heteroaryl group does not exceed 1. Unless otherwise specified, a heteroaryl group may be attached to the parent structure by a carbon or nitrogen atom, where valence permits. For example, "pyridyl" includes 2-pyridyl, 3-pyridyl, and 4-pyridyl groups, and "pyrrolyl" includes 1-pyrrolyl, 2-pyrrolyl, and 3-pyrrolyl groups. When nitrogen is present in a heteroaryl ring, it may be in any oxidized state (i.e., N) when the nature of the adjacent atoms and groups permits. + -O - In addition, when sulfur is present in a heteroaryl ring, it may be present in an oxidized state (i.e., S+ -O - or SO2). Heteroaryl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic).
[0030] In some examples, the heteroaryl group is monocyclic. Examples include pyrrole, pyrazole, imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole), tetrazole, furan, isoxazole, oxazole, oxadiazole (e.g., 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole), thiophene, isothiazole, thiazole, thiadiazole (e.g., 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole), pyridine, pyridazine, pyrimidine, pyrazine, triazine (e.g., 1,2,4-triazine, 1,3,5-triazine), and tetrazine.
[0031] In some cases, both rings of the polycyclic heteroaryl group are aromatic. Examples include indole, isoindole, indazole, benzimidazole, benzotriazole, benzofuran, benzoxazole, benzisoxazole, benzoxadiazole, benzothiophene, benzothiazole, benzisothiazole, benzothiadiazole, 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine, 3H-imidazo[4,5-b]pyridine, 3H-[1,2,3]triazolo[4,5-b]pyridine, 1H-pyrrolo[3,2-b]pyridine, 1H-pyrazolo[4,3- b]pyridine, 1H-imidazo[4,5-b]pyridine, 1H-[1,2,3]triazolo[4,5-b]pyridine, 1H-pyrrolo[2,3-c]pyridine, 1H-pyrazolo[3,4-c]pyridine, 3H-imidazo[4,5-c]pyridine, 3H-[1,2,3]triazolo[4,5-c]pyridine, 1H-pyrrolo[3,2-c]pyridine, 1H-pyrazolo[4,3-c]pyridine, 1H-imidazo[4,5-c]pyridine, 1H-[1,2,3]triazolo[4,5-c]pyridine, furo[2,3-b]pyridine, oxazolo[5,4 -b]pyridine, isoxazolo[5,4-b]pyridine, [1,2,3]oxadiazolo[5,4-b]pyridine, furo[3,2-b]pyridine, oxazolo[4,5-b]pyridine, isoxazolo[4,5-b]pyridine, [1,2,3]oxadiazolo[4,5-b]pyridine, furo[2,3-c]pyridine, oxazolo[5,4-c]pyridine, isoxazolo[5,4-c]pyridine, [1,2,3]oxadiazolo[5,4-c]pyridine, furo[3,2-c]pyridine, oxazolo[4,5-c]pyridine, isoxazolo[5,4-c]pyridine, thiazolo[4,5-c]pyridine, [1,2,3]oxadiazolo[4,5-c]pyridine, thieno[2,3-b]pyridine, thiazolo[5,4-b]pyridine, isothiazolo[5,4-b]pyridine, [1,2,3]thiadiazolo[5,4-b]pyridine, thieno[3,2-b]pyridine, thiazolo[4,5-b]pyridine, isothiazolo[4,5-b]pyridine, [1,2,3]thiadiazolo[4,5-b]pyridine, thieno[2,3-c]pyridine, thiazolo[5,4-c]pyridine, isothiazolo[5,4-c]pyridine, [1,2,3]thiadiazolo[5,4-c]pyridine, thieno[3,2-c]pyridine, thiazolo[4,5-c]pyridine, isothiazolo[4,5-c]pyridine, [1,2,3]thiadiazolo[4,5-c]pyridine, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, naphthyridine (e.g., 1,8-naphthyridine, 1,7-naphthyridine, 1,6-naphthyridine, 1,5-naphthyridine, 2,7-naphthyridine, 2,6-naphthyridine), imidazo[1,2-a]pyridine, 1H-pyrazolo[3,4-d]thiazole, 1H-pyrazolo[4,3-d]thiazole and imidazo[2,1-b]thiazole.
[0032] In other examples, polycyclic heteroaryl groups may contain non-aromatic rings (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) fused to a heteroaryl ring, provided that the polycyclic heteroaryl group is attached to the parent structure through an atom in an aromatic ring. For example, 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl (wherein the moiety is attached to the parent structure through an aromatic carbon atom) is considered a heteroaryl group, while 4,5,6,7-tetrahydrobenzo[d]thiazol-5-yl (wherein the moiety is attached to the parent structure through a non-aromatic carbon atom) is not considered a heteroaryl group.
[0033] "Heterocycloalkyl" refers to a non-aromatic, saturated or partially unsaturated ring having the indicated number of atoms (e.g., 3-10 or 3-7 membered heterocycloalkyl) composed of one or more heteroatoms (e.g., 1, 2, 3, or 4 heteroatoms) selected from N, O, and S, with the remaining ring atoms being carbon. The term "heterocycloalkyl" includes heterocycloalkenyl groups (i.e., heterocycloalkyl groups having at least one double bond) and includes one or more oxo (=O) or N-oxide (-O) groups. -) moieties. Heterocycloalkyl groups may be monocyclic (i.e., heteromonocyclic) or polycyclic (including, for example, bicyclic (i.e., heterobicyclic), spirocyclic and bridged ring systems). Thus, the definition of heterobicyclic encompasses heteromonocyclic rings that are 1,1-disubstituted with a cycloalkyl or heteromonocyclic group, as well as ring systems in which a heteromonocyclic ring is 1,2- or 1,3-fused to another cycloalkyl or heteromonocyclic ring (where the carbon or nitrogen atoms can form a ring junction (where this structure is chemically feasible)), as well as ring systems in which a heteromonocyclic ring has a C1-C2 alkyl bridge, as well as ring systems in which a heteromonocyclic ring is 1,2-fused to an aromatic or aromatic heterocyclic ring, provided that the moiety is attached to the parent structure through a non-aromatic carbon or nitrogen atom.
[0034] Examples of monocyclic heterocycloalkyl (ie, heteromonocyclic) groups include oxiranyl, aziridinyl, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, and thiomorpholinyl.
[0035] Examples of C6 heterobicyclyl groups include 3-azabicyclo[3.1.0]hexan-3-yl.
[0036] C8-C with aromatic ring 10 Examples of heterobicyclyl groups include indolin-1-yl, isoindolin-2-yl, 1,2,3,4-tetrahydroquinolin-2-yl, 3,4-dihydroquinolin-1(2H)-yl, and 7,8-dihydro-1,6-naphthyridin-6(5H)-yl.
[0037] Examples of heterobicyclyl ring systems containing spiro rings include 1-oxa-5-azaspiro[3.3]heptan-5-yl, 1-oxa-6-azaspiro[3.3]heptan-6-yl, 6-oxa-1-azaspiro[3.3]heptan-1-yl, 2-oxa-6-azaspiro[3.3]heptan-6-yl, 1,5-diazaspiro[3.3]heptan-1-yl, 1,6-diazaspiro[3.3]heptan-6-yl, 1,6-diazaspiro[3.3]heptan-1-yl, 2,6-diazaspiro[3.3]heptan-2-yl, ... 1-oxa-6-azaspiro[3.4]octan-6-yl, 2-oxa-5-azaspiro[3.4]octan-5-yl, 2-oxa-6-azaspiro[3.4]octan-6-yl, 1,5-diazaspiro[3.4]octan-5-yl, 1,6-diazaspiro[3.4]octan-6-yl, 2,5-diazaspiro[3.4]octan-5-yl, 2,6-diazaspiro[3.4]octan-6-yl, 1-oxa-5-azaspiro[3.5]nonan-5-yl, 1-oxa-6-azaspiro[3.5]nonan-5-yl 1-oxa-7-azaspiro[3.5]nonan-7-yl, 2-oxa-5-azaspiro[3.5]nonan-5-yl, 2-oxa-6-azaspiro[3.5]nonan-6-yl, 2-oxa-7-azaspiro[3.5]nonan-7-yl, 1,5-diazaspiro[3.5]nonan-5-yl, 1,6-diazaspiro[3.5]nonan-6-yl, 1,7-diazaspiro[3.5]nonan-7-yl, 2,5-diazaspiro[3.5]nonan-5-yl, 2,6-diazaspiro[3.5]nonan-6-yl, 2,7-diazaspiro [3.5]nonan-7-yl, 1-oxa-5-azaspiro[3.6]decan-5-yl, 1-oxa-6-azaspiro[3.6]decan-6-yl, 1-oxa-7-azaspiro[3.6]decan-7-yl, 2-oxa-5-azaspiro[3.6]decan-5-yl, 2-oxa-6-azaspiro[3.6]decan-6-yl, 2-oxa-7-azaspiro[3.6]decan-7-yl, 1,5-diazaspiro[3.6]decan-5-yl, 1,6-diazaspiro[3.6]decan-6-yl, 1,7-diazaspiro[3.6]decan-7-yl 2,5-diazaspiro[3.6]decan-5-yl, 2,6-diazaspiro[3.6]decan-6-yl, and 2,7-diazaspiro[3.6]decan-7-yl.
[0038] Examples of heterobicyclyl ring systems containing a C1-C4 bridged alkylene include 2-azabicyclo[2.2.1]heptan-2-yl, 2-azabicyclo[3.2.1]octan-2-yl, 3-azabicyclo[3.2.1]octan-3-yl, and 6-azabicyclo[3.2.1]octan-6-yl.
[0039] When nitrogen is present in a heterocycloalkyl ring, it may be present in an oxidized state (i.e., N + -O - ) Examples include piperidinyl N-oxide and morpholinyl-N-oxide. In addition, when sulfur is present in a heterocycloalkyl ring, it may be present in an oxidized state (i.e., S + -O - or -SO2-). Examples include thiomorpholine S-oxide and thiomorpholine S,S-dioxide.
[0040] "Solvate" refers to an association or complex of one or more solvent molecules with a compound described herein. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethylsulfoxide, ethyl acetate, acetic acid, and ethanolamine.
[0041] "Prodrug" refers to any compound that releases an active parent drug according to the structures described herein in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds described herein are prepared by modifying functional groups present in the compounds described herein such that the modification can be cleaved in vivo to release the parent compound. Prodrugs can be prepared by modifying functional groups present in the compounds described herein such that the modification can be cleaved to the parent compound either in routine manipulation or in vivo. Prodrugs include compounds described herein in which a hydroxy, amino, carboxyl, or sulfhydryl group in the compounds described herein is bonded to any group that can be cleaved in vivo to regenerate the free hydroxy, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, esters (e.g., acetate, formate, and benzoate derivatives at a hydroxy group), amides (e.g., at an amino group), guanidines (e.g., at an amino group), carbamates (e.g., N,N-dimethylaminocarbonyl at a hydroxy group) derived from functional groups, etc. in the compounds described herein. The preparation, selection and use of prodrugs are discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the ACS Symposium Series; "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985; and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, each of which is incorporated herein by reference in its entirety.
[0042] The term "substituted" as used herein means that any one or more hydrogens on the designated atom or group are replaced with one selected from the indicated group, provided that the normal valence of the designated atom is not exceeded. When a substituent is oxo (i.e. =O), then two hydrogens on the atom are replaced. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to suggest a compound that is robust enough to survive isolation from a reaction mixture and subsequent formulation as a drug having at least practical utility. Unless otherwise specified, the substituents are named along with the core structure. For example, when (cycloalkyl)alkyl is listed as a possible substituent, it will be understood that the attachment point of this substituent to the core structure is in the alkyl moiety.
[0043] The terms "substituted" alkyl (including, without limitation, C1-C4 alkyl), cycloalkyl, aryl, heterocycloalkyl, and heteroaryl mean that, unless expressly defined otherwise, one or more (e.g., up to five, e.g., up to three) hydrogen atoms are independently replaced by -R a , -OR b , -O(C1-C2 alkyl)O- (e.g. methylenedioxy-), -SR b , guanidine (-NHC(=NH)NH2), guanidine (wherein one or more of the guanidine hydrogens are replaced with a C1-C4 alkyl group), -NR b R c , halo, cyano, oxo (as a substituent of heterocycloalkyl), nitro, -COR b , -CO2R b , -CONR b R c , -OCOR b , -OCO2R a , -OCONR b R c , -NR c COR b , -NR c CO2R a , -NR c CONRb R c , -SOR a , -SO2R a , -SO2NR b R c , and -NR c SO2R a each of which refers to an alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl, each of which is substituted by a substituent independently selected from: Here, R a is selected from C1-C6 alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; R b is selected from H, C1-C6 alkyl, aryl and heteroaryl, and R c is selected from hydrogen and C1-C4 alkyl, or R b and R cand the nitrogen to which they are attached form a heterocycloalkyl group, and wherein each C1-C6 alkyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl is selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, aryl, heteroaryl, aryl-C1-C4 alkyl-, heteroaryl-C1-C4 alkyl-, C1-C4 haloalkyl-, -OC1-C4 alkyl, -OC1-C4 alkylphenyl, -C1-C4 alkyl-OH, -C1-C4 alkyl-O-C1-C4 alkyl, -OC1-C4 haloalkyl, halo, -OH, -NH2, -C1-C4 alkyl-NH2, -N(C1-C4 alkyl)(C1-C4 alkyl), -NH(C1-C4 alkyl), -N(C1-C4 alkyl)(C1-C4 alkylphenyl), -NH(C1-C4 alkylphenyl), cyano, nitro, oxo (as a heteroaryl substituent), -CO2H , -C(O)OC1~C4 alkyl, -CON(C1~C4 alkyl)(C1~C4 alkyl), -CONH(C1~C4 alkyl), -CONH2, -NHC(O)(C1~C4 alkyl), -NHC(O)(phenyl), -N(C1~C4 alkyl)C(O)(C1~C4 alkyl), -N(C1~C4 alkyl)C(O)(phenyl), -C(O)C1~C4 alkyl, -C(O)C1~C4 phenyl, -C(O)C1~C4 haloalkyl and optionally substituted with one or more (e.g., 1, 2 or 3) substituents independently selected from -OC(O)C1-C4 alkyl, -SO2(C1-C4 alkyl), -SO2(phenyl), -SO2(C1-C4 haloalkyl), -SO2NH2, -SO2NH(C1-C4 alkyl), -SON2NH(phenyl), -NHSO2(C1-C4 alkyl), -NHSO2(phenyl), and -NHSO2(C1-C4 haloalkyl).
[0044] "Stereoisomer" refers to one of a set of compounds that are composed of the same atoms linked by the same bonds but have different three-dimensional structures and cannot be interconverted. The term "enantiomer" refers to one of a pair of stereoisomers that are non-superimposable mirror images of each other. Compounds depicted as single stereoisomers are intended to encompass mixtures of stereoisomers. In particular, asymmetric ("chiral") carbon centers may be enriched or racemic mixtures with respect to each such center in the compound.
[0045] The compounds described herein include, but are not limited to, their optical isomers, racemates, and other mixtures thereof. In such situations, single enantiomers or diastereomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent or chromatography, for example, using a chiral high pressure liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) column. In addition, such compounds include Z- and E-forms (or cis- and trans-forms) of compounds having carbon-carbon double bonds. In cases where the compounds described herein exist in various tautomeric forms, the term "compound" is intended to include all tautomeric forms of the compound. Such compounds also include crystalline forms, including polymorphs and clathrates. Similarly, the term "salt" is intended to include all tautomeric and crystalline forms of the compound.
[0046] "Pharmaceutically acceptable salts" include salts with inorganic acids, such as hydrochlorides, phosphates, diphosphates, hydrobromides, sulfates, sulfinates, nitrates, and the like, as well as salts with organic acids, such as malates, maleates, fumarates, tartrates, succinates, citrates, acetates, lactates, methanesulfonates, p-toluenesulfonates, 2-hydroxyethylsulfonates, benzoates, salicylates, stearates, and alkanoates such as acetates, HOOC-(CH2) q-COOH, where q is 0 to 4, and similar salts. Similarly, pharma- ceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
[0047] In addition, when the compounds described herein are obtained as acid addition salts, the free base can be obtained by basifying a solution of the acid salt. Conversely, when the product is a free base, an addition salt, particularly a pharma- ceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional methods for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic, pharma-ceutically acceptable addition salts.
[0048] As used herein, the terms "group," "moiety," "radical," or "fragment" are synonymous and are intended to refer to a functional group or fragment of a molecule that is capable of attachment to a bond or other fragment of the molecule.
[0049] The term "active agent" is used to refer to a compound having biological activity or a pharma- ceutically acceptable salt thereof. In some embodiments, an "active agent" is a compound having pharmaceutical utility or a deuterated analog, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof. For example, an active agent may be an anti-neurodegenerative therapeutic agent.
[0050] The term "therapeutically effective amount" means an amount effective when administered to a human or non-human patient to impart a therapeutic benefit, such as amelioration of symptoms, delaying progression of a disease, or preventing a disease; for example, a therapeutically effective amount may be an amount sufficient to reduce the symptoms of a disease responsive to inhibition of ROCK activity.
[0051] The terms "ROCK inhibitor" and "inhibitor of ROCK" are intended to mean a compound described herein, or a deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof, that is capable of interacting with ROCK and inhibiting its enzymatic activity.
[0052] As used herein, the term "condition or disorder mediated by ROCK" refers to a condition or disorder in which ROCK and / or the action of ROCK is important or necessary for, e.g., the initiation, progression, development, etc., of the condition, or a condition known to be treated by a ROCK inhibitor.
[0053] The term "effect" describes a change or no change in cell phenotype or cell proliferation. "Effect" can also describe a change or no change in the catalytic activity of ROCK. "Effect" can also describe a change or no change in the interaction between ROCK and a natural binding partner.
[0054] The term "inhibiting ROCK activity" is intended to mean decreasing the enzymatic activity of ROCK. The concentration of an inhibitor that decreases the activity of a ROCK enzyme to 50% of the activity of the uninhibited enzyme is called the IC 50 In some embodiments, such reduction in ROCK enzyme activity is at least 50%, such as at least about 75%, such as at least about 90%. In some embodiments, the ROCK enzyme activity is reduced by at least 95%, such as at least 99%. In some embodiments, the IC 50 In some embodiments, the IC value of the compounds described herein and their pharma- ceutically acceptable salts is less than 100 nanomolar. 50 In some embodiments, the IC values of the compounds described herein and their pharma- ceutically acceptable salts are between 100 nanomolar and 1 micromolar. 50 Values are between 1 and 25 micromolar.
[0055] "Treatment" or "treating" means any treatment of a disease condition in a patient; a) To prevent disease, i.e. to stop the clinical signs of a disease from appearing b) Inhibiting disease c) delaying or arresting the onset of clinical signs, and / or d) remission of the disease, i.e., causing regression of clinical signs Includes.
[0056] "Subject" or "patient" refers to an animal, e.g., a mammal, who is or will be the object of treatment, observation or experiment. The methods described herein can be useful in both human therapy and veterinary applications. In some embodiments, the subject is a mammal, and in some embodiments, the subject is a human.
[0057] It is to be understood that some features described herein that are described in the context of separate embodiments for clarity can also be provided in the form of a combination in a single embodiment. Conversely, various features described herein that are described in the context of a single embodiment for brevity can also be provided separately or in any suitable subcombination. All combinations of the embodiments with respect to the chemical groups represented by the variables contained in formula I, to the extent that such combinations include compounds that result in stable compounds (i.e., compounds that can be isolated, characterized, and tested for biological activity), are specifically encompassed by this specification as if each and every combination were individually and explicitly recited. Furthermore, all subcombinations of the chemical groups recited in the embodiments describing such variables, as well as all subcombinations of the uses and medical applications described herein, e.g., conditions or disorders mediated by ROCK, are also specifically encompassed by this specification as if each and every subcombination of the chemical groups and subcombinations of the uses and medical applications were individually and explicitly recited herein. Additionally, some embodiments include every combination of one or more additional agents disclosed herein, as if each and every combination were individually and expressly listed.
[0058] Table of Abbreviations and Acronyms
[0059] [Table 1] TIFF0007593956000003.tif151164
[0060] compound Formula I:
[0061] [ka] [In formula: Ring B is a 6- to 10-membered aryl or 6- to 10-membered heteroaryl ring, and is selected from the group consisting of 1 to 5 R4 is optionally replaced by; X is -O- or -N(R 3 )-and; R 1 is H or optionally substituted C 1~3 is alkyl; R 2 , oxo, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, C 1~3 Hydroxyalkyl or C 1~3 is alkoxy; or The Two R's 2 together with the carbon atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; R 3 is H or C 1~3 is alkyl; or R 2 and R 3 together with the atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; Each R 4 Independently, halo, C 1~3 Alkyl, C 1~3 Alkoxy or C 1~3 haloalkoxy; or The Two R's 4 together with the atoms to which they are attached, are joined together to form a heterocycloalkyl ring, wherein the heterocycloalkyl ring is selected from the group consisting of 1 to 3 halo or C 1~3 optionally substituted with alkyl; n is 0, 1 or 2. or a deuterated analog, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof.
[0062] In some embodiments, the compound of formula Ia:
[0063] [ka] [In formula: Ring B is a 6- to 10-membered aryl or 6- to 10-membered heteroaryl ring, and is selected from the group consisting of 1 to 5 R 4 is optionally replaced by; X is -O- or -N(R 3 )-and; R 1 is H or optionally substituted C 1~3 is alkyl; R 2 , oxo, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, C 1~3 Hydroxyalkyl or C 1~3 is alkoxy; or The Two R's 2 together with the carbon atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; R 3 is H or C 1~3 is alkyl; or R 2 and R 3 together with the atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; Each R 4 Independently, halo, C 1~3 Alkyl, C 1~3 Alkoxy or C 1~3 haloalkoxy; or The Two R's 4 together with the atoms to which they are attached, are joined together to form a heterocycloalkyl ring, wherein the heterocycloalkyl ring is selected from the group consisting of 1 to 3 halo or C 1~3 optionally substituted with alkyl; Each R 5 are independently halo; m is 1 or 2; n is 0, 1 or 2. or a deuterated analog, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof.
[0064] In some embodiments, the compound of formula I has formula II:
[0065] [ka] It is a compound of the formula:
[0066] In some embodiments, the compound of formula I has formula II(a):
[0067] [ka] [In the formula, p is 0, 1 or 2] It is a compound of the formula:
[0068] In some embodiments, n is 0.
[0069] In some embodiments, n is 1 and R 2 is methyl.
[0070] In some embodiments, n is 2 and each R 2 is methyl.
[0071] In some embodiments, the compound of formula I has formula III:
[0072] [ka] It is a compound of the formula:
[0073] In some embodiments, the compound of formula I has formula III(a):
[0074] [ka] It is a compound of the formula:
[0075] In some embodiments, the compound of formula I has formula III(b):
[0076] [ka] It is a compound of the formula:
[0077] In some embodiments, the compound of formula I has formula IV(a):
[0078] [ka] is a compound of R 1 is the possibly substituted C 1~3 It is an alkyl.
[0079] In some embodiments, the compound of formula I has formula IV(b):
[0080] [ka] is a compound of R 1 is the possibly substituted C 1~3 It is an alkyl.
[0081] In some embodiments, the compound of formula I has formula IV(c):
[0082] [ka] is a compound of R 1 is the possibly substituted C 1~3 It is an alkyl.
[0083] In some embodiments, the compound of formula I has formula IV(d):
[0084] [ka] is a compound of R 1 is the possibly substituted C 1~3 It is an alkyl.
[0085] In some embodiments, the compound of formula I has formula V:
[0086] [ka] It is a compound of the formula:
[0087] In some embodiments, the compound of formula I has formula V(a):
[0088] [ka] [In the formula, p is 0, 1 or 2] It is a compound of the formula:
[0089] In some embodiments, the compound of formula I has formula V(b):
[0090] [ka] [In the formula, p is 0, 1 or 2] It is a compound of the formula:
[0091] In some embodiments, the compound of formula I has formula V(c):
[0092] [ka] wherein each J is independently H, D, or F, and p is 0, 1, or 2. In some embodiments of formula V(c), each J is H.
[0093] In some embodiments, the compound of formula I has formula V(d):
[0094] [ka] [In the formula, p is 0, 1 or 2] It is a compound of the formula:
[0095] In some embodiments, the compound of formula I has formula V(e):
[0096] [ka] [In the formula, p is 0, 1 or 2] It is a compound of the formula:
[0097] In some embodiments, the compound of formula I has formula V(f):
[0098] [ka] [In the formula, p is 0, 1 or 2] It is a compound of the formula:
[0099] In some embodiments, X is -N(R 3 )-.
[0100] In some embodiments, R 3 is H.
[0101] In some embodiments, R 1 is H. In some embodiments, R 1 is optionally replaced by C 1~3 In some embodiments, R 1 is H, methyl, or CD3. In some embodiments, R 1 is methyl.
[0102] In some embodiments, R 2 Halo, C 1~3 Alkyl, C 1~3 Haloalkyl, C 1~3 Hydroxyalkyl or C 1~3 In some embodiments, R 2 is C 1~3 Alkyl, C 1~3 Haloalkyl or C 1~3 In some embodiments, R 2 is C 1~3 In some embodiments, R 2 is methyl.
[0103] In some embodiments, two R 2 together with the carbon atom to which they are attached, are joined to each other to form a cyclopropyl. 2 are linked together to form bridging methylenes.
[0104] In some embodiments, R 1 is methyl, R 2 is methyl.
[0105] In some embodiments, X is -N(R 3 )- and R 2 and R 3 together with the atoms to which they are attached, are joined to each other to form a 5- or 6-membered unsubstituted cycloalkyl ring.
[0106] In some embodiments, ring B is halo, C 1~3 Alkyl, C 1~3 Alkoxy and C 1~3 haloalkoxy; or two R 4 and together with the atoms to which they are attached, are bonded to each other to form a heterocycloalkyl ring. In some embodiments, ring B is halo, C 1~3 Alkyl, C 1~6 Alkoxy and C 1~3 In some embodiments, ring B is phenyl optionally substituted with 1 to 3 substituents selected from halo, C 1~6 Alkyl, C 1~6 Alkoxy and C 1~3 and phenyl substituted with one substituent selected from haloalkoxy.
[0107] In some embodiments, ring B is phenyl and has two R 4 together with the atoms to which they are attached, are joined to each other to form a heterocycloalkyl ring.
[0108] In some embodiments, ring B is halo, C 1~3 Alkyl, C 1~6 Alkoxy and C 1~3 and 6-10 membered heteroaryl optionally substituted with 1-3 substituents selected from haloalkoxy.
[0109] In some embodiments, X is -N(H)-. In some embodiments, X is O.
[0110] In some embodiments, R 4 is selected from F, Cl, Br, methyl, CD3, methoxy, OCD3 and OCHF2.
[0111] In some embodiments, each R 5 is independently selected from Cl and F. In some embodiments, each R 5 is F.
[0112] In some embodiments, m is 1 and R 5 is F.
[0113] In some embodiments, a compound selected from those described in the Examples section provided herein is provided.
[0114] In some embodiments, a pharmaceutical composition is provided that includes a compound provided herein and a pharma- ceutically acceptable carrier.
[0115] Treatment Methods and Uses The compounds disclosed herein are useful for treating or preventing conditions or disorders mediated at least in part by ROCK.Treatment for such conditions may be in the form of oral products, intravenous injections, topical agents, suppositories, direct injection into the tissue of interest, and other delivery methods.Treatment may include co-administration of the compounds described herein with other therapeutic agents and / or pharma- ceutically acceptable vehicles.
[0116] In some embodiments, provided is a method of treating or preventing a condition or disorder mediated at least in part by ROCK in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound or pharmaceutical composition provided herein.
[0117] Exemplary conditions or disorders mediated at least in part by ROCK are as follows:
[0118] Huntington's Disease (HD) ROCK signaling components have been reported to be elevated in brain and blood cell components from HD patients. Accordingly, identification of a primary and secondary set of proteins interacting with huntingtin (HTT) led to the identification of Rho GTPase signaling components that act as modifiers of mutant HTT (mHTT) toxicity. In addition, sequential network interaction screens applied across known and novel HTT interactors identified ROCK1 as an HTT interactor, suggesting that altered levels of ROCK in HD may play a role in the pathogenesis of the disease.
[0119] Increased expression of the ROCK downstream protein profilin in cell cultures expressing polyglutamine fragments (as in mutated HTT) or treatment with ROCK inhibitors results in a decrease in mHTT aggregation.
[0120] Oral administration of the ROCK inhibitor Y27632 reduces mutant huntingtin levels and improves motor performance in the R6 / 2 mouse model of HD. Intravitreal administration of the ROCK inhibitor HA-1077 (fasudil) improves electroretinogram responses and reduces retinal neuropathology in the R6 / 2 mouse model of HD.
[0121] Spinal Cord and Brain Injury Intrathecal administration of the ROCK inhibitor Y27632 induced more axonal sprouting than vehicle and improved motor function after cervical dorsal column transection in rats.
[0122] Chronic pulmonary hypertension Subcutaneous injection of the ROCK inhibitor Y27632 attenuated right ventricular hypertrophy and normalized right ventricular systolic function in rats exposed to hypoxia.
[0123] Parkinson's disease Administration of the ROCK inhibitor fasudil reduces molecular, neuropathological (dopamine cell loss, α-synuclein accumulation) and behavioral abnormalities in a lipopolysaccharide (LPS)-induced model of Parkinson's disease (PD).
[0124] Cultured neurons exposed to the MPTP metabolite MPP+ under fasudil treatment showed greater survival and neurite length. Correspondingly, fasudil treatment increased the number of TH neurons, improved striatal innervation by dopaminergic fibers, and increased motor performance in MPTP-treated animals.
[0125] Amyotrophic lateral sclerosis In vitro exposure of cultured primary motor neurons to the ROCK inhibitor Y27632 improved survival and increased neurite length. SOD1 in ALS G93A In vivo oral administration of Y27632 to a mouse model improved motor function in male mice. In vitro application of the ROCK inhibitor fasudil to kainic acid-injured cultured motor neurons increased survival. SOD1 upregulation in ALS with the ROCK inhibitor fasudil G93A In vivo treatment of mouse models increased their survival and improved motor function. In addition, treated animals showed increased survival of motor neurons and modulation of spinal cord glial infiltration.
[0126] Cerebral cavernous hemangioma Brain tissue from patients with cerebral cavernous hemangiomas (CCMs) showed increased ROCK signaling. Ccm1+ / - and Ccm2+ / - models of CCMs showed increased ROCK signaling, and the interaction between CCMs and ROCK is important for regulating vascular leakage. The ROCK inhibitor fasudil reverses vascular leakage in these animal models.
[0127] ROCK inhibition appears to have a disease-modifying effect, as a Ccm1+ / - Msh2- / - mouse model of CCM treated with fasudil from weaning to 5 months of age showed reduced pathology prevalence, indicating that ROCK activation plays a role in the pathogenesis of CCM.
[0128] Fasudil treatment reduced iron deposition at late stages and increased survival in the Ccm+ / - Msh2- / - mouse model of CCM.
[0129] cardiovascular disease ROCK pathway activation is elevated in patients with coronary artery disease (CAD), as demonstrated by increased phosphorylation levels of myosin light chain (MLC). Oral administration of the ROCK inhibitor fasudil exerted beneficial effects by increasing flow-mediated vasodilation in patients with CAD, but not in healthy subjects.
[0130] In a phase 2 clinical trial with a ROCK inhibitor for stable angina, fasudil increased the ischemic threshold for angina by increasing exercise duration compared to those taking a placebo.
[0131] Utilizing the deoxycorticosterone acetate (DOCA)-salt hypertensive rat model of elevated blood pressure (HBP), it was demonstrated that ROCK activation (and IP3 signaling) is involved in the development of arterial tone in the DOCA model in parallel, and ROCK2 gene polymorphisms were identified as influencers of increased systemic vascular resistance and altered responsiveness to the renin / angiotensin system resulting in elevated blood pressure.
[0132] Rats with cardiac hypertrophy induced by suprarenal abdominal aortic constriction were treated with the ROCK inhibitor GSK-576371, which reduced left ventricular thickness and collagen deposition.
[0133] Alzheimer's Disease (AD) Alterations in the ROCK signaling pathway have been reported in various cellular and animal models of disease, although in some cases the changes appear to be in a biphasic manner depending on age, brain region or subcellular compartment.
[0134] ROCK protein levels and its signaling pathway activation are promoted in the brains of patients with mild cognitive impairment and Alzheimer's disease. Accordingly, reducing ROCK1 expression through RNAi treatment in primary cortical neurons reduced amyloid-β levels.
[0135] Intracranial injection of ROCK-II siRNA in a senescence-accelerated mouse model of AD resulted in an increase in the number of hippocampal cholinergic (ChAT+) neurons and a decrease in escape latency and mean swimming distance in the Morris water maze (MWW) test. Altogether, these suggest that ROCK inhibition plays a beneficial role at the histopathological and behavioral levels of recovery in AD.
[0136] Glaucoma The ROCK inhibitor Y27632 inhibits carbachol-induced contraction of ciliary muscle strips as well as cell body rounding and disruption of actin bundles and focal adhesion formation in cultured human trabecular meshwork cells. Topical, intracameral or intravitreal administration of the same inhibitor in vivo to rabbit eyes resulted in reduced intraocular pressure, increased outflow and pupil dilation.
[0137] Topical administration of the dual ROCK and LIMK inhibitor LX7101 to mice with dexamethasone-induced ocular hypertension reduced intraocular pressure to levels even lower than the current treatment options timolol and latanoprost.
[0138] The effect of the ROCK inhibitor ripasudil on open-angle glaucoma and ocular hypertension was examined through a multicenter, randomized, open-label, crossover study. Significant reduction in intraocular pressure was detected 1 to 7 hours after instillation.
[0139] Multiple sclerosis (MS) Increased ROCK signaling activity was detected in serum from MS patients compared to healthy controls. Similarly, enhanced ROCK activity was detected in the autoimmune encephalomyelitis (EAE) mouse model of MS. MS serum-induced impairment of synaptogenesis in cultured primary neurons was rescued by treatment with the ROCK inhibitor fasudil, which restored cell viability and neurite length.
[0140] Behavioral rescue of induced EAE in mice was obtained by in vivo intraperitoneal treatment with either fasudil or the Y27632 derivative WAR-5. WAR-5 treatment also reduced ROCK activity in the brain, spinal cord, and spleen; reversed spinal cord demyelination and reduced inflammatory responses and infiltration.
[0141] Intranasal delivery of the fasudil derivative FSD-C10 to an EAE mouse model of MS reduced ROCK activation in the spinal cord and spleen (although not significantly in the brain). Treatment also reduced spinal inflammatory responses and infiltration, as well as behavioral dysfunction, while increasing expression of the neurotrophic markers BDNF and NGF.
[0142] Corneal lesions Topical application of the ROCK inhibitor Y27632, six times daily for seven days, to cryo-injured primate retinas demonstrated beneficial effects consistent with corneal endothelial recovery and a higher density of corneal endothelial cells with greater ZO-1 and Na / K ATPase expression. A similar treatment scheme was followed in four patients with central corneal edema and four with widespread corneal edema. No significant increase in visual acuity was detected, but beneficial reductions in corneal thickness and progression of remodeling were noted.
[0143] Treatment of organ-cultured human corneas with Y27632 demonstrated that cell viability was not compromised and cell proliferation was not induced by the treatment. Importantly, no toxicity was detected and the treatment promoted adhesion and enhanced wound healing.
[0144] diabetes ROCK activity is promoted in the renal cortex of the db / db mouse model of diabetes. The effects of ROCK inhibition on diabetic profile and nephropathy were assessed by 16-long intraperitoneal administration of fasudil, which produced a wide range of beneficial changes comparable to those of simvastatin, including reduced urinary albumin and collagen IV excretion, reductions in mesangial matrix and in glomerular basement membrane thickness.
[0145] A streptozotocin-induced diabetic rat model was used to evaluate ROCK inhibition as a potential modulator of diabetic microvascular retinopathy. Both activated Rho-GTP and phosphorylated MYPT1 were elevated in retinas from diabetic rats. Intravitreal injection of fasudil every 3 days for 2 weeks reversed the effects of neutrophils on retinal endothelial cells and reduced the number of dead or damaged cells.
[0146] Borderline significant increases in ROCK-I and ROCK-II were present in myocardial tissue from a streptozocin-induced rat model of diabetes. Coronary vasculature responded to fasudil (administered IV) with greater vasodilation than controls, in addition to a reduced incidence of segmental constriction. Together, these results indicate that ROCK inhibition promotes enhanced perfusion in the early diabetic heart.
[0147] Chronic and Neuropathic Pain The effect of the ROCK inhibitor AS1892802 was examined in monoiodoacetic acid-induced arthritis and streptozotocin-induced neuropathy rat models. While a single oral dose showed only a small and short-lived effect, frequent dosing induced a prolonged analgesic effect in both models.
[0148] Intrathecal administration of the ROCK inhibitor H-1152 had beneficial effects by reducing neuropathic pain induced by L5 spinal nerve transection and by reducing the magnitude of the second phase of pain in a formalin-induced model of inflammatory pain.
[0149] Stroke and ischemia Partial hepatic ischemia was performed in rats for 2 hours, followed by reperfusion. Pretreatment with the ROCK inhibitor Y27632 by oral administration resulted in a 75% increase in survival compared to 25% in vehicle-treated animals at 1 week after ischemia. Accordingly, treated animals also show higher hepatic tissue blood flow after ischemia, reduced sinusoidal derangement and necrosis, and improved liver function compared to controls. Thereby, ROCK inhibitor pretreatment plays a protective role in hepatic ischemia / reperfusion.
[0150] Ischemic reperfusion modeled by middle cerebral artery occlusion in rats was utilized to examine the effect of pretreatment with ROCK inhibitors 2 days before inducing ischemia. Pretreatment with either fasudil or Y27632 resulted in a reduction in infarct volume, restoration of eNOS levels, and improvement of neurological scores, indicating that ROCK inhibition may be beneficial for the management of cerebral ischemic events.
[0151] Animal models of stroke suggest that ROCK activation constitutes a pathogenic factor in stroke. Blood samples collected from patients suffering from acute ischemic stroke within 24 hours of the event showed that ROCK signaling was enhanced in leukocytes, peaking at 48 hours after the event. In vitro treatment of leukocytes with the ROCK inhibitor fasudil resulted in a decrease in ROCK signaling, indicating that enhanced ROCK signaling is common to human stroke and animal models.
[0152] Retinopathy In vivo intravitreal administration of the ROCK inhibitor AMA0428 in a laser-induced choroidal neovascularization (CNV) mouse model of macular degeneration showed several beneficial effects, including preventing the inflammatory response, reducing angiogenesis, vascular leakage, fibrosis, and choroidal neovascular area.
[0153] Spinal Muscular Atrophy (SMA) Mutations or deletions of the gene survival motor neuron 1 (SMN1) gene result in SMA. Smn depletion in mice induces increased activity of RhoA, prompting the use of ROCK inhibition as a promising therapeutic strategy. Survival, neuromuscular junction (NMJ) size, NMJ with mature terminals, and muscle histopathology were beneficially altered in the Smn2B / + mouse model of SMA in response to in vivo administration of the ROCK inhibitor Y27632.
[0154] Oral administration of fasudil resulted in improved survival, increased muscle fiber size, and increased postsynaptic endplate size in an Smn2B / + mouse model of SMA.
[0155] Erectile dysfunction The effects of chronic exposure to fasudil in a rat model of vasculogenic erectile dysfunction were examined. Treatment with fasudil for 6 weeks produced beneficial effects consisting of reduced pelvic atherosclerosis, lowered plasma levels of von Willebrand factor (an indicator of endothelial damage), normalized ROCK activation, eNOS expression, and rescued erectile function.
[0156] Nephropathy (non-hypertensive) In a puromycin-induced mouse model of nephrosis, treatment with the ROCK inhibitor Y-27632 improved renal function and histopathology, demonstrating that the beneficial effects of ROCK inhibition on nephropathy are not solely related to its effects on systemic blood pressure.
[0157] Hypertensive nephropathy In subtotally nephrectomized spontaneously hypertensive rats, treatment with the ROCK inhibitor fasudil had no effect on systolic blood pressure but improved the urinary protein excretion profile and reversed the histological profile of nephropathy.
[0158] Hypertension (high blood pressure) Administration of the ROCK inhibitor Y-27632 in three different models of hypertension in rats (spontaneous hypertension, renal hypertension, and DOCA-salt hypertension) reduced blood pressure to a greater extent than in control rats.
[0159] Optic nerve lesions The ROCK inhibitor Y-27632 dose-dependently increased retinal ganglion cell regeneration in a rat optic nerve crush model. Another RICK inhibitor, dimethylfasudil, showed a similar trend toward efficacy at intermediate concentrations. Similar positive results were reported after application of the ROCK inhibitor Y-39983 to the vitreous and crushed cat optic nerve.
[0160] Liver fibrosis Utilizing a rat model of dimethylnitrosamine-induced liver fibrosis, it was demonstrated that oral administration of the ROCK inhibitor Y-27632 reduced not only the levels of molecular markers of liver injury but also the development of liver fibrosis.
[0161] Lupus Peripheral blood mononuclear cells from systemic lupus erythematosus showed high levels of ROCK activity that also correlated with indicators of disease severity.Treatment with the ROCK inhibitor fasudil improved survival, renal function, and immune profile in a NZB / W F1 female mouse model of lupus, similar to what was reported in the MRL / lpr mouse model of lupus.
[0162] Post-transplant liver failure Treatment of both donor and recipient rats with the ROCK inhibitor Y-27632 resulted in improved survival of the recipients as well as reduced AST and ALT aminotransferase levels and reduced necrosis.
[0163] Encephalomyelitis ROCK inhibitors and the fasudil derivative FaD-1 reversed neurological dysfunction and reduced demyelination and neuroinflammation in a myelin oligodendrocyte glycoprotein (MOG 35-55) immunotherapy-induced mouse model of encephalomyelitis.
[0164] Epilepsy The ROCK inhibitors Y-27632 and fasudil reduced myoclonic, clonic, and tonic seizures in a kindling model of epilepsy.
[0165] Glioblastoma Intravenous fasudil limited the dispersion of eGFP-T98G glioblastoma cells seeded in the mouse striatum and increased animal survival.
[0166] In some embodiments, the condition or disorder is selected from Huntington's disease (HD), spinal cord and / or brain injury, chronic pulmonary hypertension, Parkinson's disease, amyotrophic lateral sclerosis, cerebral cavernous hemangioma, cardiovascular disease, Alzheimer's disease (AD), glaucoma, multiple sclerosis (MS), corneal lesions, diabetes, chronic and / or neuropathic pain, stroke, ischemia, retinopathy, spinal muscular atrophy (SMA), erectile dysfunction, nephropathy (non-hypertensive), hypertensive nephropathy, hypertension (elevated blood pressure), optic nerve lesions, hepatic fibrosis, lupus, post-transplant liver failure, encephalomyelitis, epilepsy, and glioblastoma.
[0167] In some embodiments, the condition or disorder is Huntington's disease.
[0168] Pharmaceutical Compositions and Methods of Administration In some embodiments, the compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or stereoisomer mixtures are administered as pharmaceutical compositions.Therefore, pharmaceutical compositions are provided that include at least one compound described herein or its deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or stereoisomer mixtures, together with at least one pharma- ceutically acceptable vehicle selected from carriers, adjuvants and excipients.The compounds of the present invention can be formulated into pharmaceutical compositions using techniques well known to those skilled in the art.
[0169] Pharmaceutically acceptable vehicles must be of sufficiently high purity and sufficiently low toxicity to make them suitable for administration to the animal being treated. The vehicle can be inert or it can have pharmaceutical benefits. The amount of vehicle utilized in conjunction with the compound or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers is sufficient to provide a practical amount of material for administration per unit dose of the compound or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers.
[0170] Exemplary pharma- ceutically acceptable carriers or components thereof are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and methylcellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants such as stearic acid and magnesium stearate; calcium sulfate; synthetic oils; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; polyols such as propylene glycol, glycerin, sorbitol, mannitol and polyethylene glycol; alginic acid; phosphate buffer solutions; emulsifiers such as TWEEN®; wetting agents such as sodium lauryl sulfate; colorants; flavorings; tabletting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.
[0171] Any active agent may be included in the pharmaceutical composition that does not substantially interfere with the activity of the compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers, or mixtures of stereoisomers.
[0172] An effective concentration of at least one compound described herein or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers is mixed with a suitable pharma- ceutically acceptable vehicle. In cases where the compound or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers exhibits insufficient solubility, methods for dissolving the compound may be used. Such methods are known to those skilled in the art and include, but are not limited to, using a co-solvent such as dimethylsulfoxide (DMSO), using a surfactant such as TWEEN®, or dissolving in aqueous sodium bicarbonate.
[0173] Upon mixing or addition of the compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers, the resulting mixture may be a solution, suspension, emulsion, etc. The form of the resulting mixture will depend on several factors, including the intended method of administration and the solubility of the compound or its deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers in the selected vehicle. Concentrations sufficient to ameliorate the symptoms of the disease being treated may be empirically determined.
[0174] The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers may be administered orally, topically, parenterally, intravenously, by intramuscular injection, by inhalation or aerosol, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, intravitreally, or by other means in a dosage unit formulation.
[0175] The pharmaceutical compositions may be formulated for oral use, such as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Pharmaceutical compositions intended for oral use may be prepared according to any method known to one of skill in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents, such as sweeteners, flavorings, colorants, and preservatives, to provide a medicamentically simple and palatable product. In some embodiments, the oral pharmaceutical composition contains 0.1-99% of at least one compound described herein, a deuterated analogue, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or a mixture of stereoisomers thereof. In some embodiments, the oral pharmaceutical composition contains at least 5% (by weight) of at least one compound described herein, a deuterated analogue, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or a mixture of stereoisomers thereof. In some embodiments, the composition contains 25%-50%, or 5%-75%, of at least one compound described herein or a deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof.
[0176] Orally administered pharmaceutical compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, etc. Pharmaceutically acceptable carriers suitable for preparing such compositions are well known in the art. Oral pharmaceutical compositions may also contain preservatives, flavoring agents, sweeteners such as sucrose or saccharin, taste masking agents, and coloring agents.
[0177] Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. Syrups and elixirs may be formulated with sweeteners, such as glycerol, propylene glycol, sorbitol or sucrose. Such pharmaceutical compositions may also contain a demulcent.
[0178] The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers, or mixtures of stereoisomers may be incorporated into oral liquid products such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs. Additionally, pharmaceutical compositions containing the compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers, or mixtures of stereoisomers may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid products may contain conventional additives such as suspending agents (e.g., sorbitol syrup, methylcellulose, glucose / sugar syrup, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gels and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monooleate or acacia), non-aqueous vehicles, which are edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p-hydroxybenzoates and sorbic acid).
[0179] For suspensions, typical suspending agents include methylcellulose, sodium carboxymethylcellulose, Avicel® RC-591, tragacanth, and sodium alginate, typical wetting agents include lecithin and polysorbate 80, and typical preservatives include methylparaben and sodium benzoate.
[0180] Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents may be naturally occurring phosphatides, such as lecithin, or condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain aliphatic alcohols, such as heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with fatty acids and partial esters derived from hexitols, such as polyethylene sorbitol substitutes, or condensation products of ethylene oxide with fatty acids and partial esters derived from hexitol anhydrides, such as polyethylene sorbitan substitutes. Aqueous suspensions may also contain one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate.
[0181] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral product. These pharmaceutical compositions may be preserved by the addition of an antioxidant, such as ascorbic acid.
[0182] The pharmaceutical composition may also be in the form of an oil-in-water emulsion.The oily phase may be a vegetable oil, such as olive oil or peanut oil, or a mineral oil, such as liquid paraffin, or a mixture thereof.Suitable suspending agents may be naturally occurring gums, such as gum acacia or gum tragacanth, naturally occurring phosphatides, such as soybean, lecithin, and esters or partial esters derived from fatty acids and hexitols, anhydrides, such as sorbitan monooleate, and the condensation products of the partial esters with ethylene oxide, such as polyethylene sorbitan monooleate.
[0183] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.
[0184] Tablets typically contain, as inert diluents, conventional pharma- ceutically acceptable adjuvants, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders, such as starch, gelatin and sucrose; disintegrants, such as starch, alginic acid and croscarmellose; lubricants, such as magnesium stearate, stearic acid and talc. Lubricants, such as silicon dioxide, can be used to improve the flow properties of the powder mixture. Coloring agents, such as FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint and fruit flavors, can be useful adjuvants for chewable tablets. Capsules (including time-release and sustained-release formulations) typically contain one or more solid diluents as disclosed above. The selection of carrier components is often driven by secondary considerations, such as taste, cost and storage stability.
[0185] Such pharmaceutical compositions may also be coated by conventional methods, typically with a pH or time dependent coating, such that the compound or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers is released in the gastrointestinal tract near the desired local application or at various times to prolong the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate, ethylcellulose, Eudragit® coatings, waxes and shellac.
[0186] Pharmaceutical compositions for oral use may also be presented as hard gelatin capsules, in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules, in which the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
[0187] The pharmaceutical composition may be in the form of a sterile injectable, aqueous or oleaginous suspension. The suspension may be formulated according to known techniques using those suitable dispersing or wetting agents and suspending agents mentioned above. The sterile injectable product may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable vehicle, for example, a solution in 1,3-butanediol. Among the acceptable vehicles that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any non-irritating fixed oil may be used, including synthetic mono- and diglycerides. In addition, fatty acids such as oleic acid may be useful in the preparation of injectables.
[0188] The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers may be administered parenterally in a sterile medium. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrathecal injections or infusion techniques. The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers may be either suspended or dissolved in the vehicle, depending on the vehicle or concentration used. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents may be dissolved in the vehicle. In many pharmaceutical compositions for parenteral administration, the carrier comprises at least 90% by weight of the total composition. In some embodiments, the carrier for parenteral administration is selected from propylene glycol, ethyl oleate, pyrrolidone, ethanol and sesame oil.
[0189] The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers may also be administered in the form of suppositories for rectal administration of the drug.These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at normal temperature but liquid at rectal temperature, and thus melts in the rectum to release the drug.Such materials include cocoa butter and polyethylene glycol.
[0190] The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers may be formulated for local or topical application, e.g., for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams and lotions, and for application to the eye. Topical pharmaceutical compositions may be in any form, including, for example, solutions, creams, ointments, gels, lotions, emulsions, cleansers, moisturizers, sprays, skin patches, and the like.
[0191] Such solutions may be formulated with appropriate salts, at 0.01% to 10% isotonic solutions, pH 5 to 7. The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers may also be formulated for transdermal administration as a transdermal patch.
[0192] Topical pharmaceutical compositions comprising at least one compound described herein or a deuterated analogue thereof, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers may be mixed with a variety of carrier materials known in the art, such as water, alcohol, aloe vera gel, allantoin, glycerin, vitamin A and E oil, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.
[0193] Other materials suitable for use in topical carriers include, for example, emollients, solvents, humectants, thickeners, and powders. Examples of each of these types of materials, which may be used alone or in mixtures with one or more other materials, are as follows:
[0194] Representative softening agents include stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecane-2-ol, isocetyl alcohol, cetyl palmitate, and dimethylpolysiloxane. , di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, peanut oil, castor oil, acetylated lanolin alcohol, petroleum oil, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate and myristyl myristate; propellants such as propane, porcine, glyceryl stearate, sorbitol, sorbitol stearate ... solvents such as ethyl alcohol, methylene chloride, isopropanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulfoxide, dimethylformamide, tetrahydrofuran; humectants such as glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate and gelatin; and powders such as chalk, talc, fuller's earth, kaolin, starch, gum, colloidal silicon dioxide, sodium polyacrylate, tetraalkylammonium smectites, trialkylarylammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymers, sodium carboxymethylcellulose and ethylene glycol monostearate.
[0195] The compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers may also be administered in liposome delivery systems. Liposomes may be classified into small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes may be formed from a variety of amphiphilic molecules, particularly phospholipids. Liposome constituents include cholesterol, stearylamine, and / or phosphatidylcholine. Liposomes are suitable for a variety of routes of administration, including topical and injection into a variety of tissues. Thus, intravitreal (e.g., in the treatment of glaucoma), intraperitoneal, intravenous, intravascular, intraarticular, and intramuscular administration of liposomes are contemplated.
[0196] Other pharmaceutical compositions useful for achieving systemic delivery of the compound or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers include sublingual, buccal and nasal dosage forms.Such pharmaceutical compositions typically contain one or more of soluble filler materials such as sucrose, sorbitol and mannitol, and binders such as acacia, microcrystalline cellulose, carboxymethylcellulose and hydroxypropylmethylcellulose.The lubricants, lubricants, sweeteners, colorants, antioxidants and flavorings disclosed above may also be included.
[0197] For inhalation, a pharmaceutical composition will typically be provided in the form of a solution, suspension or emulsion, which may be administered as a dry powder or in the form of an aerosol using conventional propellants such as dichlorodifluoromethane or trichlorofluoromethane.
[0198] The pharmaceutical compositions may also optionally include an enhancer. The enhancer may be selected from a wide variety of molecules that function in different ways to enhance the therapeutic effect of the compounds described herein or their deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers or mixtures of stereoisomers, or that are independent therefrom. Particular classes of enhancers include skin penetration enhancers and absorption enhancers.
[0199] The pharmaceutical composition may also contain additional active agents, which may be selected from a wide variety of molecules that may function to enhance in different ways the therapeutic effect of at least one compound described herein or a deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof. These optional other active agents, when present, are typically utilized in the pharmaceutical composition at levels ranging from 0.01% to 15%. In some embodiments, they comprise 0.1% to 10% by weight of the composition. In other embodiments, they comprise 0.5% to 5% by weight of the composition.
[0200] packaging Also provided are packaged pharmaceutical compositions. Such packaged compositions include a pharmaceutical composition comprising at least one compound described herein or a deuterated analog thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers, and instructions for using the composition to treat a subject (typically a human patient). In some embodiments, the instructions are for using the pharmaceutical composition to treat a subject suffering from a condition or disorder mediated by ROCK. The packaged pharmaceutical composition can include providing prescribing information, for example, to a patient or health care provider, or as a label in the packaged pharmaceutical composition. Prescribing information can include, for example, efficacy, dosage and administration, contraindications, and adverse reaction information related to the pharmaceutical composition.
[0201] In all of the foregoing, the compound or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers may be administered alone, as a mixture, or in combination with other active agents.
[0202] Combination treatment The methods described herein include methods of treating or preventing Huntington's disease, including treating loss of motor control, psychiatric symptoms, memory and / or cognitive impairment associated with Huntington's disease, comprising administering to a subject, either simultaneously or sequentially, at least one compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and one or more additional agents used in the treatment of Huntington's disease, including, but not limited to, carbamazepine, clonazepam, diazepam, fluoxetine, escitalopram, valproate, lamotrigine, amitriptyline, imipramine, desipramine, nortriptyline, paroxetine, fluoxetine, sertraline, tetrabenazine, haloperidol, chlorpromazine, thioridazine, sulpride, quetiapine, clozapine, and risperidone. In the method using simultaneous administration, the agent can be in a combination composition or can be administered separately.As a result, also provided are pharmaceutical compositions comprising at least one compound described herein or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and one or more additional pharmaceutical agents used in the treatment of Huntington's disease, including, but not limited to, carbamazepine, clonazepam, diazepam, fluoxetine, escitalopram, valproate, lamotrigine, amitriptyline, imipramine, desipramine, nortriptyline, paroxetine, fluoxetine, sertraline, tetrabenazine, haloperidol, chlorpromazine, thioridazine, sulpride, quetiapine, clozapine and risperidone.Also provided are packaged pharmaceutical compositions containing a pharmaceutical composition comprising at least one compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers, as well as another composition comprising one or more additional pharmaceutical agents used in the treatment of Huntington's disease, including, but not limited to, carbamazepine, clonazepam, diazepam, fluoxetine, escitalopram, valproate, lamotrigine, amitriptyline, imipramine, desipramine, nortriptyline, paroxetine, fluoxetine, sertraline, tetrabenazine, haloperidol, chlorpromazine, thioridazine, sulpride, quetiapine, clozapine, and risperidone.
[0203] Also provided is a method for treating or preventing Alzheimer's disease, including treating memory and / or cognitive impairment associated with Alzheimer's disease, comprising administering to a subject, simultaneously or sequentially, at least one compound described herein or its deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and one or more additional agents used in the treatment of Alzheimer's disease, including but not limited to Reminyl®, Cognex®, Aricept®, Exelon®, Acatinol®, Neotropin™, Eldepryl®, estrogen and clioquinol. In methods using simultaneous administration, the agents can be present in a combination composition or can be administered separately. Also provided are pharmaceutical compositions comprising at least one compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and one or more additional pharmaceutical agents used in the treatment of Alzheimer's disease, including, but not limited to, Reminyl®, Cognex®, Aricept®, Exelon®, Acatinol®, Neotropin™, Eldepryl®, estrogen, and Clioquinol. Also provided are packaged pharmaceutical compositions containing a pharmaceutical composition comprising at least one compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers, as well as another composition comprising one or more additional pharmaceutical agents used in the treatment of Alzheimer's disease, including, but not limited to, Reminyl®, Cognex®, Aricept®, Exelon®, Acatinol®, Neotropin™, Eldepryl®, estrogen, and Clioquinol.
[0204] In methods using simultaneous administration, the agents can be in a combination composition or can be administered separately. Also provided are pharmaceutical compositions comprising at least one compound described herein or a deuterated analog thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and one or more antitumor agents described herein. Also provided are packaged pharmaceutical compositions comprising a pharmaceutical composition comprising at least one compound described herein or a deuterated analog thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, and another composition comprising one or more antitumor agents described herein. When used in combination with one or more additional pharmaceutical agents, the compounds described herein may be administered prior to, simultaneously with, or subsequent to administration of the additional pharmaceutical agents.
[0205] dosage The dosage of the compounds described herein will depend on a variety of factors, including the particular syndrome to be treated, the severity of the symptoms, the route of administration, the frequency of dosing intervals, the particular compound utilized, the efficacy, toxicology profile, pharmacokinetic profile of the compound, and the presence of any adverse side effects, among other considerations.
[0206] The compounds described herein, or deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers, or mixtures of stereoisomers thereof, are typically administered at dosage levels and in manners customary for ROCK inhibitors. For example, the compounds, or deuterated analogs, pharma- ceutically acceptable salts, solvates, prodrugs, stereoisomers, or mixtures of stereoisomers thereof, may be administered by oral administration, in single or multiple doses, generally at dosage levels of 0.001-100 mg / kg / day, e.g., 0.01-100 mg / kg / day, e.g., 0.1-70 mg / kg / day, e.g., 0.5-10 mg / kg / day. A unit dosage form can generally contain 0.01-1000 mg of at least one compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers, for example, 0.1-50 mg of at least one compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers. For intravenous administration, the compounds can be administered at dosage levels of, for example, 0.001-50 mg / kg / day, for example, 0.001-10 mg / kg / day, for example, 0.01-1 mg / kg / day, in single or multiple doses. A unit dosage form can contain, for example, 0.1-10 mg of at least one compound described herein or a deuterated analogue thereof, a pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers.
[0207] Compound synthesis The compounds can be prepared using the methods disclosed herein and routine variations thereof that are evident from the disclosures herein and methods well known in the art. Conventional and well known synthetic methods can be used in addition to the teachings herein. The synthesis of exemplary compounds described herein can be achieved as described in the following examples. Where available, reagents can be purchased commercially, for example from Sigma Aldrich or other chemical suppliers.
[0208] The compounds of the present invention can be prepared, for example, from readily available starting materials using the following general methods and procedures. Where typical or preferred process conditions (i.e., reaction temperatures, times, molar ratios of reactants, solvents, pressures, etc.) are given, it is understood that other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the specific reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
[0209] In addition, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups and suitable conditions for protecting and deprotecting certain functional groups are well known in the art. For example, numerous protecting groups are described in Wuts, PGM, Greene, TW, & Greene, TW (2006). Greene's protective groups in organic synthesis. Hoboken, NJ, Wiley-Interscience and the references cited therein.
[0210] Furthermore, the compounds of the present invention may contain one or more chiral centers. Thus, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are within the scope of the present invention, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) can be prepared, for example, using optically active starting materials or stereoselective reagents well known in the art. Alternatively, racemic mixtures of such compounds can be separated, for example, using chiral column chromatography, supercritical fluid chromatography, chiral resolving agents, and the like.
[0211] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures described in standard reference works such as Fieser and Fieser's Reagents for Organic Synthesis, volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, volumes 1-5 and supplements (Elsevier Science Publishers, 1989) organic Reactions, volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th ed., 2001) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), or obvious modifications thereof.
[0212] The terms "solvent", "inert organic solvent" or "inert solvent" refer to a solvent that is inert under the conditions of the reaction being described therewith (e.g., benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine, and the like). Unless otherwise specified, the solvents used in the reactions of the present invention are inert organic solvents and the reactions are carried out under an inert gas, preferably nitrogen.
[0213] The term "qs" means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
[0214] It is also understood that the addition of any of the substituents in each of the above schemes may result in the production of multiple isomeric products (including but not limited to, enantiomers or one or more diastereomers), any or all of which may be isolated or purified using conventional techniques. Where enantiomerically pure or enriched compounds are desired, chiral chromatography and / or enantiomerically pure or enriched starting materials may be utilized as conventionally used in the art or as described in the Examples. EXAMPLES
[0215] The following examples are included to demonstrate specific embodiments of the disclosure. It should be understood by those skilled in the art that the techniques disclosed in the following examples represent fully functional techniques in the practice of the invention and can therefore be considered to constitute specific modes for its implementation. However, in light of the present invention, those skilled in the art should appreciate that numerous modifications can be made to the specific embodiments disclosed and still achieve similar results without departing from the spirit and scope of the invention.
[0216] Compounds were named using Cambridgesoft Chemistry Cartridge (v.16.0.0.82) software.
[0217] Analysis method Analysis method 1:
[0218] [Table 2]
[0219] Analysis method 2:
[0220] [Table 3]
[0221] Analysis method 3:
[0222] [Table 4]
[0223] Analysis method 4:
[0224] [Table 5]
[0225] SFC method: Analysis method SFC1:
[0226] [Table 6]
[0227] Analysis method SFC4:
[0228] [Table 7]
[0229] General synthesis method
[0230] [ka] [In the formula, R 1 , R 2 , R 5 , m, n, X and ring B are as defined herein.
[0231] Method A - Urea formation (in situ carbamate generation). To a stirred solution of 4-nitrophenyl chloroformate (0.5 mmol, 1 eq.) in DCM (2 mL) at rt was added dropwise a solution of the amine (0.5 mmol, 1 eq.) in DCM (1 mL) and TEA (1-3 eq.). The mixture was stirred at rt for 30 min, then a solution of piperazine (0.5 mmol, 1 eq.) in DCM (1 mL) was added (additional TEA was added if salt was used). The reaction mixture was then concentrated.
[0232] Method B - Urea formation To a stirred solution of activated carbamate (1 eq) in DCM (0.1 M) at rt was added piperazine (1.1 eq) and TEA (1-3 eq.). The mixture was stirred at rt for 2-17 h. The reaction mixture was washed with H2O and the biphasic mixture was passed through a phase separator. The organics were concentrated to dryness.
[0233] Method C-Boc deprotection Boc-piperazine (1 eq.) and 4N HCl were combined in dioxane (10 eq.) and stirred for 35 min to 24 h. The reaction mixture was then evaporated to dryness and used directly in the next step.
[0234] method ds N Ar coupling A solution of piperazine (1 eq.), fluorinated heterocycle (1 eq.) and Cs2CO3 (1 eq.) in anhydrous DMF (0.1 M) was stirred for 2-17 h at 80° C. The reaction was then diluted with EtOAc, washed with water (2x), dried (MgSO4) and evaporated to dryness.
[0235] Method E-Buchwald coupling A mixture of brominated pyridine (1 eq), Boc-protected piperazine (1.1 eq.), RuPhos Pd G1 (0.05 eq.), RuPhos (0.05 eq.), sodium tert-butoxide (1.1 eq.) in dry dioxane (ca. 0.1 M) was degassed with nitrogen for 10 min and then heated to 100° C. under nitrogen in a sealed tube for 18 h. The mixture was partitioned between EtOAc and saturated NaHCO3 solution. The organics were separated, washed with water and brine, passed through a phase separator and concentrated to dryness.
[0236] Method F - Activated Carbamate Formation 4-Nitrophenyl chloroformate (1.2 eq.) and dichloromethane (0.25M) were combined under nitrogen atmosphere. The amine (1 eq.) was added followed by pyridine (2.4 eq.). After 2-18 h, the reaction mixture was evaporated to dryness onto silica and purified by flash chromatography to give the activated carbamate.
[0237] If the amine is not commercially available, the following route:
[0238] [ka] [In the formula, R 1 and Ring B is as defined herein. from the corresponding aldehyde or carboxylic acid by
[0239] Method G - Weinreb Amide Formation A solution of 2-methylbenzofuran-4-carboxylic acid (1 eq.) in DCM (0.25 M) was treated with DIPEA (3.0 mL, 17.0 mmol), 1-hydroxybenzotriazole (1 eq., 5.68 mmol) and then N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.2 eq.). The reaction was stirred for 10 min, treated with N,O-dimethylhydroxylamine hydrochloride (1.5 eq.) and then stirred for 18 h. The mixture was washed with water, saturated NaHCO3 solution and brine before being passed through a hydrophobic frit and concentrated to near dryness. The residue was purified by column chromatography.
[0240] Method H - Reduction to aldehyde A solution of the Weinreb amide (1.18 g, 5.38 mmol) in anhydrous THF (0.1 M) was cooled to -78 °C under N2 and treated dropwise with lithium aluminum hydride (1 M in THF, 1.25 eq.). The reaction was allowed to warm to room temperature and stirred for 3 h. The mixture was cooled to 0 °C, quenched by the addition of EtOAc and poured into a rapidly stirring mixture of 10% citric acid solution and EtOAc. The organics were separated and washed with saturated NaHCO3 solution and brine before being passed through a hydrophobic frit and concentrated to dryness to give the aldehyde which was used without further purification.
[0241] Method I - Sulfinamide Formation The aldehyde (1 eq.) and THF (0.5M) were combined under nitrogen atmosphere. Ti(OiPr)4 (2 eq.) was added followed by (S)-(-)-2-methyl-propanesulfinamide (1 eq.). The reaction was stirred for 18 h and then quenched with water. The mixture was filtered through Celite and the filter cake was rinsed with DCM. The filtrate was extracted with DCM (4x) and the organics were combined and passed through a hydrophobic frit. The organics were evaporated to near dryness and the residue was purified by column chromatography.
[0242] Method J - Grignard addition A solution of the sulfinamide (1 eq., 366 mg, 1.39 mmol) in DCM (0.1 M) was cooled to -78 °C under N2 and treated dropwise with methylmagnesium bromide (3 M in diethyl ether, 2 to 4 eq.). The reaction was allowed to warm to room temperature and after 18 h the reaction was quenched with saturated aqueous NH4Cl, extracted with dichloromethane (2x), the organics passed through a hydrophobic frit, evaporated to near dryness and the residue purified by column chromatography.
[0243] 4-Nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1) [ka]
[0244] A stirred solution of p-nitrophenyl chloroformate (3.27 g, 16.3 mmol) in DCM (40 mL) was treated dropwise with a solution of (R)-1-(3-methoxyphenyl)ethylamine (2.00 mL, 13.5 mmol) and pyridine (1.3 mL, 16.3 mmol) in DCM (20 mL) at 0° C. under nitrogen. The reaction was allowed to warm to room temperature and stirred for 17 h. The mixture was diluted with DCM and washed with water, saturated NaHCO3 solution, 10% (wt / vol) citric acid solution and brine before being dried (phase separator) and concentrated to dryness. The crude material was purified by gradient column chromatography, 0-25% EtOAc in i-hexane to give the title compound. 1 H NMR (400 MHz, CDCl3) 8.23 (2H, d, J=9.2 Hz), 7.33 - 7.28 (3H, m), 6.95 (1H, d, J=7.7 Hz), 6.91 - 6.89 (1H, m), 6.87 - 6.83 (1H, m), 5.38 (1H, d, J=7.3 Hz), 4.93 - 4.85 (1H, m), 3.83 (3H, s), 1.58 (3H, d, J=6.3 Hz).
[0245] The following intermediates were prepared from commercially available starting materials as described below using the methods illustrated above:
[0246] [Table 8] TIFF0007593956000032.tif143169
[0247] 4-Nitrophenyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl-2,2,2-d3)carbamate (Intermediate 29)
[0248] [ka]
[0249] Step 1: 3-(Methoxy-d3)benzaldehyde 3-Hydroxybenzaldehyde (2 g, 16.3 mmol), potassium carbonate (2.3 g, 16.6 mmol), DMF (20 mL) and CD3-I (1 mL, 16.3 mmol) were combined and stirred at room temperature for 23 h. The reaction mixture was diluted with EtOAc, washed with water (3x), brine (1x), dried (MgSO4) and the organics were evaporated to dryness to give 3-(methoxy-d3)benzaldehyde.
[0250] Step 2: Follow Method I 3-(Methoxy-d3)benzaldehyde (2.27 g, 16.3 mmol) gave (S,E)-N-(3-(methoxy-d3)benzylidene)-2-methylpropane-2-sulfinamide.
[0251] Step 3: Follow Method J 3-(Methoxy-d3)benzaldehyde (2.27 g, 16.3 mmol) gave (S,E)-N-(3-(methoxy-d3)benzylidene)-2-methylpropane-2-sulfinamide.
[0252] Step 4: Follow Method C (S)-N-((R)-1-(3-(methoxy-d3)phenyl)ethyl-2,2,2-d3)-2-methylpropane-2-sulfinamide (2.18 g, 8.38 mmol) gave (R)-1-(3-(methoxy-d3)phenyl)ethane-2,2,2-d3-1-amine hydrochloride.
[0253] Step 5: Follow Method F (R)-1-(3-(methoxy-d3)phenyl)ethane-2,2,2-d3-1-amine hydrochloride (598 mg, 3.09 mmol) gave 4-nitrophenyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl-2,2,2-d3)carbamate.
[0254] 4-Nitrophenyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl)carbamate (Intermediate 30)
[0255] [ka]
[0256] Step 1: (R)-3-(1-aminoethyl)phenol (R)-1-(3-Methoxyphenyl)ethan-1-amine (1 g, 6.62 mmol) and dichloromethane (50 mL) were combined under a nitrogen atmosphere. The reaction was cooled in an ice bath and BBr3 (1.3 mL, 13.25 mmol) was added. The ice bath was removed and the reaction was stirred for 2 days. The reaction was cooled in an ice bath, quenched with MeOH and evaporated to dryness to give (R)-3-(1-aminoethyl)phenol, which was used directly in the next step.
[0257] Step 2: tert-Butyl (R)-(1-(3-hydroxyphenyl)ethyl)carbamate (R)-3-(1-aminoethyl)phenol (crude product from previous step), triethylamine (4 mL), dichloromethane (5 mL) and di-t-butyl dicarbonate (1.6 g, 7.33 mol) were combined and stirred for 1 h. The reaction mixture was then evaporated to dryness onto silica and purified by flash chromatography to give tert-butyl (R)-(1-(3-hydroxyphenyl)ethyl)carbamate.
[0258] Step 3: (R)-(1-(3-(methoxy-d3)phenyl)ethyl)carbamate tert-Butyl (R)-(1-(3-hydroxyphenyl)ethyl)carbamate (1.69 g), potassium carbonate (967 mg, 7 mmol), DMF (10 mL) and D3-iodomethane (0.41 mL, 6.62 mmol) were combined and stirred for 22 h. The reaction mixture was diluted with EtOAc and washed with water (2x) and brine (1x). Evaporation to dryness onto silica and purification by flash chromatography gave tert-butyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl)carbamate.
[0259] Step 4: (R)-1-(3-(methoxy-d3)phenyl)ethan-1-amine hydrochloride tert-Butyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl)carbamate (1.19 g, 4.68 mmol) and 4N HCl were combined in dioxane (10 mL) and stirred for 20 h. The reaction mixture was then evaporated to dryness to give (R)-1-(3-(methoxy-d3)phenyl)ethan-1-amine hydrochloride.
[0260] Step 5: (R)-(1-(3-(methoxy-d3)phenyl)ethyl)carbamate 4-Nitrophenyl chloroformate (1.09 g, 5.4 mmol) and dichloromethane (20 mL) were combined under nitrogen atmosphere. (R)-1-(3-(methoxy-d3)phenyl)ethan-1-amine hydrochloride (857 mg, 4.5 mmol) was added followed by pyridine (0.87 mL, 10.8 mmol). After 3 h, the reaction mixture was evaporated to dryness onto silica and purified by flash chromatography to give 4-nitrophenyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl)carbamate.
[0261] 4-Nitrophenyl(benzofuran-4-ylmethyl)carbamate (Intermediate 31)
[0262] [ka]
[0263] The intermediate was synthesized from benzofuran-4-carbonitrile following the literature procedure reported in Journal of Medicinal Chemistry, 59(7), 3215-3230; 2016.
[0264] The following intermediates were either commercially available or made via the methods described below.
[0265] [Table 9]
[0266] (R)-1-(2-Fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 33)
[0267] [ka]
[0268] Step 1: tert-Butyl (R)-4-(2-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxylate Method E was followed from tert-butyl (R)-3-methylpiperazine-1-carboxylate (1.5 g, 7.49 mmol) and 4-bromo-2-fluoropyridine (1.20 g, 6.81 mmol). Purification by flash silica chromatography (gradient elution i-hex / EtOAc) afforded the title compound.
[0269] (R)-1-(3-Fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34)
[0270] [ka]
[0271] Step 1: tert-Butyl (R)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxylate Method D was followed from tert-butyl (R)-2-methylpiperazine-1-carboxylate (1.0 g, 4.99 mmol) and 3,4-difluoropyridine (0.57 g, 4.99 mmol). Purification by flash silica chromatography (gradient elution i-hex to 50% EtOAc in i-hex) gave the title compound.
[0272] Step 2: (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride The title compound (1.78 mmol) was obtained from tert-butyl (R)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxylate (527 mg, 1.78 mmol) following method C.
[0273] (S)-1-(2-Fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 36)
[0274] [ka]
[0275] Step 1: tert-Butyl (S)-4-(2-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxylate Method D was followed from tert-butyl (S)-3-methylpiperazine-1-carboxylate (1.0 g, 4.99 mmol) and 3,4-difluoropyridine (0.57 g, 4.99 mmol). Purification by flash silica chromatography gave the title compound.
[0276] Step 2: (S)-1-(2-fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride The title compound was obtained from tert-butyl (S)-4-(2-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxylate (239 mg, 0.81 mmol) following Method C.
[0277] (R)-1-(2-Fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37)
[0278] [ka]
[0279] Step 1: Method E was followed. tert-Butyl (R)-2-methylpiperazine-1-carboxylate (1.5 g, 7.49 mmol) and 3-fluoro-4-bromopyridine (1.2 g, 6.81 mmol). Purification by flash silica chromatography (gradient elution i-hex to 50% EtOAc in i-hex) afforded the title compound.
[0280] Step 2: (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine HCl The title compound was obtained from tert-butyl (R)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxylate (1.47 g, 4.98 mmol) following method C.
[0281] (R)-1-(3-Fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 38)
[0282] [ka]
[0283] Step 1: tert-Butyl (R)-4-(3-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxylate Method E was followed from 4-bromo-3-fluoropyridine (250 mg, 1.42 mmol) and tert-butyl (R)-3-methylpiperazine-1-carboxylate (313 mg, 1.56 mmol). Purification by flash silica chromatography (5 to 100% EtOAc in i-hex) gave the title compound which was used in the next step.
[0284] Step 2: (R)-1-(3-fluoropyridin-4-yl)-2-methylpiperazine Tert-butyl (R)-4-(3-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxylate (166 mg, 0.56 mmol), acetonitrile (10 mL) and 4N HCl were combined in dioxane (1 mL) and stirred at room temperature for 18 h. The reaction mixture was then evaporated to dryness and azeotroped with toluene to give the crude diHCl salt of the title compound, which was used crude in the next step.
[0285] (S)-1-(3-Fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 39)
[0286] [ka]
[0287] Step 1: tert-Butyl (S)-4-(3-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxylate Method E was followed from 4-bromo-3-fluoropyridine (250 mg, 1.42 mmol) and tert-butyl (S)-3-methylpiperazine-1-carboxylate (313 mg, 1.56 mmol). The crude material was purified by Interchim reverse phase C18 column in acetonitrile and water with 1% formic acid to give the title compound.
[0288] Step 2: (S)-1-(3-fluoropyridin-4-yl)-2-methylpiperazine The title compound was obtained from tert-butyl (S)-4-(3-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxylate (172 mg, 0.56 mmol) following Method C and was used crude in the next step.
[0289] (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 40)
[0290] [ka]
[0291] Step 1: tert-Butyl (2R,6R)-4-(3-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxylate A suspension of 3,4-difluoropyridine (268 mg, 2.33 mmol), tert-butyl (2R,6R)-2,6-dimethylpiperazine-1-carboxylate (500 mg, 2.33 mmol) and TEA (1.0 mL, 7.0 mmol) in 1,4-dioxane was heated at 100 °C for 5 days. The reaction was filtered, concentrated and the residue was partitioned between EtOAc and saturated NaHCO3 solution. The organics were separated and washed with water and brine before passing through a phase separator and concentrating to dryness. The crude material was partially purified by gradient column chromatography 0-60% EtOAc in i-hex to give the title compound. The crude product was used in the next step.
[0292] Step 2: (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride The title compound was obtained from tert-butyl (2R,6R)-4-(3-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxylate (191 mg, 0.61 mmol) following method C. The crude product was used in the next step.
[0293] (3R,5R)-1-(2-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 41)
[0294] [ka]
[0295] Step 1: tert-Butyl (2R,6R)-4-(2-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxylate Method E was followed from 4-bromo-2-fluoropyridine (373 mg, 2.12 mmol) and tert-butyl (2R,6R)-2,6-dimethylpiperazine-1-carboxylate (500 mg, 2.33 mmol). Purification by gradient column chromatography, 0-100% EtOAc in iso-hexane afforded the title compound. 1 H NMR (400 MHz, CDCl3) 7.89 (1H, d, J=6.1 Hz), 6.39 (1H, d, J=5.8 Hz), 6.03 (1H, s), 4.25 - 4.24 (2H, m), 3.71 (2H, dd, J=3.8, 12.1 Hz), 3.36 (2H, d, J=11.9 Hz), 1.50 (9H, s), 1.25 (6H, d, J=6.6 Hz).
[0296] Step 2: (3R,5R)-1-(2-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride The title compound was obtained from tert-butyl (2R,6R)-4-(2-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxylate (0.56 g, 1.81 mmol) following method C. The crude product was used in the next step.
[0297] (R)-3-Ethyl-1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 42)
[0298] [ka]
[0299] Step 1: tert-Butyl (R)-2-ethyl-4-(3-fluoropyridin-4-yl)piperazine-1-carboxylate Method E was followed from tert-butyl (R)-2-ethylpiperazine-1-carboxylate (0.50 g, 2.33 mmol) and 3,4-difluoropyridine (0.27 g, 2.33 mmol). Purification by flash silica chromatography (i-hex to 100% EtOAc in i-hex gradient elution) gave the title compound.
[0300] Step 2: (R)-3-Ethyl-1-(3-fluoropyridin-4-yl)piperazine dihydrochloride The title compound was obtained from tert-butyl (R)-2-ethyl-4-(3-fluoropyridin-4-yl)piperazine-1-carboxylate (493 mg, 1.59 mmol) following method C. The crude product was used in the next step.
[0301] The final compounds were synthesized from the aforementioned intermediates via the synthesis described below.
[0302] Example 1 (R)-4-(2-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)-2-methylpiperazine-1-carboxamide
[0303] [ka]
[0304] Method B was followed from Intermediate 37 (250 mg, 1.08 mmol) and 4-nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 341 mg, 1.08 mmol). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 373 (M+H). + , RT 3.06 minutes (Analysis method 1) 1 H NMR (400 MHz, DMSO) 7.80 (1H, d, J=6.1 Hz), 7.22 (1H, dd, J=8.1, 8.1 Hz), 6.91 - 6.89 (2H, m), 6.82 - 6.76 (3H, m), 6.50 - 6.48 (1H, m), 4.89 - 4.80 (1H, m), 4.33 - 4.29 (1H, m), 3.86 - 3.77 (3H, m), 3.74 (3H, s), 3.20 - 3.09 (2H, m), 2.99 - 2.90 (1H, m), 1.37 (3H, d, J=7.2 Hz), 1.06 (3H, d, J=6.5 Hz), 6.83 - 6.75 (2H, m), 6.71 (1H, d, J=6.4 Hz), 4.89 - 4.81 (1H, m), 4.36 - 4.32 (1H, m), 3.87 (1H, d, J=13.2 Hz), 3.75 (3H, s), 3.66 (2H, dd, J=12.5, 19.8 Hz), 3.19 - 3.09 (2H, m), 2.98 - 2.90 (1H, m), 1.37 (3H, d, J=7.1 Hz), 1.14 (3H, d, J=6.6 Hz).
[0305] Example 2 (R)-1-(3-Methoxyphenyl)ethyl (R)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxylate
[0306] [ka]
[0307] Method A was followed from 4-nitrophenyl chloroformate (100 mg, 0.497 mmol) in DCM (2 mL), (R)-1-(3-methoxyphenyl)ethan-1-ol (75 mg, 0.493 mmol) in DCM (2 mL) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 134 mg, 0.493 mmol) and TEA (0.21 mL, 1.48 mmol) in DCM (5 mL). After 3 days the reaction mixture was washed with saturated NaHCO3 solution and brine, passed through a hydrophobic frit and concentrated to dryness. Purification by preparative HPLC gave the title compound. LCMS (ES+) 374 (M+H) + , RT 3.37 minutes (Analysis method 2) 1 H NMR (400 MHz, CDCl3) 7.89 (1H, d, J=6.1 Hz), 7.30 - 7.26 (1H, m), 6.93 (1H, d, J=7.7 Hz), 6.88 (1H, s), 6.83 (1H, dd, J=2.4, 8.1 Hz), 6.49 (1H, d, J=6.0 Hz), 6.14 (1H, s), 5.83 (1H, q, J=6.6 Hz), 4.46 - 4.39 (1H, m), 4.05 - 3.98 (1H, m), 3.81 (3H, s), 3.70 - 3.64 (1H, m), 3.54 (1H, d, J=12.6 Hz), 3.42 - 3.25 (2H, m), 3.12 - 3.04 (1H, m), 1.56 (3H, d, J=6.5 Hz), 1.24 (3H, d, J=6.6 Hz).
[0308] Example 3 (R)-N-((R)-1-(2-chloro-5-methoxyphenyl)ethyl)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0309] [ka]
[0310] Method B was followed from 4-nitrophenyl (R)-(1-(2-chloro-5-methoxyphenyl)ethyl)carbamate (Intermediate 4, 0.222 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 0.222 mmol). Purification by preparative HPLC afforded the title compound (48 mg). LCMS (ES+) 407 (M+H) + , RT 3.24 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 7.81 (1H, d, J=6.2 Hz), 7.27 (1H, d, J=8.7 Hz), 6.98 (1H, d, J=2.9 Hz), 6.83 - 6.76 (2H, m), 6.44 (1H, dd, J=2.3, 2.3 Hz), 5.29 - 5.23 (1H, m), 4.42 - 4.36 (1H, m), 3.96 - 3.79 (3H, m), 3.79 (3H, s), 3.42 - 3.34 (2H, m, unclear), 3.19 - 3.10 (1H, m), 1.46 (3H, d, J=7.1 Hz), 1.23 (3H, d, J=6.6 Hz).
[0311] Example 4 (R)-4-(2-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(2-methylbenzofuran-4-yl)ethyl)piperazine-1-carboxamide
[0312] [ka]
[0313] Method B was followed from 4-nitrophenyl (R)-(1-(2-methylbenzofuran-4-yl)ethyl)carbamate (Intermediate 5, 0.138 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 0.138 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 397 (M+H) + , RT 3.26 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 7.80 (1H, d, J=6.2 Hz), 7.28 (1H, dd, J=3.1, 6.0 Hz), 7.18 - 7.15 (2H, m), 6.76 (1H, d, J=6.9 Hz), 6.62 (1H, s), 6.42 (1H, dd, J=2.3, 2.3 Hz), 5.31 - 5.23 (1H, m), 4.39 - 4.34 (1H, m), 3.95 - 3.77 (3H, m), 3.39 - 3.29 (2H, m, unclear), 3.34 (2H, s), 3.17 - 3.08 (1H, m), 2.46 (3H, s), 1.57 (3H, d, J=7.1 Hz), 1.22 (3H, d, J=6.7 Hz).
[0314] Example 5 (R)-N-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0315] [ka]
[0316] Method B was followed from 4-nitrophenyl((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)carbamate (Intermediate 6, 0.213 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 0.213 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 409 (M+H) + , RT 3.19 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 7.81 (1H, d, J=6.2 Hz), 7.14 - 7.10 (3H, m), 6.77 (1H, dd, J=2.0, 4.3 Hz), 6.43 (1H, dd, J=2.1, 2.1 Hz), 4.49 (2H, dd, J=15.5, 18.6 Hz), 4.33 (1H, ddd, J=3.3, 6.6, 13.3 Hz), 3.94 - 3.78 (3H, m), 3.44 - 3.36 (2H, m), 3.20 - 3.12 (1H, m), 1.25 (3H, d, J=6.6 Hz).
[0317] Example 6 (R)-N-(benzo[d][1,3]dioxol-4-ylmethyl)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0318] [ka]
[0319] Method B was followed from 4-nitrophenyl(benzo[d][1,3]dioxol-4-ylmethyl)carbamate (Intermediate 7, 0.237 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 0.237 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 373 (M+H) + , RT 2.95 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 7.81 (1H, d, J=6.2 Hz), 6.81 (2H, d, J=4.9 Hz), 6.78 - 6.73 (2H, m), 6.43 (1H, dd, J=2.1, 2.1 Hz), 5.96 (2H, s), 4.41 - 4.30 (3H, m), 3.93 - 3.77 (3H, m), 3.42 - 3.35 (2H, m), 3.20 - 3.12 (1H, m), 1.24 (3H, d, J=6.7 Hz).
[0320] Example 7 (R)-N-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0321] [ka]
[0322] Method B was followed from 4-nitrophenyl((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)carbamate (Intermediate 8, 0.227 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 0.227 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 387 (M+H) + , RT 2.98 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 7.81 (1H, d, J=6.2 Hz), 6.80 - 6.74 (4H, m), 6.43 (1H, dd, J=2.3, 2.3 Hz), 4.40 - 4.25 (7H, m), 3.93 - 3.77 (3H, m), 3.43 - 3.35 (2H, m), 3.21 - 3.13 (1H, m), 1.24 (3H, d, J=6.6 Hz).
[0323] Example 8 (R)-N-(benzofuran-4-ylmethyl)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0324] [ka]
[0325] Method B was followed from (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 145 mg, 0.63 mmol) and 4-nitrophenyl(benzofuran-4-ylmethyl)carbamate (Intermediate 9, 200 mg, 0.63 mmol). Purification by SCX afforded the title compound. LCMS (ES+) 373 (M+H). + , RT 2.82 minutes (Analysis method 1), 1 H NMR (400 MHz, MeOD) 7.82 - 7.76 (2H, m), 7.43 - 7.40 (1H, m), 7.29 - 7.17 (2H, m), 7.01 (1H, dd, J=1.0, 2.3 Hz), 6.78 - 6.75 (1H, m), 6.42 (1H, t, J=2.2 Hz), 4.67 (2H, d, J=8.9 Hz), 4.39 - 4.32 (1H, m), 3.95 - 3.78 (3H, m), 3.39 (2H, d, J=19.5 Hz), 3.20 - 3.12 (1H, m), 1.23 (3H, d, J=6.7 Hz).
[0326] Examples 9 and 10 (R)-4-(2-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)piperazine-1-carboxamide and (R)-4-(2-fluoropyridin-4-yl)-2-methyl-N-((S)-1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)piperazine-1-carboxamide
[0327] [ka]
[0328] Method B was followed from 4-nitrophenyl-(1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)carbamate (Intermediate 10, 0.70 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 0.56 mmol). Purification by preparative HPLC and SFC to separate the isomers afforded the title compound.
[0329] Example 9: LCMS (ES+) 397 (M+H) + , RT 2.34 minutes (Analysis method 1), 1 H NMR (400 MHz, MeOD) 7.81 (1H, d, J=6.3 Hz), 7.42 (1H, d, J=7.9 Hz), 7.35 (1H, s), 7.24 (1H, dd, J=7.1, 9.0 Hz), 6.96 (1H, d, J=6.9 Hz), 6.78 (1H, dd, J=1.8, 4.1 Hz), 6.44 (1H, dd, J=2.1, 2.1 Hz), 5.87 (1H, q, J=6.8 Hz), 4.44 - 4.38 (1H, m), 3.95 - 3.80 (3H, m), 3.45 - 3.36 (2H, m), 3.19 - 3.11 (1H, m), 2.85 (3H, s), 1.59 (3H, d, J=6.9 Hz), 1.24 (3H, d, J=6.7 Hz); SFC RT 1.3 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 55% IPA).
[0330] Example 10: LCMS (ES+) 397 (M+H) + , RT 2.78 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 7.81 (1H, d, J=6.3 Hz), 7.44 - 7.42 (1H, m), 7.37 (1H, s), 7.26 (1H, dd, J=7.0, 8.9 Hz), 6.98 (1H, d, J=6.5 Hz), 6.78 (1H, dd, J=1.9, 4.3 Hz), 6.44 (1H, dd, J=2.1, 2.1 Hz), 5.88 (1H, q, J=6.9 Hz), 4.41 - 4.36 (1H, m), 3.98 - 3.89 (2H, m), 3.81 (1H, dd, J=1.2, 13.2 Hz), 3.44 - SFC RT 2.13 minutes (SFC4, LUX Cellulose-4 + 0.1% DEAISO 55% IPA).
[0331] Example 11 (R)-4-(2-fluoropyridin-4-yl)-2-methyl-N-((2-methyl-2H-indazol-4-yl)methyl)piperazine-1-carboxamide
[0332] [ka]
[0333] Method A was followed from 4-aminomethyl-2-methyl-indazole dihydrochloride (65 mg, 0.331 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 90 mg, 0.331 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 383 (M+H) + , RT 2.79 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.29 (1H, s), 7.81 (1H, d, J=6.2 Hz), 7.50 (1H, d, J=8.7 Hz), 7.27 (1H, dd, J=6.8, 8.7 Hz), 7.01 (1H, d, J=6.8 Hz), 6.77 (1H, d, J=6.2 Hz), 6.42 (1H, dd, J=2.3, 2.3 Hz), 4.67 (2H, d, J=4.2 Hz), 4.39 - 4.34 (1H, m), 4.23 (3H, s), 3.96 - 3.77 (3H, m), 3.44 - 3.37 (2H, m), 3.20 - 3.12 (1H, m), 1.24 (3H, d, J=6.7 Hz).
[0334] Example 12 (R)-N-((R)-1-(benzo[d][1,3]dioxol-4-yl)ethyl)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0335] [ka]
[0336] Method A was followed from (R)-1-(benzo[d][1,3]dioxol-4-yl)ethan-1-amine dihydrochloride (45 mg, 0.224 mmol) and (R)-1-(2-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 37, 60 mg, 0.224 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 387 (M+H). + , RT 3.09 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.12 (1H, d, J=5.7 Hz), 7.01 (1H, dd, J=5.7, 8.3 Hz), 6.81 (2H, d, J=4.5 Hz), 6.73 (1H, dd, J=4.5, 4.5 Hz), 5.97 (2H, d, J=7.2 Hz), 5.13 - 5.05 (1H, m), 4.39 - 4.36 (1H, m), 3.95 (1H, d, J=13.3 Hz), 3.77 - 3.69 (2H, m), 3.34 (1H, m), 3.18 (1H, dd, J=3.5, 12.5 Hz), 3.05 - 2.97 (1H, m), 1.50 (3H, d, J=7.1 Hz), 1.32 (3H, d, J=6.6 Hz).
[0337] Example 13 (R)-N-((R)-1-(2-chlorophenyl)ethyl)-4-(2-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxamide
[0338] [ka]
[0339] Method B was followed from (R)-1-(2-fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 33, 54 mg, 0.23 mmol) and Intermediate 3 (75 mg, 0.23 mmol). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 377 (M+H). + , RT 3.27 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 7.82 (1H, d, J=6.1 Hz), 7.48 (1H, dd, J=1.5, 7.7 Hz), 7.38 (1H, d, J=7.7 Hz), 7.32 (1H, dd, J=7.1, 7.1 Hz), 7.26 - 7.21 (1H, m), 7.03 (1H, d, J=7.5 Hz), 6.78 (1H, d, J=6.2 Hz), 6.46 (1H, s), 5.22 - 5.17 (1H, m), 4.19 - 4.17 (1H, m), 4.04 (1H, d, J=13.3 Hz), 3.94 (1H, d, J=13.3 Hz), 3.69 - 3.64 (1H, m), 3.17 - 2.94 (3H, m), 1.35 (3H, d, J=7.1 Hz), 1.06 (3H, d, J=6.5 Hz).
[0340] Example 14 (R)-N-((R)-1-(2-chloro-4-fluorophenyl)ethyl)-4-(2-fluoropyridin-4-yl)-3-methylpiperazine-1-carboxamide
[0341] [ka]
[0342] Method B was followed from (R)-1-(2-fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 33, 63 mg, 0.19 mmol) and 4-nitrophenyl(1-(2-chloro-4-fluorophenyl)ethyl)carbamate (Intermediate 11, 43 mg, 0.19 mmol). Purification by prep-HPLC and chiral SFC afforded the title compound. Percentage ee: 100%. LCMS (ES+) 395 (M+H) + , RT 3.24 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 7.82 (1H, d, J=6.1 Hz), 7.53 - 7.48 (1H, m), 7.38 - 7.35 (1H, m), 7.25 - 7.19 (1H, m), 7.03 (1H, d, J=7.4 Hz), 6.77 (1H, d, J=6.1 Hz), 6.45 (1H, s), 5.20 - 5.12 (1H, m), 4.20 - 4.16 (1H, m), 4.03 (1H, dd, J=1.1, 12.4 Hz), 3.92 (1H, d, J=13.3 Hz), 3.69 - 3.64 (1H, m), 3.16 - 2.94 (3H, m), 1.36 - 1.33 (3H, m), 1.05 (3H, d, J=6.5 Hz); SFC RT 3.36 min (SFC4, YMC amylose-C + 0.1% DEAISO 20% IPA).
[0343] Example 15 (2R,6R)-4-(2-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)-2,6-dimethylpiperazine-1-carboxamide
[0344] [ka]
[0345] Method B was followed from (3R,5R)-1-(2-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 41, 85 mg, 0.316 mmol) and 4-nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 100 mg, 0.316 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 387 (M+H). + , RT 4.08 minutes (Analysis method 4), 1H NMR (400 MHz, MeOD) 7.82 (1H, d, J=6.2 Hz), 7.25 (1H, dd, J=7.8, 7.8 Hz), 6.95 (2H, d, J=7.3 Hz), 6.82 - 6.79 (1H, m), 6.66 (1H, d, J=6.2 Hz), 6.45 (1H, d, J=7.7 Hz), 6.30 (1H, dd, J=2.2, 2.2 Hz), 5.05 - 4.96 (1H, m), 4.36 (2H, dd, J=2.4, 2.4 Hz), 3.83 - 3.77 (5H, m), 3.57 (2H, d, J=11.6 Hz), 1.52 (3H, d, J=7.1 Hz), 1.28 (6H, d, J=6.7 Hz).
[0346] Example 16 (R)-4-(3-fluoropyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)piperazine-1-carboxamide
[0347] [ka]
[0348] Step 1: (R)-4-((1-(3-methoxyphenyl)ethyl)carbamoyl)piperazine-1-carboxylate The title compound was obtained from tert-butyl piperazine-1-carboxylate (162 mg, 0.87 mmol) and 4-nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 250 mg, 0.79 mmol) according to method B.
[0349] Step 2: (R)-N-(1-(3-methoxyphenyl)ethyl)piperazine-1-carboxamide hydrochloride The title compound was obtained from tert-butyl (R)-4-((1-(3-methoxyphenyl)ethyl)carbamoyl)piperazine-1-carboxylate (90 mg, 0.248 mmol) following method C. The crude product was used in the next step.
[0350] Step 3: (R)-4-(3-fluoropyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)piperazine-1-carboxamide A mixture of (R)-N-(1-(3-methoxyphenyl)ethyl)piperazine-1-carboxamide hydrochloride (65 mg, 0.247 mmol), 3-fluoro-4-iodopyridine (110 mg, 0.494 mmol), sodium tert-butoxide (95 mg, 0.988 mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (16 mg, 0.025 mmol) in toluene (1 mL) was degassed with N2 for 10 min and then heated at 115°C in a CEM microwave for 1 h. The reaction was charged with EtOAc, washed with brine, passed through an SPE cartridge to dryness and evaporated to give the crude product. The crude product was purified by preparative HPLC to give the title compound. LCMS (ES+) 359 (M+H) + , RT 2.93 minutes (Analysis method 2), 1 H NMR (400 MHz, DMSO), 8.29 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.5 Hz), 7.22 (1H, dd, J=8.1, 8.1 Hz), 7.01 (1H, dd, J=5.5, 8.3 Hz), 6.92 - 6.87 (3H, m), 6.78 (1H, dd, J=2.1, 8.1 Hz), 4.87 - 4.79 (1H, m), 3.75 (3H, s), 3.50 (4H, dd, J=5.0, 5.0 Hz), 3.23 (4H, dd, J=5.0, 5.0 Hz), 1.37 (3H, d, J=7.2 Hz).
[0351] Example 17 (R)-1-(3-Methoxyphenyl)ethyl 4-(3-fluoropyridin-4-yl)piperazine-1-carboxylate
[0352] [ka]
[0353] To a stirred solution of 4-nitrophenyl chloroformate (132 mg, 0.657 mmol) in DCM (5 mL) at rt was added a solution of (R)-1-(3-methoxyphenyl)ethan-1-ol (100 mg, 0.657 mmol) and TEA (0.27 mL, 1.97 mmol) in DCM (5 mL) dropwise. The mixture was stirred at rt for 30 min and then treated with 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 167 mg, 0.657 mmol). After 2 days the reaction mixture was washed with saturated NaHCO3 solution and brine, passed through a hydrophobic frit and concentrated to dryness. Purification by preparative HPLC afforded the title compound. LCMS (ES+) 360 (M+H) + , RT 2.30 minutes (Analysis method 2), 1 H NMR (400 MHz, CDCl3) 8.25 (1H, d, J=5.4 Hz), 8.19 (1H, d, J=5.4 Hz), 7.30 - 7.25 (1H, m), 6.94 (1H, d, J=7.7 Hz), 6.89 (1H, s), 6.83 (1H, dd. Hz), 1.56 (3H, d, J=6.5 Hz).
[0354] Example 18 (R)-N-(1-(2-fluoro-3-methoxyphenyl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0355] [ka]
[0356] Method A was followed from (R)-1-(2-fluoro-3-methoxyphenyl)ethan-1-amine hydrochloride (0.414 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.414 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 377 (M+H). + , RT 2.96 minutes (Analysis method 2), 1 H NMR (400 MHz, DMSO) 8.29 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.4 Hz), 7.09 (1H, dd, J=8.1, 8.1 Hz), 7.03 - 6.94 (4H, m), 5.13 - 5.08 (1H, m), 3.83 (3H, s), 3.50 (4H, dd, J=5.0, 5.0 Hz), 3.23 (4H, dd, J=5.0, 5.0 Hz), 1.36 (3H, d, J=7.1 Hz).
[0357] Example 19 (R)-N-(1-(2-bromophenyl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0358] [ka]
[0359] Method A was followed from (R)-1-(2-bromophenyl)ethan-1-amine hydrochloride (0.414 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.414 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 407 (M+H). + , RT 3.11 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.29 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.5 Hz), 7.55 (1H, d, J=7.8 Hz), 7.50 - 7.47 (1H, m), 7.38 (1H, dd, J=7.3, 7.3 Hz), 7.18 - 7.13 (1H, m), 7.10 (1H, d, J=7.3 Hz), 7.02 (1H, dd, J=5.6, 8.3 Hz), 5.14 - 5.09 (1H, m), 3.51 (4H, dd, J=5.0, 5.0 Hz), 3.24 (4H, dd, J=5.0, 5.0 Hz), 1.34 (3H, d, J=7.0 Hz).
[0360] Example 20 (R)-N-((R)-1-(2-chlorophenyl)ethyl)-4-(2-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0361] [ka]
[0362] Method B was followed from 4-nitrophenyl (R)-(1-(2-chloro-3-methoxyphenyl)ethyl)carbamate (Intermediate 23, 0.60 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.60 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate minor amounts of the (S) isomer afforded the title compound. LCMS (ES+) 393 (M+H). + , RT 3.05 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.29 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.5 Hz), 7.29 (1H, dd, J=8.0, 8.0 Hz), 7.09 - 6.98 (4H, m), 5.24 - 5.15 (1H, SFC RT 4.28 min (SFC1, YMC amylose-C + 0.1% DEAISO 25% IPA).
[0363] Example 21 (R)-N-(1-(2-chloro-4-fluorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0364] [ka]
[0365] Method B was followed from 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 40 mg, 0.19 mmol) and 4-nitrophenyl(1-(2-chloro-4-fluorophenyl)ethyl)carbamate (Intermediate 11, 63 mg, 0.19 mmol). Purification by prep-HPLC afforded the title compound. Percentage ee: 84.1%. LCMS (ES+) 381 (M+H) + , RT 2.62 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.29 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.4 Hz), 7.52 (1H, dd, J=6.3, 8.7 Hz), 7.37 (1H, dd, J=2.6, 8.9 Hz), 7.26 - SFC RT 1.7 min (SFC1, YMC amylose-C + 0.1% DEAISO 25% EtOH).
[0366] Examples 22 and 23 N-(1-(2-chloro-3-fluorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide (enantiomer 1) and N-(1-(2-chloro-3-fluorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide (enantiomer 2).
[0367] [ka]
[0368] Method B was followed from 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 74 mg, 0.34 mmol) and 4-nitrophenyl(1-(2-chloro-3-fluorophenyl)ethyl)carbamate (Intermediate 12, 115 mg, 0.34 mmol). Purification by prep-HPLC and chiral SFC afforded the title compound.
[0369] Example 22: Percentage ee: 98.2%. LCMS (ES+) 381 (M+H) + , RT 3.13 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.08 - 7.99 (2H, m), 7.22 - 7.13 (2H, m), 7.03 - 6.97 (1H, m), 6.91 - 6.86 (1H, m), 5.23 - 5.16 (1H, m), 3.52 - 3.48 (4H, m), 3.28 - 3.24 (4H, m), 1.36 - 1.33 (3H, m); SFC RT 1.76 min (SFC4, YMC amylose-C + 0.1% DEAISO 20% EtOH).
[0370] Example 23: Percentage ee: 100%. LCMS (ES+) 381 (M+H) + , RT 3.13 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.17 (2H, dd, J=5.8, 26.2 Hz), 7.36 - 7.26 (2H, m), 7.16 - 7.10 (1H, m), 7.02 (1H, dd, J=5.7, 8.2 Hz), 5.32 (1H, q, SFC RT 2.73 min (SFC4, YMC amylose-C + 0.1% DEAISO 20% EtOH).
[0371] Example 24 (R)-N-(1-(2-chloro-5-methoxyphenyl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0372] [ka]
[0373] Method B was followed from 4-nitrophenyl (R)-(1-(2-chloro-5-methoxyphenyl)ethyl)carbamate (Intermediate 4, 0.222 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.222 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 393 (M+H) + , RT 3.15 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.20 (1H, d, J=6.0 Hz), 8.13 (1H, d, J=5.6 Hz), 7.27 (1H, d, J=8.8 Hz), 7.04 - 6.99 (2H, m), 6.81 (1H, dd, J=3.1, 8.8 SFC RT 2.59 min (SFC1, LUX cellulose-4 + 0.1% DEAISO 40% MeOH).
[0374] Example 25 4-(3-fluoropyridin-4-yl)-N-(3-methoxybenzyl)piperazine-1-carboxamide
[0375] [ka]
[0376] Method A was followed from (3-methoxyphenyl)methanamine (0.31 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.31 mmol). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 354 (M+H). + , RT 2.97 minutes (Analysis method 2). 1H NMR (400 MHz, DMSO) 8.29 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.5 Hz), 7.26 - 7.16 (2H, m), 7.01 (1H, dd, J=5.5, 8.3 Hz), 6.86 (2H, d, J=7.0 Hz), 6.80 (1H, dd, J=1.8, 7.2 Hz), 4.25 (2H, d, J=5.8 Hz), 3.74 (3H, s), 3.51 (4H, dd, J=5.1, 5.1 Hz), 3.24 (4H, dd, J=5.0, 5.0 Hz).
[0377] Example 26 N-(1-(2-chloro-6-fluorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0378] [ka]
[0379] Method B was followed from 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 40 mg, 0.19 mmol) and 4-nitrophenyl(1-(2-chloro-6-fluorophenyl)ethyl)carbamate (Intermediate 13, 170 mg, 0.50 mmol). Purification by prep-HPLC afforded the title compound. ee: 49.1%. LCMS (ES+) 381 (M+H) + , RT 2.74 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.28 (1H, d, J=5.6 Hz), 8.16 (1H, d, J=5.4 Hz), 7.30 - 7.15 (2H, m), 7.00 (1H, dd, J=5.6, 8.2 Hz), 6.90 (1H, d, J=6.5 SFC RT 4.06 min (SFC1, LUX cellulose-4 + 0.1% DEAISO 30% MeOH).
[0380] Example 27 (R)-N-(1-(benzo[d][1,3]dioxol-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0381] [ka]
[0382] Method A was followed from (R)-1-(benzo[d][1,3]dioxol-4-yl)ethan-1-amine hydrochloride (45 mg, 0.224 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 57 mg, 0.224 mmol). Purification by preparative HPLC afforded the title compound after lyophilization. LCMS (ES+) 373 (M+H). + , RT 3.00 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.13 (1H, d, J=5.6 Hz), 7.01 (1H, dd, J=5.7, 8.1 Hz), 6.83 - 6.81 (2H, m), 6.73 (1H, dd, J=3.2, 5.7 Hz), 5.97 (2H, d, J=8.4 Hz), 5.07 (1H, q, J=7.1 Hz), 3.63 (4H, dd, J=3.9, 6.3 Hz), 3.42 - 3.38 (4H, m), 1.49 (3H, d, J=7.1 Hz).
[0383] Example 28 (R)-N-(1-(2,3-dihydrobenzofuran-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0384] [ka]
[0385] Method A was followed from (R)-1-(2,3-dihydrobenzofuran-4-yl)ethan-1-amine hydrochloride (0.56 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.56 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 371 (M+H). + , RT 3.13 minutes (Analysis method 2). 1H NMR (400 MHz, DMSO) 8.26 (1H, d, J=5.6 Hz), 8.14 (1H, d, J=5.5 Hz), 7.04 (1H, dd, J=7.8, 7.8 Hz), 6.98 (1H, dd, J=5.3, 8.2 Hz), 6.87 (1H, d, J=7.8 Hz), 6.83 (1H, d, J=7.8 Hz), 6.58 (1H, d, J=7.8 Hz), 4.84 - 4.75 (1H, m), 4.53 - 4.47 (2H, m), 3.47 (4H, dd, J=5.0, 5.0 Hz), 3.23 - 3.15 (6H, m), 1.33 (3H, d, J=7.1 Hz).
[0386] Example 29 (R)-N-(1-(benzofuran-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0387] [ka]
[0388] Method A was followed from (R)-1-(benzofuran-4-yl)ethan-1-amine (0.5 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.5 mmol). Purification by preparative-HPLC afforded the title compound. LCMS (ES+) 395 (M+H) + , RT 3.39 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.28 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.5 Hz), 7.98 (1H, d, J=2.3 Hz), 7.45 (1H, d, J=8.0 Hz), 7.27 (1H, dd, J=7.8, 7.8 Hz), 7.21 (1H, d, J=7.2 Hz), 7.15 (1H, d, J=2.3 Hz), 7.05 - 6.98 (2H, m), 5.25 - 5.16 (1H, m), 3.53 - 3.48 (4H, m), 3.22 (4H, dd, J=5.0, 5.0 Hz), 1.47 (3H, d, J=7.0 Hz).
[0389] Example 30 (R)-N-(1-(2,2-dimethyl-2,3-dihydrobenzofuran-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0390] [ka]
[0391] Method A was followed from (R)-1-(2,2-dimethyl-2,3-dihydrobenzofuran-4-yl)ethan-1-amine hydrochloride (0.430 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.430 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 399 (M+H) + , RT 2.62 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.21 (1H, d, J=5.2 Hz), 8.13 (1H, d, J=5.3 Hz), 7.11 - 7.00 (2H, m), 6.84 (1H, d, J=7.7 Hz), 6.55 (1H, d, J=7.8 Hz), 4.92 - 4.86 (1H, m), 3.62 (4H, dd, J=3.7, 6.4 Hz), 3.40 (4H, dd, J=5.1, 5.1 Hz), 3.17 (1H, d, J=15.4 Hz), 3.02 (1H, d, J=15.4 Hz), 1.48 - 1.44 (9H, m); SFC RT 1.4 minutes (SFC1, YMC Amylose-C + 0.1% DEAISO 25% MeOH).
[0392] Example 31 (R)-4-(3-fluoropyridin-4-yl)-N-(1-(2-methylbenzofuran-4-yl)ethyl)piperazine-1-carboxamide
[0393] [ka]
[0394] Method B was followed from 4-nitrophenyl (R)-(1-(2-methylbenzofuran-4-yl)ethyl)carbamate (Intermediate 5, 0.138 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.138 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 384 (M+H) + , RT 2.65 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.12 (1H, d, J=5.6 Hz), 7.30 - 7.26 (1H, m), 7.19 - 7.17 (2H, m), 7.00 (1H, dd, J=5.7, 8.2 Hz), SFC RT 1.95 min (SFC1, LUX cellulose-3 + 0.1% DEAISO 15% MeOH).
[0395] Examples 32 and 33 (R)-4-(3-fluoropyridin-4-yl)-N-(1-(1-methyl-1H-indol-7-yl)ethyl)piperazine-1-carboxamide and (S)-4-(3-fluoropyridin-4-yl)-N-(1-(1-methyl-1H-indol-7-yl)ethyl)piperazine-1-carboxamide
[0396] [ka]
[0397] Method B was followed from 4-nitrophenyl (R)-(1-(1-methyl-1H-indol-7-yl)ethyl)carbamate (Intermediate 14, 0.91 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 32, 0.65 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate the isomers afforded the title compound.
[0398] Example 32: LCMS (ES+) 382 (M+H) + , RT 3.15 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.26 (1H, d, J=5.8 Hz), 8.14 (1H, d, J=5.5 Hz), 7.40 (1H, d, J=7.3 Hz), 7.25 - 7.22 (2H, m), 7.01 - 6.94 (3H, m), 6.39 (1H, d, J=3.0 Hz), 5.84 - 5.75 (1H, m), 4.40 - 4.35 (1H, m), 4.07 (3H, s), 3.89 (1H, d, J=13.3 Hz), 3.62 - 3.52 (2H, m), 3.17 - 3.08 (1H, m), 3.01 (1H, dd, J=3.5, 12.4 Hz), 2.88 - 2.79 (1H, m), 1.49 (3H, d, J=6.9 Hz), 1.16 (3H, d, J=6.7 Hz); SFC RT 1.3 min (SFC1, YMC Amino-C + 0.1% DEAISO 40% MeOH).
[0399] Example 33: LCMS (ES+) 382 (M+H) + , RT 3.15 points (Analysis Method 2), 1 H NMR (400 MHz, DMSO) 8.28 (1H, d, J=5.6 Hz), 8.16 (1H, d, J=5.5 Hz), 7.39 (1H, dd, J=1.1, 7.8 Hz), 7.25 - 7.22 (2H, m), 7.06 (1H, d, J=7.5 Hz), 7.02 - 6.97 (2H, m), 6.39 (1H, d, J=3.1 Hz), 5.81 - 5.76 (1H, m), 4.08 (3H, s), 3.52 - 3.48 (4H, m), 3.24 - 3.19 (4H, m), 1.49 (3H, d, J=6.9 Hz); SFC RT 2.46 points (SFC1, YMCアミロース-C + 0.1% DEAISO 40% MeOH).
[0400] Examples 34 and 35 (R)-4-(3-fluoropyridin-4-yl)-N-(1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)piperazine-1-carboxamide and (S)-4-(3-fluoropyridin-4-yl)-N-(1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)piperazine-1-carboxamide
[0401] [ka]
[0402] Method B was followed from 4-nitrophenyl (R)-(1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)carbamate (Intermediate 10, 1.31 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.65 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate the isomers afforded the title compound.
[0403] Example 34: LCMS (ES+) 383 (M+H) + , RT 2.72 minutes (Analysis method 2), 1 H NMR (400 MHz, DMSO) 8.28 (1H, d, J=5.6 Hz), 8.16 (1H, d, J=5.4 Hz), 7.39 (1H, d, J=7.5 Hz), 7.25 - 7.22 (2H, m), 7.06 (1H, d, J=7.7 Hz), 7.02 - 6.97 (2H, m), 6.39 (1H, d, J=3.1 Hz), 5.81 - 5.76 (1H, m), 4.08 (3H, s), 3.50 (4H, dd, J=5.0, 5.0 Hz), 3.22 (4H, dd, J=5.0, 5.0 Hz), 1.49 (3H, d, J=6.9 Hz); SFC RT 4.33 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 25% MeOH).
[0404] Example 35: LCMS (ES+) 383 (M+H) + , RT 2.71 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.20 (1H, d, J=6.0 Hz), 8.14 (1H, d, J=5.6 Hz), 7.43 (1H, dd, J=1.1, 9.0 Hz), 7.36 (1H, s), 7.25 (1H, dd, J=7.2, 8.9 SFC RT 5.37 minutes (SFC4, LUX cellulose-4 + 0.1% DEAISO 25% MeOH).
[0405] Example 36 (R)-N-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0406] [ka]
[0407] Method B was followed from 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 137 mg, 0.633 mmol) and 4-nitrophenyl (R)-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)carbamate (Intermediate 15, 232 mg, 0.633 mmol). Purification via chiral SFC afforded the title compound (97.2% purity, 100% ee). LCMS (ES+) 409 (M+H) + , RT 3.13 minutes (Analysis method 3), 1H NMR (400 MHz, CDCl3) 8.26 - 8.18 (2H, m), 7.05 - 6.95 (3H, m), 6.73 (1H, dd, J=5.5, 7.9 Hz), 5.16 - 5.08 (1H, m), 4.96 - 4.92 (1H, m), 3.62 - 3.50 (4H, m), 3.32 - 3.28 (4H, m), 1.55 (3H, d, J=49.3 Hz); SFC RT 1.96 min (SFC4, LUX cellulose-4 + 0.1% DEAISO 20% MeOH).
[0408] Example 37 N-(benzo[d][1,3]dioxol-4-ylmethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0409] [ka]
[0410] Method B was followed from 4-nitrophenyl(benzo[d][1,3]dioxol-4-ylmethyl)carbamate (Intermediate 7, 0.237 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.237 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 359 (M+H). + , RT 2.91 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.13 (1H, d, J=5.6 Hz), 7.02 (1H, dd, J=5.7, 8.2 Hz), 6.83 - 6.80 (2H, m), 6.76 - 6.73 (1H, m), 5.97 (2H, s), 4.39 (2H, s), 3.64 - 3.60 (4H, m), 3.41 - 3.37 (4H, m).
[0411] Example 38 N-(benzofuran-4-ylmethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0412] [ka]
[0413] Method B was followed from 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 137 mg, 0.63 mmol) and 4-nitrophenyl(benzofuran-4-ylmethyl)carbamate (Intermediate 9, 200 mg, 0.63 mmol). Purification by SCX afforded the title compound. LCMS (ES+) 355 (M+H). + , RT 3.02 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.20 - 8.12 (2H, m), 7.78 - 7.77 (1H, m), 7.44 - 7.41 (1H, m), 7.30 - 7.19 (2H, m), 7.03 - 6.99 (2H, m), 4.67 (2H, s), 3.65 - 3.61 (4H, m), 3.42 - 3.33 (4H, M).
[0414] Example 39 N-(benzo[d]oxazol-7-ylmethyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0415] [ka]
[0416] Method A was followed from benzo[d]oxazol-7-ylmethanamine hydrochloride (0.542 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.542 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 356 (M+H). + , RT 2.38 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.77 (1H, s), 8.29 (1H, d, J=5.6 Hz), 8.17 (1H, d, J=5.5 Hz), 7.70 - 7.66 (1H, m), 7.40 - 7.30 (3H, m), 7.02 (1H, dd, J=5.6, 8.3 Hz), 4.58 (2H, d, J=5.6 Hz), 3.52 (4H, dd, J=5.0, 5.0 Hz), 3.25 (4H, dd, J=5.0, 5.0 Hz).
[0417] Example 40 N-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0418] [ka]
[0419] Method B was followed from 4-nitrophenyl((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)carbamate (Intermediate 8, 0.227 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 0.227 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 373 (M+H). + , RT 2.89 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.20 (1H, d, J=6.0 Hz), 8.13 (1H, d, J=5.6 Hz), 7.02 (1H, dd, J=5.6, 8.2 Hz), 6.82 - 6.73 (3H, m), 4.38 (2H, s), 4.33 - 4.24 (4H, m), 3.65 - 3.61 (4H, m), 3.43 - 3.38 (4H, m).
[0420] Example 41 N-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-4-(3-fluoropyridin-4-yl)piperazine-1-carboxamide
[0421] [ka]
[0422] Method B was followed from 4-nitrophenyl((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)carbamate (Intermediate 6, 75 mg, 0.213 mmol) and 1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 32, 54 mg, 0.213 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 395 (M+H) + , RT 4.00 min (Analysis method 4), 1 H NMR (400 MHz, MeOD) 8.48 (1H, d, J=8.7 Hz), 8.19 (1H, d, J=7.1 Hz), 7.35 - 7.30 (1H, m), 7.16 - 7.09 (3H, m), 4.49 (2H, s), 3.94 - 3.90 (4H, m), 3.74 - 3.70 (4H, m).
[0423] Example 42 (R)-N-((R)-1-(2-chlorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0424] [ka]
[0425] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 50 mg, 0.21 mmol) and 4-nitrophenyl (R)-(1-(2-chlorophenyl)ethyl)carbamate (Intermediate 3, 69 mg). LCMS (ES+) 377 (M+H).+ , RT 3.34 minutes (Analysis method 2), 1 H NMR (400 MHz, DMSO) 8.31 (1H, d, J=5.6 Hz), 8.19 (1H, d, J=5.6 Hz), 7.55 - 7.50 (1H, m), 7.45 - 7.34 (2H, m), 7.31 - 7.24 (1H, m), 7.07 - 6.99 (2H, m), 5.26 - 5.20 (1H, m), 4.43 - 4.39 (1H, m), 3.93 (1H, d, J=13.1 Hz), 3.63 (2H, dd, J=12.4, 21.7 Hz), 3.25 - 3.15 (1H, m), 3.08 (1H, dd, J=3.2, 12.3 Hz), 2.95 - 2.85 (1H, m), 1.39 (3H, d, J=7.1 Hz), 1.20 (3H, d, J=6.6 Hz).
[0426] Example 43 (R)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)-2-methylpiperazine-1-carboxamide
[0427] [ka]
[0428] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine HCl (Intermediate 34, 1.08 mmol) and 4-nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 1.08 mmol). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 373 (M+H). + , RT 3.14 minutes (Analysis method 1) 1H NMR (400 MHz, DMSO) 8.27 (1H, d, J=5.6 Hz), 8.15 (1H, d, J=5.5 Hz), 7.22 (1H, dd, J=8.0, 8.0 Hz), 7.00 (1H, dd, J=5.5, 8.3 Hz), 6.91 - 6.89 (2H, m), 6.82 - 6.76 (2H, m), 4.90 - 4.81 (1H, m), 4.33 (1H, dd, J=3.0, 6.3 Hz), 3.89 (1H, d, J=13.2 Hz), 3.75 (3H, s), 3.58 (2H, dd, J=12.0, 22.1 Hz), 3.19 - 3.10 (1H, m), 3.02 (1H, dd, J=3.5, 12.3 Hz), 2.90 - 2.81 (1H, m), 1.37 (3H, d, J=7.2 Hz), 1.17 (3H, d, J=6.5 Hz), LUX cellulose-4 + 0.1% DEAISO 40% MeOH).
[0429] Example 44 (R)-N-((R)-1-(2-fluoro-3-methoxyphenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0430] [ka]
[0431] Method A was followed from (R)-1-(2-fluoro-3-methoxyphenyl)ethan-1-amine hydrochloride (0.384 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.384 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 391 (M+H). + , RT 2.53 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.27 (1H, d, J=5.6 Hz), 8.19 - 8.14 (1H, m), 7.09 (1H, dd, J=8.1, 8.1 Hz), 7.03 - 6.93 (3H, m), 6.87 (1H, d, J=7.7 Hz), 5.16 - 5.09 (1H, m), 4.35 - 4.32 (1H, m), 3.88 (1H, d, J=13.3 Hz), 3.83 (3H, s), 3.57 (2H, dd, J=12.5, 22.4 Hz), 3.19 - 3.10 (1H, m), 3.02 (1H, dd, J=3.4, 12.3 Hz), 2.90 - 2.81 (1H, m), 1.36 (3H, d, J=7.1 Hz), 1.15 (3H, d, J=6.6 Hz).
[0432] Example 45 (R)-N-((R)-1-(2-bromophenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0433] [ka]
[0434] Method A was followed from (R)-1-(2-bromophenyl)ethan-1-amine hydrochloride (0.384 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.384 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 421 (M+H). + , RT 3.21 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.1 Hz), 8.12 (1H, d, J=5.6 Hz), 7.56 (1H, d, J=7.9 Hz), 7.44 (1H, dd, J=1.6, 7.8 Hz), 7.34 (1H, dd, J=7.5, 7.5 Hz), 7.17 - 7.12 (1H, m), 7.01 (1H, dd, J=5.7, 8.3 Hz), 5.28 (1H, q, J=7.0 Hz), 4.43 - 4.36 (1H, m), 3.95 (1H, d, J=13.3 Hz), 3.73 (2H, dd, J=12.5, 12.5 Hz), 3.41 - 3.32 (1H, m, unclear), 3.18 (1H, dd, J=3.5, 12.5 Hz), 3.05 - 2.96 (1H, m), 1.47 (3H, d, J=7.1 Hz), 1.31 (3H, d, J=6.7 Hz).
[0435] Example 46 (R)-1-(3-Methoxyphenyl)ethyl (R)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxylate
[0436] [ka]
[0437] To a stirred solution of 4-nitrophenyl chloroformate (100 mg, 0.497 mmol) in DCM (2 mL) at rt was added dropwise a solution of (R)-1-(3-methoxyphenyl)ethan-1-ol (75 mg, 0.493 mmol) in DCM (2 mL). The mixture was stirred at rt for 15 min and then treated with (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 134 mg, 0.493 mmol) in DCM (5 mL) and TEA (0.21 mL, 1.48 mmol). After 3 days the reaction mixture was washed with saturated NaHCO3 solution and brine, passed through a hydrophobic frit and concentrated to dryness. Purification by preparative HPLC afforded the title compound. LCMS (ES+) 374 (M+H) + , RT 3.39 minutes (Analysis method 2), 1 H NMR (400 MHz, CDCl3) 8.23 (1H, d, J=5.4 Hz), 8.17 (1H, d, J=5.5 Hz), 7.29 (1H, d, J=7.9 Hz), 6.94 (1H, d, J=7.7 Hz), 6.89 (1H, s), 6.83 (1H, dd, J=2.3, 8.2 Hz), 6.71 (1H, dd, J=5.6, 7.9 Hz), 5.83 (1H, q, J=6.5 Hz), 4.45 (1H, dd, J=2.9, 6.1 Hz), 4.06 (1H, d, J=13.2 Hz), 3.82 (3H, s), 3.59 - 3.51 (2H, m), 3.39 - 3.30 (1H, m), 3.06 (1H, dd, J=3.5, 12.3 Hz), 2.95 - 2.86 (1H, m), 1.56 (3H, d, J=7.1 Hz), 1.33 (3H, d, J=6.6 Hz).
[0438] Examples 47 and 48 (R)-N-((R)-1-(2-chloro-3-fluorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide and (R)-N-((S)-1-(2-chloro-3-fluorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0439] [ka]
[0440] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 79 mg, 0.29 mmol) and 4-nitrophenyl(1-(2-chloro-3-fluorophenyl)ethyl)carbamate (Intermediate 12, 100 mg, 0.29 mmol). Purification by preparative-HPLC and chiral SFC afforded the title compound:
[0441] Example 47: %ee: 100%. LCMS (ES+) 395 (M+H) + , RT 3.21 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.03 (2H, dd, J=5.8, 27.5 Hz), 7.22 - 7.12 (2H, m), 7.02 - 6.97 (1H, m), 6.88 (1H, dd, J=5.6, 8.3 Hz), 5.20 (1H, q, J=7.0 Hz), 4.30 - 4.24 (1H, m), 3.83 - 3.78 (1H, m), 3.66 - 3.56 (2H, m), 3.28-3.22 (1H, unclear with MeOH) 3.08 - 3.02 (1H, m), 2.91 - 2.83 (1H, m), 1.35 (3H, d, J=7.0 Hz), 1.18 (3H, d, J=6.8 Hz); SFC RT 1.5 min (SFC4, YMC amylose-C + 0.1% DEAISO 20% EtOH).
[0442] Example 48: %ee: 95.7%. LCMS (ES+) 395 (M+H) + , RT 3.21 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.15 (2H, dd, J=5.8, 27.0 Hz), 7.36 - 7.26 (2H, m), 7.16 - 7.10 (1H, m), 7.01 (1H, dd, J=5.7, 8.2 Hz), 5.35 (1H, q, J=7.0 Hz), 4.35 (1H, s), 3.98 - 3.92 (1H, m), 3.80 - 3.68 (2H, m), 3.41-3.34 (1H, obscured by MeOH), 3.16 (1H, dd, J=3.7, 12.6 Hz), 3.05 - 2.97 (1H, m), 1.49 - 1.47 (3H, m), 1.35 - 1.32 (3H, m); SFC RT 2.15 min (SFC4, YMC amylose-C + 0.1% DEAISO 20% EtOH).
[0443] Example 49 (R)-N-((R)-1-(2-chloro-5-methoxyphenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0444] [ka]
[0445] Method B was followed from 4-nitrophenyl (R)-(1-(2-chloro-5-methoxyphenyl)ethyl)carbamate (Intermediate 4, 0.222 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.222 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 407 (M+H) + , RT 3.21 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.12 (1H, d, J=5.6 Hz), 7.27 (1H, d, J=8.8 Hz), 7.03 - 6.98 (2H, m), 6.81 (1H, dd, J=3.1, 8.8 Hz), 5.27 (1H, q, J=7.1 Hz), 4.43 - 4.38 (1H, m), 3.95 (1H, d, J=13.2 Hz), 3.81 - 3.70 (5H, m), 3.42 - 3.35 (1H, m), 3.19 (1H, dd, J=3.7, 12.5 Hz), 3.05 - 2.97 (1H, m), 1.46 (3H, d, J=7.0 Hz), 1.32 (3H, d, J=6.6 Hz).
[0446] Example 50 (R)-N-((R)-1-(2-chloro-4-fluorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0447] [ka]
[0448] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 63 mg, 0.19 mmol) and 4-nitrophenyl(1-(2-chloro-4-fluorophenyl)ethyl)carbamate (Intermediate 11, 50 mg, 0.19 mmol). Purification by prep-HPLC and chiral SFC afforded the title compound. %ee: 100%. LCMS (ES+) 395 (M+H) + , RT 3.23 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.27 (1H, d, J=5.6 Hz), 8.16 (1H, d, J=5.5 Hz), 7.51 (1H, dd, J=6.3, 8.7 Hz), 7.37 (1H, dd, J=2.6, 8.8 Hz), 7.26 - 7.20 (1H, m), 7.03 - 6.97 (2H, m), 5.19 - 5.11 (1H, m), 4.36 - 4.33 (1H, m), 3.90 - 3.85 (1H, m), 3.63 - 3.53 (2H, m), 3.20 - 3.11 (1H, m), 3.03 (1H, dd, J=3.5, 12.3 SFC RT 1.4 min (SFC4, YMC Amylose-C + 0.1% DEAISO 20% EtOH).
[0449] Example 51 (R)-N-((R)-1-(3-fluoro-5-methoxyphenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0450] [ka]
[0451] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 179 mg, 0.67 mmol) and 4-nitrophenyl(1-(3-fluoro-5-methoxyphenyl)ethyl)carbamate (Intermediate 16, 223 mg, 0.67 mmol). Purification by prep-HPLC and chiral SFC afforded the title compound. %ee: 100%. LCMS (ES+) 391 (M+H) + , RT 2.61 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=23.7 Hz), 8.12 (1H, d, J=26.1 Hz), 7.00 (1H, dd, J=42.7 Hz), 6.75 (1H, s), 6.68 (1H, d, J=19.0 Hz), 6.56-6.55 (1H, m), 4.91 (1H, q, J=37.9 Hz), 4.40 (1H, m), 3.94 (1H, d, J=52.2 Hz), 3.78 - 3.68 (3H, m), 3.17 (1H, dd, J=42.7 Hz), 3.01 - 2.96 (1H, m), 1.48 (3H, d, J=45.1 Hz), 1.31 (3H, d, J=45.1 Hz); SFC RT 2.82 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 30% IPA).
[0452] Example 52 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(pyridin-3-yl)ethyl)piperazine-1-carboxamide
[0453] [ka]
[0454] Method A was followed from (R)-1-(pyridin-3-yl)ethan-1-amine (0.331 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.331 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 344 (M+H). + , RT 2.72 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.55 (1H, s), 8.42 (1H, d, J=4.0 Hz), 8.18 (1H, d, J=6.1 Hz), 8.11 (1H, d, J=5.6 Hz), 7.84 (1H, d, J=8.1 Hz), 7.42 (1H, dd, J=5.1, 7.6 Hz), 7.00 (1H, dd, J=5.8, 8.1 Hz), 5.01 (1H, q, J=7.0 Hz), 4.41 - 4.34 (1H, m), 3.93 (1H, d, J=13.1 Hz), 3.73 (2H, dd, J=13.6, 13.6 Hz), 3.43 -3.28 (1H, m, unclear), 3.17 (1H, dd, J=3.3, 12.4 Hz), 3.04 - 2.94 (1H, m), 1.54 (3H, d, J=7.1 Hz), 1.30 (3H, d, J=6.6 Hz).
[0455] Example 53 (R)-N-((R)-1-(4-fluoro-3-methoxyphenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0456] [ka]
[0457] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 189 mg, 0.70 mmol) and 4-nitrophenyl (R)-(1-(4-fluoro-3-methoxyphenyl)ethyl)carbamate (Intermediate 17, 235 mg, 0.70 mmol). Purification by prep-HPLC and chiral SFC afforded the title compound. %ee: 100%. LCMS (ES+) 391 (M+H) + , RT 3.10 minutes (Analysis method 2), 1H NMR (400 MHz, CDCl3) 8.24 - 8.16 (2H, m), 7.06 - 6.93 (2H, m), 6.87 - 6.83 (1H, m), 6.72 (1H, dd, J=5.5, 8.0 Hz), 5.03 - 4.98 (1H, m), 4.62 (1H, d, J=6.9 Hz), 4.18 - 4.14 (1H, m), 3.89 - 3.89 (3H, m), 3.63 - 3.54 (2H, m), 3.36 - 3.27 (1H, m), 3.10 (1H, dd, J=3.6, 12.2 Hz), 2.98 - 2.90 (1H, m), 1.50 (3H, d, J=6.9 Hz), 1.35 - 1.32 (3H, m).
[0458] Example 54 (R)-N-(2-chlorobenzyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0459] [ka]
[0460] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 90 mg, 0.39 mmol) and 4-nitrophenyl(2-chlorobenzyl)carbamate (Intermediate 2, 119 mg, 0.39 mmol). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 363 (M+H). + , RT 2.57 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.32 (1H, d, J=5.8 Hz), 8.20 (1H, d, J=5.6 Hz), 7.47 (1H, d, J=7.6 Hz), 7.40 - 7.31 (3H, m), 7.20 (1H, dd, J=5.6, 5.6 Hz), 7.05 (1H, dd, J=5.6, 8.3 Hz), 4.42 - 4.33 (3H, m), 3.94 (1H, d, J=13.1 Hz), 3.65 (2H, dd, J=12.5, 27.4 Hz), 3.30 - 3.19 (1H, m), 3.11 (1H, dd, J=3.3, 12.4 Hz), 2.99 - 2.90 (1H, m), 1.26 (3H, d, J=6.6 Hz).
[0461] Example 55 (R)-N-(2-fluoro-5-methoxybenzyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0462] [ka]
[0463] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 258 mg, 0.80 mmol) and 4-nitrophenyl (2-fluoro-5-methoxybenzyl)carbamate (Intermediate 18, 216 mg, 0.80 mmol). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 377 (M+H). + , RT 3.03 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.28 - 8.26 (1H, m), 8.18 - 8.14 (1H, m), 7.14 - 6.98 (3H, m), 6.86 - 6.79 (2H, m), 4.35 - 4.21 (3H, m), 3.91 - 3.85 (1H, m), 3.72 (3H, s), 3.65 - 3.53 (2H, m), 3.22-3.13 (1H, m), 3.05 (1H, dd, J=3.5, 12.5 Hz), 2.92 - 2.83 (1H, m), 1.20 (3H, d, J=6.7 Hz).
[0464] Example 56 (R)-4-(3-fluoropyridin-4-yl)-N-((2-methoxypyridin-3-yl)methyl)-2-methylpiperazine-1-carboxamide
[0465] [ka]
[0466] Method A was followed from 4-nitrophenyl chloroformate (0.50 mmol, 1 eq), (2-methoxypyridin-3-yl)methanamine (0.50 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.50 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 360 (M+H) + , RT 2.21 minutes (Analysis method 3), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.12 (1H, d, J=5.6 Hz), 8.03 (1H, dd, J=1.9, 5.1 Hz), 7.58 (1H, dd, J=1.2, 7.1 Hz), 7.02 (1H, dd, J=5.8, 8.3Hz), 6.95 (1H, dd, J=5.1, 7.3Hz), 4.41 - 4.35 (3H, m), 3.99 (3H, s), 3.97 - 3.91 (1H, m), 3.79 - 3.70 (2H, m), 3.42 - 3.36 (1H, m), 3.24 - 3.16 (1H, m), 3.08 - 3.00 (1H, m), 1.34 (3H, d, J=6.7 Hz).
[0467] Example 57 (R)-N-((R)-1-(2,2-dimethyl-2,3-dihydrobenzofuran-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0468] [ka]
[0469] Method A was followed from (R)-1-(2,2-dimethyl-2,3-dihydrobenzofuran-4-yl)ethan-1-amine hydrochloride (0.430 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.430 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 414 (M+H). + , RT 2.66 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.18 (1H, d, J=6.0 Hz), 8.12 (1H, d, J=5.6 Hz), 7.08 (1H, dd, J=7.9, 7.9 Hz), 7.00 (1H, dd, J=5.7, 8.3 Hz), 6.83 (1H, d, J=7.7 Hz), 6.55 (1H, d, J=7.8 Hz), 4.95 - 4.89 (1H, m), 4.42 - 4.35 (1H, m), 3.95 (1H, d, J=13.3 Hz), 3.72 (2H, dd, J=12.9, 12.9 Hz), 3.38 - 3.30 (1H, m, unclear), 3.19 - 3.14 (2H, m), 3.04 - 2.98 (2H, m), 1.48 - 1.44 (9H, m), 1.31 (3H, d, J=6.6 Hz).
[0470] Examples 58 and 59 (R)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(imidazo[1,2-a]pyridin-5-yl)ethyl)-2-methylpiperazine-1-carboxamide and (R)-4-(3-fluoropyridin-4-yl)-N-((S)-1-(imidazo[1,2-a]pyridin-5-yl)ethyl)-2-methylpiperazine-1-carboxamide
[0471] [ka]
[0472] Method B was followed from 4-nitrophenyl (R)-(1-(imidazo[1,2-a]pyridin-5-yl)ethyl)carbamate (Intermediate 19, 0.50 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.50 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate the isomers afforded the title compound.
[0473] Example 58: LCMS (ES+) 383 (M+H)+ , RT 2.70 points (Analysis Method 2), 1 H NMR (400 MHz, DMSO) 8.27 (1H, d, J=5.6 Hz), 8.15 (1H, d, J=5.5 Hz), 7.97 (1H, s), 7.65 (1H, s), 7.53 (1H, d, J=9.0 Hz), 7.29 (1H, dd, J=7.0, 9.0 Hz), 7.07 (1H, d, J=7.9 Hz), 7.00 (1H, dd, J=5.5, 8.3 Hz), 6.89 (1H, d, J=6.9 Hz), 5.31 (1H, dd, J=7.2, 7.2 Hz), 4.34 - 4.32 (1H, m), 3.87 (1H, d, 3H, d, J=13.3 Hz), 3.62 - 3.52 (2H, m), 3.17 - 3.10 (1H, m), 3.02 (1H, dd, J=3.5, 12.5 Hz), 2.90 - 2.83 (1H, m), 1.54 (3H, d, J=6.9 Hz), 1.18 (3H, d, J=6.7 Hz); SFC RT 1.83 min (SFC4, YMC Amino-C + 0.1% DEAISO 20% MeOH).
[0474] Example 59: LCMS (ES+) 383 (M+H) + , RT 2.69 points (Analysis Method 2), 1H NMR (400 MHz, DMSO) 8.27 (1H, d, J=5.6 Hz), 8.15 (1H, d, J=5.5 Hz), 7.95 (1H, s), 7.65 (1H, d, J=1.1 Hz), 7.53 (1H, d, J=9.0 Hz), 7.30 (1H, dd, J=7.0, 9.0 Hz), 7.08 (1H, d, J=7.7 Hz), 7.00 (1H, dd, J=5.5, 8.4 Hz), 6.89 (1H, d, J=6.9 Hz), 5.32 - 5.27 (1H, m), 4.32 - 4.29 (1H, m), 3.93 - 3.87 (1H, m), 3.63 - 3.51 (2H, m), 3.21 - 3.12 (1H, m), 3.03 (1H, dd, J=3.5, 12.5 Hz), 2.90 - 2.81 (1H, m), 1.53 (3H, d, J=6.9 Hz), 1.14 (3H, d, J=6.7 Hz); SFC RT 2.6 min (SFC4, YMC amylose-C + 0.1% DEAISO 20% MeOH).
[0475] Example 60 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(2-methylbenzofuran-4-yl)ethyl)piperazine-1-carboxamide
[0476] [ka]
[0477] Method B was followed from 4-nitrophenyl (R)-(1-(2-methylbenzofuran-4-yl)ethyl)carbamate (Intermediate 5, 0.138 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.138 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 397 (M+H) + , RT 3.25 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.1 Hz), 8.11 (1H, d, J=5.6 Hz), 7.28 (1H, dd, J=2.9, 6.0 Hz), 7.18 - 7.16 (2H, m), 7.01 (1H, dd, J=5.7, 8.3 Hz), 6.63 (1H, s), 5.28 (1H, q, J=7.1 Hz), 4.41 - 4.34 (1H, m), 3.95 (1H, d, J=13.2 Hz), 3.73 (2H, dd, J=12.9, 14.7 Hz), 3.38 - 3.29 (1H, m, unclear), 3.18 (1H, dd, J=3.7, 12.5 Hz), 3.06 - 2.97 (1H, m), 2.47 (3H, s), 1.57 (3H, d, J=7.0 Hz), 1.31 (3H, d, J=6.6 Hz); SFC RT 3.56 min (SFC1, LUX cellulose-4 + 0.1% DEAISO 30% MeOH).
[0478] Examples 61 and 62 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(pyrazolo[1,5-a]pyridin-4-yl)ethyl)piperazine-1-carboxamide and (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((S)-1-(pyrazolo[1,5-a]pyridin-4-yl)ethyl)piperazine-1-carboxamide
[0479] [ka]
[0480] Method B was followed from (R)-(1-(pyrazolo[1,5-a]pyridin-4-yl)ethyl)carbamate (Intermediate 20, 0.59 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.59 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate the isomers afforded the title compound.
[0481] Example 61: LCMS (ES+) 383 (M+H) + , RT 2.81 points (Analysis Method 2), 1 H NMR (400 MHz, DMSO) 8.56 (1H, d, J=6.9 Hz), 8.27 (1H, d, J=5.6 Hz), 8.15 (1H, d, J=5.5 Hz), 7.99 (1H, d, J=2.4 Hz), 7.10 (1H, d, J=6.9 Hz), 7.02 - 6.95 (2H, m), 6.87 (1H, dd, J=7.0, 7.0 Hz), 6.73 (1H, d, J=2.3 Hz), 5.19 - 5.14 (1H, m), 4.35 - 4.33 (1H, m), 3.89 (1H, d, J=13.2 Hz), 3.57 (2H, dd, J=12.0, 22.4 Hz), 3.19 - 3.09 (1H, m), 3.02 (1H, dd, J=3.5, 12.3 Hz), 2.90 - 2.81 (1H, m), 1.49 (3H, d, J=7.0 Hz), 1.17 (3H, d, J=6.5 Hz); SFC RT 1.5 points (SFC4, LUXセルロース-4 + 0.1% DEAISO 40% IPA).
[0482] Example 62: LCMS (ES+) 383 (M+H) + , RT 2.80 points (Analysis Method 2), 1H NMR (400 MHz, DMSO) 8.56 (1H, d, J=6.9 Hz), 8.27 (1H, d, J=5.6 Hz), 8.15 (1H, d, J=5.5 Hz), 7.99 (1H, d, J=2.3 Hz), 7.11 (1H, d, J=6.9 Hz), 7.02 - 6.96 (2H, m), 6.90 - 6.85 (1H, m), 6.74 (1H, dd, J=0.9, 2.3 Hz), 5.19 - 5.11 (1H, m), 4.35 - 4.32 (1H, m), 3.94 - 3.87 (1H, m), 3.63 - 3.51 (2H, m), 3.19 - 3.09 (1H, m), 3.02 (1H, dd, J=3.5, 12.4 Hz), 2.90 - 2.80 (1H, m), 1.49 (3H, d, J=7.2 Hz), 1.15 (3H, d, J=6.5 Hz); SFC RT 2.06 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 40% IPA).
[0483] Examples 63 and 64 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(1-methyl-1H-indol-7-yl)ethyl)piperazine-1-carboxamide (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((S)-1-(1-methyl-1H-indol-7-yl)ethyl)piperazine-1-carboxamide
[0484] [ka]
[0485] Method B was followed from 4-nitrophenyl (R)-(1-(1-methyl-1H-indol-7-yl)ethyl)carbamate (Intermediate 14, 0.91 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.65 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate the isomers afforded the title compound.
[0486] Example 63: LCMS (ES+) 396 (M+H) + , RT 2.66 minutes (Analysis method 1), 1 H NMR (400 MHz, DMSO) 8.26 (1H, d, J=5.8 Hz), 8.14 (1H, d, J=5.5 Hz), 7.40 (1H, d, J=7.3 Hz), 7.25 - 7.22 (2H, m), 7.01 - 6.94 (3H, m), 6.39 (1H, d, J=3.0 Hz), 5.84 - 5.75 (1H, m), 4.40 - 4.35 (1H, m), 4.07 (3H, s), 3.89 (1H, d, J=13.3 Hz), 3.62 - 3.52 (2H, m), 3.17 - 3.08 (1H, m), 3.01 (1H, dd, J=3.5, 12.4 Hz), 2.88 - 2.79 (1H, m), 1.49 (3H, d, J=6.9 Hz), 1.16 (3H, d, J=6.7 Hz).
[0487] Example 64: LCMS (ES+) 396 (M+H) + , RT 2.68 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.26 (1H, d, J=5.6 Hz), 8.15 (1H, d, J=5.5 Hz), 7.39 (1H, dd, J=1.0, 7.8 Hz), 7.26 - 7.22 (2H, m), 7.02 - 6.97 (3H, m), 6.39 (1H, d, J=3.0 Hz), 5.83 - 5.78 (1H, m), 4.35 - 4.32 (1H, m), 4.08 (3H, s), 3.93 - 3.88 (1H, m), 3.56 (2H, dd, J=12.9, 31.7 Hz), 3.15 - 3.07 (1H, m), 3.00 (1H, dd, J=3.6, 12.4 Hz), 2.88 - 2.80 (1H, m), 1.49 (3H, d, J=6.9 Hz), 1.15 (3H, d, J=6.7 Hz); SFC RT 2.46 min (SFC1, YMC Amylose-C + 0.1% DEAISO 30% MeOH).
[0488] Examples 65 and 66 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)piperazine-1-carboxamide and (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((S)-1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)piperazine-1-carboxamide
[0489] [ka]
[0490] Method B was followed from 4-nitrophenyl (R)-(1-(3-methylimidazo[1,2-a]pyridin-5-yl)ethyl)carbamate (Intermediate 10, 0.67 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.56 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate the isomers afforded the title compound.
[0491] Example 65: LCMS (ES+) 397 (M+H) + , RT 2.75 points (Analysis Method 2), 1 H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.12 (1H, d, J=5.6 Hz), 7.44 - 7.41 (1H, m), 7.36 (1H, s), 7.25 (1H, dd, J=7.1, 9.0 Hz), 7.04 - 6.96 (2H, m), 5.87 (1H, q, J=6.9 Hz), 4.44 - 4.39 (1H, m), 3.98 - 3.93 (1H, m), 3.78 - 3.71 (2H, m), 3.43 - 3.36 (1H, m), 3.23 - 3.16 (1H, m), 3.06 - 2.98 (1H, m), 2.86 (3H, s), 1.59 (3H, d, J=6.9 Hz), 1.33 (3H, d, J=6.7 Hz); SFC RT 1.02 points (SFC4, LUXセルロース-4 + 0.1% DEAISO 55% IPA).
[0492] Example 66: LCMS (ES+) 397 (M+H) + , RT 2.74 points (Analysis Method 2), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.0 Hz), 8.12 (1H, d, J=5.6 Hz), 7.44 - 7.41 (1H, m), 7.36 (1H, s), 7.26 (1H, dd, J=7.0, 8.9 Hz), 7.04 - 6.97 (2H, m), 5.89 (1H, q, J=6.9 Hz), 4.44 - 4.37 (1H, m), 4.00 - 3.94 (1H, m), 3.79 - 3.69 (2H, m), 3.43 - 3.37 (1H, m), 3.17 (1H, dd, J=3.5, 12.7 Hz), 3.07 - 2.99 (1H, m), 2.87 (3H, s), 1.59 (3H, d, J=6.9 Hz), 1.35 (3H, d, J=6.7 Hz); SFC RT 1.68 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 55% IPA).
[0493] Example 67 (R)-N-((R)-1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0494] [ka]
[0495] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 147 mg, 0.633 mmol) and 4-nitrophenyl (R)-(1-(2,2-difluorobenzo[d][1,3]dioxol-4-yl)ethyl)carbamate (Intermediate 15, 147 mg, 0.633 mmol). Purification via chiral SFC afforded the title compound (99.6% purity, 99.7% ee). LCMS (ES+) 423 (M+H). + , RT 3.21 min (Analysis method 3), 1H NMR (400 MHz, CDCl3) 8.24 (1H, d, J=5.4 Hz), 8.18 (1H, d, J=5.4 Hz), 7.04 - 7.00 (2H, m), 6.96 (1H, dd, J=2.0, 7.2 Hz), 6.72 (1H, dd, J=5.5, 7.9 Hz), 5.16 - 5.08 (1H, m), 4.91 (1H, d, J=7.8 Hz), 4.18 - 4.14 (1H, m), 3.91 - 3.86 (1H, m), 3.62 - 3.55 (2H, m), 3.36 - 3.28 (1H, m), 3.09 (1H, dd, J=3.6, SFC RT 1.93 min (SFC4, LUX cellulose-4 + 0.1% DEAISO 20% MeOH).
[0496] Example 68 (R)-N-((R)-1-(benzo[d][1,3]dioxol-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0497] [ka]
[0498] Method A was followed from (R)-1-(benzo[d][1,3]dioxol-4-yl)ethan-1-amine hydrochloride (45 mg, 0.224 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 60 mg, 0.224 mmol). Purification by preparative HPLC afforded the title compound (22 mg). LCMS (ES+) 387 (M+H). + , RT 3.07 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 7.81 (1H, d, J=6.2 Hz), 6.81 (2H, d, J=4.4 Hz), 6.79 - 6.71 (2H, m), 6.43 (1H, dd, J=2.4, 2.4 Hz), 5.96 (2H, d, J=6.2 Hz), 5.08 (1H, q, J=7.1 Hz), 4.43 - 4.35 (1H, m), 3.94 - 3.77 (3H, m), 3.42 - 3.36 (2H, m), 3.19 - 3.10 (1H, m), 1.49 (3H, d, J=7.1 Hz), 1.22 (3H, d, J=6.7 Hz).
[0499] Examples 69 and 70 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(2-methylbenzo[d]oxazol-4-yl)ethyl)piperazine-1-carboxamide and (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((S)-1-(2-methylbenzo[d]oxazol-4-yl)ethyl)piperazine-1-carboxamide
[0500] [ka]
[0501] Method B was followed from 4-nitrophenyl (R)-(1-(2-methylbenzo[d]oxazol-4-yl)ethyl)carbamate (Intermediate 21, 0.67 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.56 mmol). Purification by preparative HPLC and chiral preparative HPLC to separate the isomers afforded the title compound.
[0502] Example 69: LCMS (ES+) 398 (M+H)+, RT 3.89 min (Analysis method 4), 1H NMR (400 MHz, MeOD) 8.18 (1H, d, J=6.1 Hz), 8.12 (1H, d, J=5.8 Hz), 7.46 - 7.43 (1H, m), 7.34 - 7.26 (2H, m), 7.07 - 6.99 (2H, m), 5.44 - 5.38 (1H, m), 4.43 - 4.35 (1H, m), 3.99 - 3.94 (1H, m), 3.79 - 3.70 (2H, m), 3.41 - 3.37 (1H, m), 3.22 - 3.16 (1H, m), 3.06 - 2.98 (1H, m), 2.68 (3H, s), 1.59 (3H, d, J=7.0 Hz), 1.32 (3H, d, J=6.7 Hz). SFC RT 2.34 points (SFC4, LUXセルロース-4 + 0.1% DEAISO 35% MeOH).
[0503] Example 70: LCMS (ES+) 398 (M+H)+, RT 3.89 minutes (Analysis Method 4), 1 H NMR (400 MHz, MeOD) 8.06 (1H, d, J=6.1 Hz), 7.99 (1H, d, J=5.6 Hz), 7.31 (1H, d, J=7.8 Hz), 7.21 - 7.12 (2H, m), 6.88 (2H, dd, J=5.8, 8.3 Hz), 5.28 (1H, q, J=7.0 Hz), 4.28 - 4.25 (1H, m), 3.87 - 3.82 (1H, m), 3.66 - 3.56 (2H, m), 3.29 - 3.24 (1H, m), 3.10 - 3.03 (1H, m), 2.94 - 2.85 (1H, m), 2.55 (3H, s), 1.46 (3H, d, J=7.0 Hz), 1.20 (3H, dd, J=7.1, 7.1 Hz). SFC RT 1.93 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 35% MeOH).
[0504] Examples 71 and 72 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((R)-1-(2-methyl-2H-indazol-4-yl)ethyl)piperazine-1-carboxamide and (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((S)-1-(2-methyl-2H-indazol-4-yl)ethyl)piperazine-1-carboxamide
[0505] [ka]
[0506] Method A was followed from 1-(2-methyl-2H-indazol-4-yl)ethan-1-amine hydrochloride (100 mg, 0.472 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 127 mg, 0.472 mmol). Purification by preparative HPLC and chiral SFC of a portion of the material afforded the title compound:
[0507] Example 71: LCMS (ES+) 397 (M+H)+, RT 3.32 min (Analysis method 4), 1H NMR (400 MHz, CD3CN) 8.18 (2H, d, J=7.7 Hz), 8.12 (1H, d, J=5.5 Hz), 7.47 (1H, d, J=8.7 Hz), 7.21 - 7.17 (1H, m), 6.97 (1H, d, J=6.8 Hz), 6.84 (1H, dd, J=5.5, 8.2 Hz), 5.64 (1H, d, J=7.2 Hz), 5.29 - 5.20 (1H, m), 4.24 - 4.22 (1H, m), 4.15 (3H, s), 3.85 - 3.79 (1H, m), 3.61 - 3.52 (2H, m), 3.26 - 3.17 (1H, m), 3.03 (1H, dd, J=3.7, 12.3 Hz), 2.91 - 2.83 (1H, m), 1.54 (3H, d, J=7.1 Hz), 1.25 - 1.22 (3H, m); 98 % ee SFC RT 1.37 points (SFC4, LUXセルロース-4 + 0.1% DEAISO 40% MeOH).
[0508] Example 72: LCMS (ES+) 397 (M+H)+, RT 3.30 minutes (Analysis Method 4), 1H NMR (400 MHz, CD3CN) 8.22 (2H, dd, J=2.8, 2.8 Hz), 8.16 (1H, d, J=5.5 Hz), 7.51 (1H, d, J=8.7 Hz), 7.26 - 7.21 (1H, m), 7.02 (1H, d, J=6.8 Hz), 6.89 (1H, dd, J=5.5, 8.2 Hz), 5.66 (1H, d, J=7.2 Hz), 5.30 - 5.24 (1H, m), 4.29 - 4.26 (1H, m), 4.19 (3H, s), 3.85 (1H, d, J=13.2 Hz), 3.60 (2H, dd, 1H, d, J=6.6 Hz); 91% ee SFC RT 1.95 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 40% MeOH).
[0509] Example 73 Imidazo[1,2-a]pyridin-5-ylmethyl (R)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxylate
[0510] [ka]
[0511] A solution of 4-nitrophenyl chloroformate (68 mg, 0.337 mmol) in DCM (3 mL) was treated with a suspension of imidazo[1,2-a]pyridin-5-ylmethanol (50 mg, 0.337 mmol) and TEA (0.14 mL, 1.01 mmol) in DCM (3 mL). The suspension was stirred for 20 min, treated with (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 92 mg, 0.337 mmol) and stirred for a further 18 h. The reaction was washed with saturated NaHCO3 solution (x3), passed through a hydrophobic frit and concentrated to dryness. Purification by preparative HPLC afforded the title compound (22 mg). LCMS (ES+) 370 (M+H) + , RT 2.85 minutes (Analysis method 2), 1 H NMR (400 MHz, CDCl3) 8.24 (1H, d, J=5.3 Hz), 8.18 (1H, d, J=5.5 Hz), 7.73 (1H, s), 7.69 (2H, d, J=8.3 Hz), 7.21 (1H, dd, J=6.8, 9.2 Hz), 6.90 (1H, d, J=6.8 Hz), 6.70 (1H, dd, J=5.5, 7.8 Hz), 5.42 (2H, d, J=2.3 Hz), 4.43 - 4.38 (1H, m), 4.00 - 4.00 (1H, m), 3.58 - 3.48 (2H, m), 3.41 - 3.32 (1H, m), 3.05 (1H, dd, J=2.9, 12.1 Hz), 2.89 (1H, dd, J=11.2, 11.2 Hz), 1.33 (3H, d, J=6.5 Hz).
[0512] Example 74 (R)-N-((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide hemiformate
[0513] [ka]
[0514] Method B was followed from 4-nitrophenyl((2,2-difluorobenzo[d][1,3]dioxol-4-yl)methyl)carbamate (Intermediate 6, 0.213 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.213 mmol). Purification by preparative HPLC afforded the title compound (89 mg). LCMS (ES+) 409 (M+H) + , RT 3.17 minutes (Analysis method 2), 1 H NMR (400 MHz, MeOD) 8.22 - 8.19 (1.5H, m), 8.12 (1H, d, J=5.6 Hz), 7.15 - 7.10 (3H, m), 7.03 (1H, dd, J=5.9, 8.3 Hz), 4.49 (2H, dd, J=15.5, 19.4 Hz), 4.38 - 4.32 (1H, m), 3.96 - 3.91 (1H, m), 3.81 - 3.72 (2H, m), 3.42 - 3.36 (1H, m), 3.23 (1H, dd, J=3.6, 12.7 Hz), 3.10 - 3.01 (1H, m), 1.34 (3H, d, J=6.7 Hz).
[0515] Example 75 (R)-N-(benzo[d][1,3]dioxol-4-ylmethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0516] [ka]
[0517] Method B was followed from 4-nitrophenyl(benzo[d][1,3]dioxol-4-ylmethyl)carbamate (Intermediate 7, 0.237 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.237 mmol). Purification by preparative HPLC afforded the title compound (63 mg). LCMS (ES+) 373 (M+H). + , RT 2.45 minutes (Analysis method 1), 1 H NMR (400 MHz, MeOD) 8.18 (1H, d, J=6.1 Hz), 8.12 (1H, d, J=5.6 Hz), 7.01 (1H, dd, J=5.7, 8.3 Hz), 6.81 (2H, d, J=4.9 Hz), 6.77 - 6.72 (1H, m), 5.97 (2H, s), 4.45 - 4.31 (3H, m), 3.95 - 3.90 (1H, m), 3.78 - 3.69 (2H, m), 3.40 - 3.36 (1H, m), 3.19 (1H, dd, J=3.7, 12.5 Hz), 3.06 - 2.98 (1H, m), 1.33 (3H, d, J=6.6 Hz).
[0518] Example 76 (R)-N-(benzofuran-4-ylmethyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide
[0519] [ka]
[0520] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 145 mg, 0.63 mmol) and 4-nitrophenyl(benzofuran-4-ylmethyl)carbamate (Intermediate 9, 200 mg, 0.63 mmol). Purification by SCX afforded the title compound (75 mg). LCMS (ES+) 369 (M+H). + , RT 3.06 minutes (Analysis method 2),1 H NMR (400 MHz, MeOD) 8.19 - 8.10 (2H, m), 7.78 - 7.76 (1H, m), 7.44 - 7.40 (1H, m), 7.30 - 7.19 (2H, m), 7.02 - 6.98 (2H, m), 4.68 (2H, d, J=16.5 Hz), 4.39 - 4.33 (1H, m), 3.98 - 3.91 (1H, m), 3.79 - 3.68 (2H, m), 3.38 (1H, d, J=26.9 Hz), 3.22 - 3.16 (1H, m), 3.06 - 2.98 (1H, m), 1.32 (3H, d, J=6.7 Hz); SFC RT 2.84 min (SFC1, LUX Cellulose-3 + 0.1% DEA5_55% MeOH).
[0521] Example 77 (R)-N-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-4-(3-fluoropyridin-4-yl)-2-methylpiperazine-1-carboxamide formate
[0522] [ka]
[0523] Method B was followed from 4-nitrophenyl((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methyl)carbamate (Intermediate 8, 0.227 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.227 mmol). Purification by preparative HPLC afforded the title compound (75 mg). LCMS (ES+) 387 (M+H) + , RT 3.00 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.21 (1H, s), 8.20 (1H, d, J=1.7 Hz), 8.12 (1H, d, J=5.7 Hz), 7.03 (1H, dd, J=5.7, 8.3 Hz), 6.79 - 6.74 (3H, m), 4.39 (2H, d, J=5.7 Hz), 4.37 - 4.25 (5H, m), 3.96 - 3.91 (1H, m), 3.83 - 3.72 (2H, m), 3.39 (1H, dd, J=3.4, 11.9 Hz), 3.24 (1H, dd, J=3.7, 12.6 Hz), 3.11 - 3.02 (1H, m), 1.33 (3H, d, J=6.7 Hz).
[0524] Example 78 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((2-methyl-2H-indazol-4-yl)methyl)piperazine-1-carboxamide
[0525] [ka]
[0526] Method A was followed from 4-aminomethyl-2-methyl-indazole hydrochloride (0.331 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 0.331 mmol). Purification by preparative HPLC afforded the title compound (45 mg). LCMS (ES+) 383 (M+H) + , RT 2.28 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.30 (1H, s), 8.22 - 8.19 (1H, m), 8.12 (1H, d, J=5.7 Hz), 7.51 (1H, d, J=8.7 Hz), 7.27 (1H, dd, J=6.8, 8.7 Hz), 7.05 - 7.00 (2H, m), 4.68 (2H, dd, J=16.2, 19.8 Hz), 4.42 - 4.36 (1H, m), 4.24 (3H, s), 3.98 - 3.93 (1H, m), 3.81 - 3.71 (2H, m), 3.43 - 3.36 (1H, m), 3.23 (1H, dd, J=3.7, 12.6 Hz), 3.10 - 3.01 (1H, m), 1.33 (3H, d, J=6.7 Hz).
[0527] Example 79 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-((1-methyl-1H-indazol-4-yl)methyl)piperazine-1-carboxamide
[0528] [ka]
[0529] Method A was followed from (1-methyl-1H-indazol-4-yl)methanamine hydrochloride (100 mg, 0.506 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 136 mg, 0.506 mmol). Purification by preparative HPLC afforded the title compound (15 mg). LCMS (ES+) 383 (M+H). + , RT 2.45 minutes (Analysis method 3), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.1 Hz), 8.12 (1H, d, J=5.6 Hz), 7.99 (1H, s), 7.69 (1H, d, J=8.1 Hz), 7.35 (1H, d, J=7.1 Hz), 7.13 (1H, dd, J=7.6, 7.6 Hz), 7.01 (1H, dd, J=5.7, 8.1 Hz), 4.94 - 4.89 (2H, m), 4.43 - 4.37 (1H, m), 4.32 (3H, s), 3.96 (1H, d, J=13.3 Hz), 3.78 - 3.69 (2H, m), 3.43 - 3.36 (1H, m), 3.20 (1H, dd, J=3.6, 12.5 Hz), 3.08 - 2.99 (1H, m), 1.35 (3H, d, J=6.6 Hz).
[0530] Example 80 (R)-4-(3-fluoropyridin-4-yl)-2-methyl-N-(quinolin-5-ylmethyl)piperazine-1-carboxamide
[0531] [ka]
[0532] Method A was followed from quinolin-5-ylmethanamine (44 mg, 0.280 mmol) and (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 75 mg, 0.280 mmol). Purification by preparative HPLC afforded the title compound (12 mg). LCMS (ES+) 380 (M+H). + , RT 2.81 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.89 - 8.88 (1H, m), 8.72 (1H, d, J=8.6 Hz), 8.18 (1H, d, J=6.0 Hz), 8.11 (1H, d, J=5.6 Hz), 7.99 (1H, d, J=8.4 Hz), 7.79 - 7.74 (1H, m), 7.65 - 7.59 (2H, m), 7.00 (1H, dd, J=5.7, 8.2 Hz), 4.92 (2H, d, J=6.1 Hz), 4.38 - 4.37 (1H, m), 3.95 (1H, d, J=13.3 Hz), 3.77 - 3.68 (2H, m), 3.42 - 3.30 (1H, m), 3.19 (1H, dd, J=3.7, 12.6 Hz), 3.06 - 2.98 (1H, m), 1.32 (3H, d, J=6.7 Hz).
[0533] Example 81 (R)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-(methoxy-d3)phenyl)ethyl-2,2,2-d3)-2-methylpiperazine-1-carboxamide
[0534] [ka]
[0535] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 50 mg, 0.21 mmol) and 4-nitrophenyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl-2,2,2-d3)carbamate (Intermediate 29, 68 mg, 0.21 mmol). Purification by prep-HPLC gave the title compound (49 mg). LCMS (ES+) 379 (M+H). + , RT 2.55 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.31 (1H, d, J=5.6 Hz), 8.19 (1H, d, J=5.6 Hz), 7.29 - 7.23 (1H, m), 7.04 (1H, dd, J=5.6, 8.1 Hz), 6.94 (2H, dd, J=2.0, 4.0 Hz), 6.86 - 6.78 (2H, m), 4.87 (1H, d, J=8.1 Hz), 4.41 - 4.34 (1H, m), 3.92 (1H, d, J=13.1 Hz), 3.62 (2H, dd, J=12.0, 22.1 Hz), 3.23 - 3.13 (1H, m), 3.06 (1H, dd, J=3.3, 12.4 Hz), 2.94 - 2.85 (1H, m), 1.20 (3H, d, J=6.6 Hz).
[0536] Example 82 (R)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-(methoxy-d3)phenyl)ethyl)-2-methylpiperazine-1-carboxamide
[0537] [ka]
[0538] Method B was followed from (R)-1-(3-fluoropyridin-4-yl)-3-methylpiperazine dihydrochloride (Intermediate 34, 90 mg, 0.39 mmol) and 4-nitrophenyl (R)-(1-(3-(methoxy-d3)phenyl)ethyl)carbamate (Intermediate 30, 124 mg, 0.39 mmol). Purification by prep-HPLC gave the title compound (80 mg). LCMS (ES+) 376 (M+H). + , RT 3.15 minutes (Analysis method 2), 1H NMR (400 MHz, DMSO) 8.31 (1H, d, J=5.8 Hz), 8.19 (1H, d, J=5.6 Hz), 7.29 - 7.23 (1H, m), 7.04 (1H, dd, J=5.6, 8.3 Hz), 6.96 - 6.92 (2H, m), 6.86 - 6.80 (2H, m), 4.94 - 4.84 (1H, m), 4.42 - 4.34 (1H, m), 3.92 (1H, d, J=13.1 Hz), 3.62 (2H, dd, J=12.0, 22.1 Hz), 3.23 - 3.13 (1H, m), 3.06 (1H, dd, J=3.2, 12.3 Hz), 2.94 - 2.85 (1H, m), 1.41 (3H, d, J=7.1 Hz), 1.20 (3H, d, J=6.6 Hz).
[0539] Example 83 (R)-2-Ethyl-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)piperazine-1-carboxamide
[0540] [ka]
[0541] Method B was followed from 4-nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 0.190 mmol) and (R)-3-ethyl-1-(3-fluoropyridin-4-yl)piperazine dihydrochloride (Intermediate 42, 0.190 mmol). Purification by preparative HPLC afforded the title compound (54 mg). LCMS (ES+) 387 (M+H). + , RT 2.62 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.19 (1H, d, J=6.1 Hz), 8.12 (1H, d, J=5.6 Hz), 7.23 (1H, dd, J=8.0, 8.0 Hz), 7.01 (1H, dd, J=5.7, 8.2 Hz), 6.94 (2H, d, J=7.1 Hz), 6.81 - 6.77 (1H, m), 4.94 (1H, q, J=7.1 Hz), 4.19 (1H, dd, J=7.5, 7.5 Hz), 3.99 (1H, d, J=13.6 Hz), 3.85 - 3.81 (4H, m), 3.71 (1H, dd, J=1.4, 11.1 Hz), 3.28 (1H, dd, J=3.2, 13.3 Hz), 3.08 (1H, dd, J=3.5, 12.6 Hz), 3.01 - 2.92 (1H, m), 1.88 - 1.73 (2H, m), 1.48 (3H, d, J=7.1 Hz), 0.95 (3H, t, J=7.5 Hz).
[0542] Examples 84 and 85 (S)-2-(3-fluoro-5-methoxybenzyl)-7-(3-fluoropyridin-4-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one and (R)-2-(3-fluoro-5-methoxybenzyl)-7-(3-fluoropyridin-4-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
[0543] [ka]
[0544] Step 1: tert-Butyl 2-(3-fluoro-5-methoxybenzyl)-3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate A rt stirred solution of tert-butyl 3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate (200 mg, 0.829 mmol) in DMF (2.0 mL) was treated with NaH (60%, 50 mg, 1.24 mmol). After 10 min, 1-(bromomethyl)-3-fluoro-5-methoxybenzene (182 mg, 0.829 mmol) was added and the reaction was stirred for 24 h. The reaction was diluted with DCM (10 mL), washed with saturated sodium bicarbonate solution (10 mLx1), water (10 mLx1) and brine (10 mLx1), the organics were dried (Na2SO4), filtered and concentrated under reduced pressure to provide the title compound. The compound was used in the next step without further purification.
[0545] Step 2: 2-(3-fluoro-5-methoxybenzyl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one 4M HCl in dioxane (2.1 mL, 8.30 mmol) was added to a solution of tert-butyl 2-(3-fluoro-5-methoxybenzyl)-3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate (315 mg, 0.830 mmol) in MeOH (3.0 mL). The reaction was irradiated in a microwave at 100° C. for 10 minutes. The reaction was concentrated under reduced pressure and the residue was loaded onto an SCX-2 column. Elution with methanol followed by 3M NH3 in MeOH gave the title compound.
[0546] Step 3: (S)-2-(3-fluoro-5-methoxybenzyl)-7-(3-fluoropyridin-4-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one and (R)-2-(3-fluoro-5-methoxybenzyl)-7-(3-fluoropyridin-4-yl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one To 2-(3-fluoro-5-methoxybenzyl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (244 mg, 0.874 mmol) in DMF (1.0 mL) was added 3,4-difluoropyridine (101 mg, 0.874 mmol) and Cs2CO3 (285 mg, 0.874 mmol). The reaction was stirred at 100 °C for 24 h. The reaction was diluted with DCM (10 mL), washed with sodium bicarbonate solution (10 mL x 1), water (10 mL x 1) and brine (10 mL x 1), the organics were dried (MgSO4), filtered and concentrated under reduced pressure. The residue was loaded onto an SCX-2 column and eluted with methanol followed by 3M NH3 in MeOH and the resulting crude product was further purified by silica gel column chromatography (gradient elution, 0-100% ethyl acetate / cyclohexane). The two enantiomers were separated via chiral SFC to give the compound. Examples 84 and 85: 99.5% ee, LCMS (ES+) 375 (M+H) + , RT 2.79 minutes (Analysis method 3), 1 H NMR (400 MHz, CDCl3) 8.23 (2H, dd, J=5.3, 24.0 Hz), 6.74 (1H, dd, J=5.5, 7.9 Hz), 6.60 - 6.51 (3H, m), 4.35 (2H, s), 4.04 - 3.98 (1H, m), 3.79 - 3.79 (4H, m), 3.64 - 3.53 (2H, m), 3.39 (1H, t, J=8.7 Hz), 3.19 (1H, ddd, J=2.4, 10.9, 14.5 Hz), 2.96 - 2.87 (2H, m), 2.74 (1H, t, J=11.4 Hz), SFC RT 3.66 minutes (SFC1, LUX Cellulose-4 + 0.1% DEAISO 35% IPA); 97.2% ee, LCMS (ES+) 375 (M+H) + , RT 2.78 minutes (Analysis method 3), 1H NMR (400 MHz, CDCl3) 8.23 (2H, dd, J=5.3, 23.9 Hz), 6.74 (1H, dd, J=5.5, 7.8 Hz), 6.60 - 6.51 (3H, m), 4.35 (2H, s), 4.03 - 3.99 (1H, m), SFC RT 4.5 minutes (SFC1, LUX cellulose-4 + 0.1% DEAISO 35% IPA).
[0547] Examples 86 and 87 (S)-7-(3-fluoropyridin-4-yl)-2-(3-methoxybenzyl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one and (R)-7-(3-fluoropyridin-4-yl)-2-(3-methoxybenzyl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one
[0548] [ka]
[0549] Examples 86 and 87 were synthesized from 3-methoxybenzyl bromide and tert-butyl 3-oxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate following the method of Examples 84 and 85. 2-(3-Methoxybenzyl)hexahydroimidazo[1,5-a]pyrazin-3(2H)-one (45 mg, 0.172 mmol) and 3,4-difluoropyridine (20 mg, 0.172 mmol) were used in step 3. Purification via chiral SFC afforded the title compound. Examples 86 and 87: 100% ee, LCMS (ES+) 358 (M+H) + , RT 2.64 minutes (Analysis method 3), 1H NMR (400 MHz, CDCl3) 8.25 (1H, d, J=5.3 Hz), 8.19 (1H, d, J=5.4 Hz), 7.28 - 7.24 (1H, m), 6.86 - 6.80 (3H, m), 6.73 (1H, dd, J=5.5, 7.8 Hz), 4.38 (2H, d, J=1.3 Hz), 4.01 (1H, dd, J=2.1, 13.4 Hz), 3.86 - 3.81 (1H, m), 3.80 (3H, s), 3.61 - 3.52 (2H, m), 3.37 (1H, dd, J=8.7, 8.7 Hz), 3.22 - 3.14 (1H, m), 2.95 - 2.85 (2H, m), 2.73 (1H, dd, J=11.4, 11.4 Hz); SFC RT 4.21 points (SFC4, LUXセルロース-4 + 0.1% DEAISO 15% IPA); 97.7% ee, LCMS (ES+) 358 (M+H) + , RT 2.63 points (Analysis Method 3), 1 H NMR (400 MHz, CDCl3) 8.25 (1H, d, J=5.1 Hz), 8.19 (1H, d, J=5.5 Hz), 7.26 (1H, s), 7.28 - 7.23 (1H, m), 6.87 - 6.79 (3H, m), 6.73 (1H, dd, J=5.5, 7.8 Hz), 4.38 (2H, d, J=1.3 Hz), 4.01 (1H, dd, J=2.2, 13.4 Hz), 3.86 - 3.81 (1H, m), 3.80 (3H, s), 3.61 - 3.52 (2H, m), 3.37 (1H, dd, J=8.7, 8.7 Hz), 3.22 - 3.14 (1H, m), 2.95 - 2.85 (2H, m), 2.73 (1H, dd, J=11.4, 11.4 Hz); SFC RT 5.11 points (SFC4, LUXセルロース-4 + 0.1% DEAISO 15% IPA).
[0550] Examples 88 and 89 (S)-2-(3-fluoropyridin-4-yl)-7-(3-methoxybenzyl)octahydro-6H-pyrazino[1,2-c]pyrimidin-6-one and (R)-2-(3-fluoropyridin-4-yl)-7-(3-methoxybenzyl)octahydro-6H-pyrazino[1,2-c]pyrimidin-6-one
[0551] [ka]
[0552] Step 1: tert-Butyl 7-(3-methoxybenzyl)-6-oxooctahydro-2H-pyrazino[1,2-c]pyrimidine-2-carboxylate A stirred solution of tert-butyl 6-oxooctahydro-2H-pyrazino[1,2-c]pyrimidine-2-carboxylate (150 mg, 0.59 mmol) in DMF (5 mL) was treated portionwise with NaH (60%, 35 mg, 0.88 mmol) under nitrogen. After 15 min, 3-methoxybenzyl bromide (0.09 mL, 0.646 mmol) was added dropwise and the reaction was stirred for 18 h. The mixture was diluted with EtOAc and water and the organics separated, washed with brine and passed through a hydrophobic frit. The organics were evaporated to dryness and the residue purified by gradient column chromatography with 0-80% EtOAc in iso-hexane to give the title compound.
[0553] Step 2: 7-(3-Methoxybenzyl)octahydro-6H-pyrazino[1,2-c]pyrimidin-6-one hydrochloride A stirred solution of tert-butyl 7-(3-methoxybenzyl)-6-oxooctahydro-2H-pyrazino[1,2-c]pyrimidine-2-carboxylate (146 mg, 0.389 mmol) in methanol (5 mL) was treated with 4M HCl in dioxane (0.97 mL, 3.89 mmol) for 18 h. The reaction was coevaporated with toluene (2x) to give the title compound, which was used directly in the next step.
[0554] Step 3: (S)-2-(3-fluoropyridin-4-yl)-7-(3-methoxybenzyl)octahydro-6H-pyrazino[1,2-c]pyrimidin-6-one and (R)-2-(3-fluoropyridin-4-yl)-7-(3-methoxybenzyl)octahydro-6H-pyrazino[1,2-c]pyrimidin-6-one A stirred solution of 7-(3-methoxybenzyl)octahydro-6H-pyrazino[1,2-c]pyrimidin-6-one hydrochloride (110 mg, 0.35 mmol) in DMF (10 mL) was treated with cesium carbonate (115 mg, 0.35 mmol) and 3,4 difluoropyridine (41 mg, 0.35 mmol). The resulting suspension was heated at 90 °C in a sealed tube under nitrogen for 18 h. The mixture was evaporated to dryness and the residue was purified by gradient column chromatography in iso-hexane, 20-80% (10% MeOH in EtOAc) to give a colorless gum. Purification by chiral preparative HPLC to separate the isomers afforded the title compound. Examples 88 and 89: LCMS (ES+) 371 (M+H) + , RT 3.84 minutes (Analysis method 4), 1 H NMR (400 MHz, MeOD) 8.20 (1H, d, J=6.0 Hz), 8.13 (1H, d, J=5.6 Hz), 7.29 - 7.24 (1H, m), 7.04 (1H, dd, J=5.7, 8.2 Hz), 6.89 - 6.84 (3H, m), 4.63 (1H, d, J=15.3 Hz), 4.50 - 4.40 (2H, m), 3.81 (5H, s), 3.69 - 3.61 (1H, m), 3.40 - 3.35 (1H, m), 3.28 - 3.22 (1H, m), 3.12 - 2.97 (2H, m), 2.79 (1H, dd, J=10.8, 12.3 Hz), 2.15 - 2.07 (1H, m), 1.88 - 1.77 (1H, m); SFC RT 1.96 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 50% IPA); LCMS (ES+) 371 (M+H) +, RT 3.84 minutes (Analysis method 4), 1 H NMR (400 MHz, MeOD) 8.20 (1H, d, J=6.0 Hz), 8.13 (1H, d, J=5.6 Hz), 7.29 - 7.24 (1H, m), 7.04 (1H, dd, J=5.7, 8.2 Hz), 6.90 - 6.84 (3H, m), 4.65 - 4.60 (1H, m), 4.50 - 4.40 (2H, m), 3.87 - 3.82 (2H, m), 3.81 (3H, s), 3.69 - 3.60 (1H, m), 3.40 - 3.35 (1H, m), 3.29 - 3.23 (1H, m), 3.12 - 2.97 (2H, m), 2.82 - 2.75 (1H, m), 2.15 - 2.07 (1H, m), 1.89 - 1.77 (1H, m); SFC RT 2.69 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 50% IPA).
[0555] Example 90 (S)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)-3-methylpiperazine-1-carboxamide
[0556] [ka]
[0557] Method B was used from (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 183 mg, 0.580 mmol) and (S)-1-(3-fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 39, 156 mg, 0.58 mmol 1.0 eq). Purification by preparative HPLC to give the title compound. LCMS (ES+) 373 (M+H) + , RT 2.54 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.27 (1H, d, J=6.0 Hz), 8.14 (1H, d, J=5.5 Hz), 7.22 (1H, dd, J=8.1, 8.1 Hz), 6.98 (1H, dd, J=5.6, 8.3 Hz), 6.92 - 6.89 (2H, m), 6.85 (1H, d, J=8.0 Hz), 6.78 (1H, dd, J=2.3, 7.9 Hz), 4.89 - 4.80 (1H, m), 4.05 - 3.99 (2H, m), 3.83 (1H, d, J=13.3 Hz), 3.75 (3H, s), 3.33 - 3.29 (1H, m), 3.25 - 3.18 (2H, m), 3.09 - 3.00 (1H, m), 1.37 (3H, d, J=7.0 Hz), 1.01 (3H, d, J=6.5 Hz).
[0558] Example 91 (R)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)-3-methylpiperazine-1-carboxamide
[0559] [ka]
[0560] Method B was used from 4-nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 173 mg, 0.548 mmol) and (R)-1-(3-fluoropyridin-4-yl)-2-methylpiperazine dihydrochloride (Intermediate 38, 147 mg, 0.548 mmol, 1.0 eq). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 373 (M+H). + , RT 2.54 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.26 (1H, d, J=6.0 Hz), 8.14 (1H, d, J=5.5 Hz), 7.21 (1H, dd, J=8.1, 8.1 Hz), 6.97 (1H, dd, J=5.6, 8.4 Hz), 6.91 - 6.88 (2H, m), 6.84 (1H, d, J=7.9 Hz), 6.78 - 6.75 (1H, m), 4.89 - 4.80 (1H, m), 4.06 - 3.98 (2H, m), 3.83 (1H, d, J=13.3 Hz), 3.74 (3H, s), 3.31 - 3.16 (3H, m), 3.01 (1H, ddd, J=3.6, 11.0, 12.9 Hz), 1.37 (3H, d, J=7.2 Hz), 1.03 (3H, d, J=6.5 Hz).
[0561] Example 92 (2R,6R)-N-(2-chlorobenzyl)-4-(3-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxamide
[0562] [ka]
[0563] Method A was followed from 2-chlorobenzylamine (0.266 mmol) and (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 40, 0.266 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 377 (M+H) + , RT 2.58 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.13 (1H, d, J=6.5 Hz), 8.05 (1H, d, J=5.7 Hz), 7.41 - 7.37 (2H, m), 7.33 - 7.24 (2H, m), 6.85 (1H, dd, J=5.7, 8.4 Hz), 4.53 (2H, dd, J=14.5, 43.6 Hz), 4.32 - 4.26 (2H, m), 4.06 (2H, dd, J=3.5, 12.7 Hz), 3.57 (2H, d, J=12.7 Hz), 1.37 (6H, d, J=6.6 Hz).
[0564] Example 93 (2R,6R)-N-((S)-1-(2-chlorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxamide
[0565] [ka]
[0566] Method B was followed from 4-nitrophenyl(1-(2-chlorophenyl)ethyl)carbamate (Intermediate 22, 0.298 mmol) and (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 40, 0.298 mmol). Purification by preparative HPLC and chiral SFC afforded the title compound after lyophilization. LCMS (ES+) 391 (M+H) + , RT 2.67 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.12 (1H, d, J=6.6 Hz), 8.05 (1H, d, J=5.7 Hz), 7.48 (1H, d, J=6.8 Hz), 7.38 (1H, d, J=7.7 Hz), 7.32 (1H, dd, J=7.4, 7.4 Hz), 7.26 - 7.22 (1H, m), 6.84 (1H, dd, J=5.9, 8.3 Hz), 5.44 - 5.39 (1H, m), 4.31 - 4.26 (2H, m), 4.02 (2H, dd, J=3.2, 12.5 Hz), 3.54 (2H, d, J=12.6 Hz), 1.50 (3H, d, J=7.1 Hz), 1.35 (6H, d, J=6.6 Hz); SFC RT 3.13 min (SFC1, LUX Cellulose-4 + 0.1% DEAISO 40% MeOH).
[0567] Example 94 (2R,6R)-N-((R)-1-(2-chlorophenyl)ethyl)-4-(3-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxamide
[0568] [ka]
[0569] Method B was followed from 4-nitrophenyl(1-(2-chlorophenyl)ethyl)carbamate (Intermediate 22, 0.298 mmol) and (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 40, 0.298). Purification by preparative HPLC and chiral SFC afforded the title compound (31 mg). LCMS (ES+) 391 (M+H) + , RT 3.24 minutes (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.13 (1H, d, J=6.5 Hz), 8.05 (1H, d, J=5.7 Hz), 7.46 (1H, dd, J=1.2, 7.7 Hz), 7.38 (1H, d, J=7.9 Hz), 7.32 (1H, dd, J=7.2, 7.2 Hz), 7.26 - 7.21 (1H, m), 6.85 (1H, dd, J=5.8, 8.4 Hz), 5.39 - 5.31 (1H, m), 4.36 - 4.28 (2H, m), 4.04 (2H, dd, J=3.4, 12.6 Hz), 3.56 (2H, d, J=12.7 Hz), 1.50 (3H, d, J=7.1 Hz), 1.31 (6H, d, J=6.6 Hz); SFC RT 1.68 min (SFC4, LUX Cellulose-4 + 0.1% DEAISO 35% MeOH).
[0570] Example 95 (2R,6R)-4-(3-fluoropyridin-4-yl)-N-(3-methoxybenzyl)-2,6-dimethylpiperazine-1-carboxamide
[0571] [ka]
[0572] Method A was followed from 3-methoxybenzylamine (0.266 mmol) and (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 40, 0.266 mmol). Purification by preparative HPLC afforded the title compound (40 mg). LCMS (ES+) 373 (M+H) + , RT 3.01 min (Analysis method 2), 1H NMR (400 MHz, MeOD) 8.14 (1H, d, J=6.6 Hz), 8.05 (1H, d, J=5.7 Hz), 7.24 (1H, dd, J=8.1, 8.1 Hz), 6.93 - 6.89 (2H, m), 6.88 - 6.79 (2H, m), 4.50 - 4.25 (4H, m), 4.06 (2H, dd, J=3.4, 12.7 Hz), 3.81 (3H, s), 3.57 (2H, d, J=12.6 Hz), 1.35 (6H, d, J=6.6 Hz); SFC RT 2.94 min (SFC1, LUX cellulose-4 + 0.1% DEAISO 40% MeOH).
[0573] Example 96 (2R,6R)-N-((R)-1-(2,3-dihydrobenzofuran-4-yl)ethyl)-4-(3-fluoropyridin-4-yl)-2,6-dimethylpiperazine-1-carboxamide
[0574] [ka]
[0575] Method A was followed from (R)-1-(2,3-dihydrobenzofuran-4-yl)ethan-1-amine hydrochloride (0.27 mmol) and (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 40, 0.266 mmol). Purification by preparative HPLC afforded the title compound (7 mg). LCMS (ES+) 399 (M+H) + , RT 2.59 minutes (Analysis method 1), 1H NMR (400 MHz, DMSO) 8.20 (1H, d, J=6.1 Hz), 8.07 (1H, d, J=5.5 Hz), 7.06 (1H, dd, J=7.8, 7.8 Hz), 6.87 (1H, d, J=7.7 Hz), 6.82 (1H, dd, J=5.6, 8.4 Hz), 6.60 (2H, dd, J=7.8, 10.8 Hz), 4.90 - 4.82 (1H, m), 4.53 (2H, dd, J=8.8, 8.8 Hz), 4.23 - 4.18 (2H, m), 3.84 (2H, dd, J=3.3, 12.5 Hz), 3.43 - 3.11 (4H, m, unclear), 1.37 (3H, d, J=7.1 Hz), 1.16 (6H, d, J=6.5 Hz).
[0576] Example 97 (2R,6R)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)-2,6-dimethylpiperazine-1-carboxamide formate
[0577] [ka]
[0578] Method A was followed from (3R,5R)-1-(3-fluoropyridin-4-yl)-3,5-dimethylpiperazine dihydrochloride (Intermediate 40, 0.617 mmol) and (R)-1-(3-methoxyphenyl)ethylamine. Purification by preparative HPLC afforded the title compound. LCMS (ES+) 387 (M+H). + , RT 2.60 minutes (Analysis method 1), 1H NMR (400 MHz, MeOD) 8.26 (1H, s), 8.16 (1H, d, J=6.7 Hz), 8.06 (1H, d, J=5.9 Hz), 7.25 (1H, dd, J=7.9, 7.9 Hz), 6.95 (2H, d, J=7.3 Hz), 6.88 (1H, dd, J=5.9, 8.4 Hz), 6.81 (1H, dd, J=1.8, 7.3 Hz), 4.99 (1H, q, J=7.1 Hz), 4.04 (2H, dd, J=3.5, 12.7 Hz), 3.82 (3H, s), 3.58 (2H, d, J=12.7 Hz), 1.51 (3H, d, J=7.1 Hz), 1.32 (6H, d, J=6.6 Hz).
[0579] Example 98 (2R,5R)-4-(3-fluoropyridin-4-yl)-N-((R)-1-(3-methoxyphenyl)ethyl)-2,5-dimethylpiperazine-1-carboxamide
[0580] [ka]
[0581] Method B was followed from 4-nitrophenyl (R)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 0.119 mmol) and (2R,5R)-1-(3-fluoropyridin-4-yl)-2,5-dimethylpiperazine dihydrochloride (Intermediate 43, 0.119 mmol). Purification by preparative HPLC afforded the title compound. LCMS (ES+) 387 (M+H) + , RT 3.07 minutes (Analysis method 2), 1H NMR (400 MHz, CDCl3) 8.19 (1H, d, J=6.1 Hz), 8.08 (1H, d, J=5.6 Hz), 7.18 (1H, dd, J=7.8, 7.8 Hz), 6.83 - 6.79 (2H, m), 6.76 (1H, dd, J=2.4, 8.1 Hz), 6.67 (1H, dd, J=5.7, 8.1 Hz), 5.02 - 4.93 (1H, m), 4.51 (1H, d, J=7.1 Hz), 4.20 (1H, dd, J=6.1, 14.1 Hz), 4.02 - 3.82 (2H, m), 3.75 (3H, s), 3.71 (1H, dd, J=5.7, 14.1 Hz), 3.10 (1H, dd, J=8.7, 14.1 Hz), 2.81 (1H, dd, J=10.4, 14.1 Hz), 2.62 (1H, s), 1.47 (3H, d, J=6.9 Hz), 1.26 (3H, d, J=6.4 Hz), 1.15 (3H, d, J=6.1 Hz); SFC RT 1.6 min (SFC1, LUX cellulose-4 + 0.1% DEAISO 40% MeOH).
[0582] Example 99 (1S,4S)-5-(3-fluoropyridin-4-yl)-N-(3-methoxybenzyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide
[0583] [ka]
[0584] Step 1: tert-Butyl (1S,4S)-5-(((R)-1-(3-methoxyphenyl)ethyl)carbamoyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Method A was followed from tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (1.02 g, 5.2 mmol) and (R)-1-(3-methoxyphenyl)ethan-1-amine (0.76 g, 5.02 mmol). Purification by flash silica chromatography (gradient elution i-hex to EtOAc) afforded the title compound.
[0585] Step 2: (1S,4S)-N-((R)-1-(3-methoxyphenyl)ethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide HCl The title compound was obtained from tert-butyl (1S,4S)-5-(((R)-1-(3-methoxyphenyl)ethyl)carbamoyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (1.15 g, 3.06 mmol) following method C.
[0586] Step 3: (1S,4S)-5-(3-fluoropyridin-4-yl)-N-(3-methoxybenzyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide Method E was followed from (1S,4S)-N-((R)-1-(3-methoxyphenyl)ethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide HCl (200 mg, 0.64 mmol) and 4-bromo-3-fluoropyridine (103 mg, 0.58 mmol). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 371 (M+H). + , RT 2.50 minutes (Analysis method 1). 1H NMR (400 MHz, DMSO) 8.17 (1H, d, J=5.9 Hz), 8.00 (1H, d, J=5.5 Hz), 7.13 (1H, dd, J=7.8, 7.8 Hz), 6.80 (2H, d, J=7.6 Hz), 6.75 - 6.70 (2H, m), 6.61 (1H, d, J=8.2 Hz), 4.82 - 4.73 (1H, m), 4.70 (1H, s), 4.62 (1H, s), 3.71-3.61 (4H, m), 3.39 (2H, s), 3.27 - 3.20 (1H, m), 1.93 (2H, dd, J=12.2, 12.2 Hz), 1.33 (3H, d, J=7.1 Hz).
[0587] Example 100 (R)-4-(3-fluoropyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)-3-oxopiperazine-1-carboxamide
[0588] [ka]
[0589] Step 1: tert-Butyl 4-(3-fluoropyridin-4-yl)-3-oxopiperazine-1-carboxylate A mixture of 3-fluoro-4-iodopyridine (500 mg, 2.24 mmol), tert-butyl 3-oxopiperazine-1-carboxylate (539 mg, 2.69 mmol), copper(I) iodide (21 mg, 0.11 mmol), tripotassium phosphate (952 mg, 4.48 mmol), and N,N-dimethylethylenediamine (20 mg, 0.22 mmol) in toluene (5 mL) was degassed with N2 for 10 min and then heated to 150 °C in a microwave for 20 min. The reaction mixture was diluted with water, extracted with EtOAc (2x), washed with brine, passed through a phase separator and evaporated to dryness. This was purified by column chromatography in i-hex using gradient elution 5-100% EtOAc to give the title compound.
[0590] Step 2: 1-(3-fluoropyridin-4-yl)piperazin-2-one A solution of tert-butyl 4-(3-fluoropyridin-4-yl)-3-oxopiperazine-1-carboxylate (200 mg, 0.677 mmol) in acetonitrile (10 ml) and 4N HCl in dioxane (1 ml) was combined and stirred at room temperature for 18 hours. The reaction mixture was then evaporated to dryness and azeotroped with toluene to give the crude diHCl salt of the title compound, which was used crude in the next step.
[0591] Step 3: (R)-4-(3-fluoropyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)-3-oxopiperazine-1-carboxamide Method A was used from 4-nitrophenyl (S)-(1-(3-methoxyphenyl)ethyl)carbamate (Intermediate 1, 212 mg, 0.67 mmol, 1 eq) and (1-(3-fluoropyridin-4-yl)piperazin-2-one diHCl salt (198 mg, 0.737 mmol, 1.1 eq). Purification by prep-HPLC afforded the title compound. LCMS (ES+) 373 (M+H). + , RT 2.82 minutes (Analysis method 1). 1 H NMR (400 MHz, DMSO) 8.67 (1H, d, J=2.4 Hz), 8.50 (1H, d, J=5.1 Hz), 7.59 (1H, dd, J=5.3, 6.4 Hz), 7.23 (1H, dd, J=8.1, 8.1 Hz), 7.01 (1H, d, J=7.9 Hz), 6.94 - 6.91 (2H, m), 6.79 (1H, dd, J=2.2, 8.0 Hz), 4.89 - 4.80 (1H, m), 4.23 (2H, d, J=1.9 Hz), 3.76 (7H, d, J=1.8 Hz), 1.39 (3H, d, J=7.2 Hz).
[0592] The following compounds were synthesized using the methods described above:
[0593] [Table 10] TIFF0007593956000133.tif234170TIFF0007593956000134.tif216170TIFF0007593956000135.tif239170TIFF0007593956000136.tif240170 TIFF0007593956000137.tif243170TIFF0007593956000138.tif217170TIFF0007593956000139.tif223170TIFF0007593956000140.tif234170
[0594] In some embodiments, there is provided a compound selected from those in Table 1, or a deuterated analog, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer, or mixture of stereoisomers thereof:
[0595] [Table 11] TIFF0007593956000142.tif242170TIFF0007593956000143.tif242170TIFF0007593956000144.tif244170TIFF0007593956 000145.tif228170TIFF0007593956000146.tif243170TIFF0007593956000147.tif243170TIFF0007593956000148.tif82170
[0596] Biological assays Example 1 Analysis of inhibition of ROCKII enzyme with Rho-associated protein kinase (ROCK) inhibitors The efficacy of Rho-associated protein kinase (ROCK) II inhibitors was quantified by measuring ROCKII kinase domain enzyme activity using the ADP-Glo™ Kinase Assay format. The S6K peptide substrate was phosphorylated by active ROCKII by transferring a phosphate group from an ATP molecule to generate an ADP molecule. ADP-Glo™ Reagent was added to stop the ROCKII reaction and deplete remaining ATP. Kinase detection reagent was added to convert ADP to ATP, allowing newly synthesized ATP to be measured by a luciferase / luciferin reaction. The light produced correlates with the amount of ADP produced in the ROCKII biochemical reaction and is an indicator of ROCKII activity.
[0597] ROCK inhibitor compound plate preparation. Lyophilized ROCK inhibitors were resuspended in 100% dimethylsulfoxide (DMSO) at a final concentration of 10 mM and the control reference compound, fasudil HCl, in 100% DMSO at a final concentration of 100 mM using a Janus automated liquid handler workstation (Perkin Elmer) and stored at room temperature under nitrogen. Stock compounds and controls were added directly to ECHO plates (Labcyte) by Janus. Ten-point concentration-response curves for each compound were dispensed in duplicate in an Echo 555 liquid handler (Labcyte) directly into 384-well, black round-bottom assay plates (Matrix Technologies Ltd) at 100X final assay concentration. Final compound or control volume per well was 100 nl (0.1 μl). Assay standards were prepared by Echo dispensing: 5 nl of 100 mM Fasudil HCl and 95 nl DMSO (50 μM final assay concentration and 1% DMSO) for full inhibition controls and 100 nl DMSO (1% DMSO) for full activity controls.
[0598] Preparation of ROCKII catalytic domain active enzyme (2.5 nM). The ROCKII catalytic domain enzyme was human catalytic domain ROCK II protein (amino acids 5-554) with an N-terminal GST tag (SignalChem). A 2X working solution of enzyme was prepared by diluting a 100 ng / μl stock aliquot of ROCKII catalytic domain to 2.2 ng / 10 μl (2.5 nM) in assay buffer (25 mM MOPS, 12.5 mM 2-glycerophosphate, 5 mM EGTA pH 8.0, 25 mM MgCl2, 2 mM EDTA, 0.25 mM DTT (added on the day of assay) and 0.01% BSA (added on the day of assay)) immediately prior to addition of enzyme to the assay.
[0599] Preparation of S6K peptide substrate (20 μM) and ATP (10 μM). The S6K peptide sequence (amino acid sequence KRRRLASLR) was based on the human 40S ribosomal protein S6 (amino acids 230-238) (SignalChem). 2X working solutions of substrate and ATP were prepared by diluting a 5 mg / ml stock aliquot of S6K peptide (dissolved in 20 mM Tris-HCl, pH 7.5) to 0.25 μg / 10 μl (20 μM) in assay buffer (25 mM MOPS, 12.5 mM 2-glycerophosphate, 5 mM EGTA pH 8.0, 25 mM MgCl2, 2 mM EDTA, 0.25 mM DTT (added on the day of assay) and 0.01% BSA (added on the day of assay)). A 10 mM ultrapure ATP stock aliquot (ADP-Glo™ kit) was added to the assay buffer containing the S6K substrate for a final assay concentration of 10 μM (ATP Km) immediately prior to addition of the peptide substrate / ATP mixture to the assay.
[0600] Assay procedure. 5 μl / well substrate / ATP mixture was added to each well of the assay plate containing compound using a 125 μl 16-channel Matrix electronic pipette (Matrix Technologies Ltd.). The plate was sealed, mixed for 10 seconds on an orbital shaker at 1000 rpm (revolutions per minute), and centrifuged for 1 minute at 1000 rpm. The assay was started by adding 5 μl / well ROCKII enzyme mixture to each well using a 125 μl 16-channel Matrix electronic pipette. The assay plate was sealed, mixed for 10 seconds on an orbital shaker at 1000 rpm, and centrifuged for 1 minute at 1000 rpm. The assay plate was incubated for 30 minutes at room temperature on an orbital shaker at 400 rpm. The enzyme reaction was stopped by the addition of 10 μl / well ADP-Glo™ solution to the assay plate using a 125 μl 16-channel Matrix electronic pipette. The assay plate was sealed, mixed on an orbital shaker at 1000 rpm for 10 seconds, and centrifuged at 1000 rpm for 1 minute. The assay plate was placed in a polystyrene box for 40 minutes at room temperature. Then, 20 μl / well of kinase detection reagent was added to the assay plate using a 125 μl 16-channel Matrix electronic pipette. The assay plate was further incubated in a polystyrene box for 30 minutes at room temperature without sealing, and the luminescence signal was measured using EnVision (Perkin Elmer) in top read mode.
[0601] Example 2 Analysis of inhibition of cellular Rho-associated protein kinase (ROCK) enzymes by Rho-associated protein kinase (ROCK) inhibitors The efficacy of Rho-associated protein kinase (ROCK) inhibitors was quantified by measuring the level of cofilin phosphorylation at serine 3 (Ser3) as a measure of cellular ROCK activity by In-Cell Western assay. After fixing and permeabilizing A7r5 rat smooth muscle cells, the level of cofilin phosphorylation was measured by immunohistochemical staining using a specific monoclonal phospho-cofilin (Ser3) antibody (Cell Signaling Technology) in combination with anti-rabbit IRDye 800CW (LICOR Biosciences) and Alexa Fluor™ 647-conjugated wheat germ agglutinin (WGA) as a measure of cell number. Assay plates were imaged and quantified on an Odyssey imager (LICOR Biosciences).
[0602] ROCK inhibitor compound plate preparation. Lyophilized ROCK inhibitors were resuspended in 100% dimethylsulfoxide (DMSO) at a final concentration of 10 mM and the control reference compound, fasudil HCl, in 100% DMSO at a final concentration of 100 mM using a Janus automated liquid handler workstation (Perkin Elmer) and stored at room temperature under nitrogen. Stock compounds and controls are added directly to ECHO plates (Labcyte) by Janus. Ten-point concentration-response curves for each compound are dispensed in duplicate directly into 384-well plates (384-well V-bottom polypropylene, Greiner) at 2000X final assay concentration in an Echo 555 liquid handler (Labcyte). Final compound or control volume per well is 100 nl (0.1 μl). Assay standards were prepared by Echo dispensing 100 nl of 100 mM Fasudil HCl for full inhibition control (50 μM final assay concentration and 0.5% DMSO) and 100 nl of DMSO for full activity control (0.5% DMSO).
[0603] A7r5 cell culture and plating. A7r5 cells were cultured following standard cell culture protocols in A7r5 growth medium (DMEM with Glutamax and 10% FBS). A7r5 cells were counted using a Coulter Counter and resuspended at 6.67x104 cells / mL in growth medium. 45μl of resuspended A7r5 cells were plated at 3000 cells / well in sterile μclear black F-bottom 384-well microplates (Greiner bio-one). Plated cells were allowed to settle in the wells for 1 hour on the bench and then incubated overnight at 37°C, 5% CO2.
[0604] Assay Reagents and Antibody Preparation. Washing buffer was prepared by adding Tween-20 to calcium and magnesium free Dulbecco's Phosphate Buffered Saline (DPBS) (1x) for a final concentration of 1% Tween-20. Blocking buffer was prepared by adding TritonX-100 to SeaBlock buffer (ThermoFisher) for a final concentration of 0.3% TritonX-100. Primary antibody mixture was prepared by diluting phospho-cofilin (Ser3) antibody (Cell Signaling Technology, 3313) 1:200 and Alexa® Fluor 647 WGA (Molecular Probes) 1:10000 in SeaBlock buffer. Secondary antibody mixture was prepared by diluting donkey anti-rabbit 800CW antibody (LICOR Biosciences) 1:1000 in SeaBlock buffer.
[0605] Assay procedure. Compound plates were diluted by addition of 19 μl / well of compound dilution buffer (DMEM with Glutamax) using 125 μl 16-channel Matrix electronic pipette. 5 μl diluted compound was stamped from compound plate to assay plate containing A7r5 cells using Bravo (384-well head from Agilent) liquid handler and incubated for 1 hour at 37° C., 5% CO2. Cells were fixed by addition of 5 μl of 37% formaldehyde using 125 μl 16-channel Matrix electronic pipette and incubated for 20 minutes at room temperature. Assay plates were washed 5 times with 60 μl / well of wash buffer. 25 μl / well of blocking buffer containing 0.3% TritonX-100 was then added to each well using 125 μl 16-channel Matrix electronic pipette, the plate was sealed, centrifuged at 1000 rpm for 5 seconds, and placed on an orbital shaker at 300 rpm for 60 minutes at room temperature. The plate was tapped on tissue paper, tapped to remove any liquid from the assay plate, and 25 μl / well of primary antibody mix was added to each well using 125 μl 16-channel Matrix electronic pipette. The assay plate was then sealed, centrifuged at 1000 rpm for 5 seconds, and incubated at 4° C. overnight on an orbital shaker at 300 rpm. The assay plate was washed 4 times with wash buffer, and 25 μl / well of secondary antibody mix was added to each well using 125 μl 16-channel Matrix electronic pipette. The assay plate was centrifuged at 1000 rpm for 5 seconds and incubated at 300 rpm for 60 minutes at room temperature on an orbital shaker. Finally, the assay plate was washed and left empty before measuring the 700 nm and 800 nm fluorescence intensity in an Odyssey imager set at a focus offset of 4.0 mm.
[0606] The example compounds of the present invention gave the assay results shown in the table below:
[0607] [Table 12] TIFF0007593956000150.tif241170TIFF0007593956000151.tif240170TIFF0007593956000152.tif242170TIFF0007593956 000153.tif241170TIFF0007593956000154.tif241170TIFF0007593956000155.tif241161TIFF0007593956000156.tif46161
[0608] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0609] The embodiments illustratively described herein may be suitably practiced in the absence of any one or more elements or limitations not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," etc., should be interpreted expansively and without limitation. In addition, the terms and expressions used herein are used as descriptive terms and not as limiting, and are shown in the use of such terms and expressions, without the intention of excluding any equivalents of the described characteristics or portions thereof, and it is recognized that various modifications are possible within the scope of the claimed subject matter.
[0610] Thus, while the present subject matter has been specifically disclosed by preferred embodiments and optional features, it should be understood that occasional modifications, improvements, and variations of the disclosed embodiments embodied herein may be reclassified by those skilled in the art, and such modifications, improvements, and variations are considered to be within the scope of the present invention. The materials, methods, and examples provided herein are representative of preferred embodiments, are illustrative, and are not intended to limit the scope of the subject matter.
[0611] The subject matter has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the scope of the generic disclosure also form part of the subject matter. This includes generic descriptions of subject matter that contain a negative limitation that excludes any subject matter from a conditional or genus, regardless of whether the excluded material is specifically recited herein.
[0612] Additionally, when a feature or aspect of the invention is described in terms of a Markush group, one of skill in the art thereby recognizes that the subject matter is also described in terms of any individual members or subgroup members of the Markush group.
[0613] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety, as if each was individually incorporated by reference. In the case of conflict, the present specification, including definitions, will control.
[0614] While the present invention has been described in conjunction with the above embodiments, it will be understood that the foregoing description and examples are intended to be illustrative and not limiting of the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains. The following is one embodiment of the present invention. (1) Formula I: [ka] [In formula: Ring B is a 6- to 10-membered aryl or 6- to 10-membered heteroaryl ring, and is selected from the group consisting of 1 to 5 R 4 is optionally replaced by; X is -O- or -N(R 3 )-and; R 1 is H or optionally substituted C 1~3 is alkyl; R 2 , oxo, halo, C1~3 Alkyl, C 1~3 Haloalkyl, C 1~3 Hydroxyalkyl or C 1~3 is alkoxy; or The Two R's 2 together with the carbon atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; R 3 is H or C 1~3 is alkyl; or R 2 and R 3 together with the atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; Each R 4 Independently, halo, C 1~3 Alkyl, C 1~3 Alkoxy or C 1~3 haloalkoxy; or The Two R's 4 together with the atoms to which they are attached, are joined together to form a heterocycloalkyl ring, wherein the heterocycloalkyl ring is selected from the group consisting of 1 to 3 halo or C 1~3 optionally substituted with alkyl; n is 0, 1 or 2. or a deuterated analogue, pharma- ceutically acceptable salt, solvate, prodrug, stereoisomer or mixture of stereoisomers thereof. (2) Formula II:
change
change
change
change
change
change
change
change
Claims
1. Formula I: 【Chemistry 1】 [In formula: Ring B is a 6- to 10-membered aryl or 6- to 10-membered heteroaryl ring and is selected from 1 to 5 R 4 is optionally replaced by; X is -O- or -N(R 3 )- and; R 1 is H or optionally substituted C 1~3 is alkyl; R 2 is oxo, halo, C 1~3 Alkyl, C 1~3 Haloalkyl, C 1~3 Hydroxyalkyl or C 1~3 is alkoxy; or The Two R's 2 together with the carbon atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; R 3 is H or C 1~3 is alkyl; or R 2 and R 3 together with the atoms to which they are attached, combine together to form a cycloalkyl or heterocycloalkyl ring; Each R 4 Independently, halo, C 1~3 Alkyl, C 1~3 Alkoxy or C 1~3 haloalkoxy; or The Two R's 4 together with the atoms to which they are attached, are joined together to form a heterocycloalkyl ring, wherein the heterocycloalkyl ring is selected from the group consisting of 1 to 3 halo or C 1~3 optionally substituted with alkyl; n is 0, 1 or 2. or a deuterated analogue, pharma- ceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers thereof.
2. Formula II: 【Chemistry 2】 2. The compound of claim 1,
3. 3. The compound according to claim 1 or 2, wherein n is 0.
4. n is 2, and each R 2 3. The compound according to claim 1 or 2, wherein is methyl.
5. Formula III: 【Chemistry 3】 3. The compound according to claim 1 or 2, which is a compound of the formula:
6. Formula III(a): 【Chemistry 4】 6. The compound of claim 5,
7. Formula III(b): 【Chemistry 5】 6. The compound of claim 5,
8. Formula IV(a): 【Chemistry 6】 is a compound of R 1 is optionally replaced by C 1~3 7. The compound of claim 6, wherein said compound is alkyl.
9. Formula IV(b): 【Chemistry 7】 is a compound of R 1 is optionally replaced by C 1~3 7. The compound of claim 6, wherein said compound is alkyl.
10. Formula IV(c): 【Chemistry 8】 is a compound of R 1 is optionally replaced by C 1~3 8. The compound of claim 7, wherein said compound is alkyl.
11. Formula IV(d): 【Chemistry 9】 is a compound of R 1 is optionally replaced by C 1~3 8. The compound of claim 7, wherein said compound is alkyl.
12. X is -N(R 3 12. The compound according to claim 1, wherein R is -.
13. R 3 The compound of claim 12, wherein is H.
14. R 1 The compound according to any one of claims 1 to 13, wherein is methyl.
15. R 2 The compound according to any one of claims 1 to 2 and 5 to 14, wherein is methyl.
16. Ring B is halo, C 1~3 Alkyl, C 1~3 Alkoxy and C 1~3 haloalkoxy; or two R 4 and together with the atoms to which they are attached, are linked together to form a heterocycloalkyl ring.
17. Ring B is halo, C 1~3 Alkyl, C1-3 alkoxy and C 1~3 16. The compound of any one of claims 1 to 15, which is a 6 to 10 membered heteroaryl optionally substituted with 1 to 3 substituents selected from haloalkoxy.
18. Ring B is halo, C 1~3 Alkyl, C1-3 alkoxy and C 1~3 17. The compound of claim 16, which is phenyl optionally substituted with one to three substituents selected from haloalkoxy.
19. Ring B is selected from halo, C1-3 alkyl, C1-3 alkoxy and C 1~3 17. The compound of claim 16, which is phenyl substituted with one substituent selected from haloalkoxy.
20. 【Table 1】 or a deuterated analogue, pharma- ceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers thereof selected from:
21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 and a pharma- ceutically acceptable carrier.
22. An agent for treating or preventing a condition or disorder mediated at least in part by rho kinase in a patient in need thereof, comprising a therapeutically effective amount of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21.
23. 22. An agent for treating or preventing a condition or disorder in a patient in need thereof, comprising a therapeutically effective amount of a compound according to any one of claims 1 to 20 or a pharmaceutical composition according to claim 21, wherein the condition or disorder is selected from Huntington's disease (HD), spinal cord and / or brain injury, chronic pulmonary hypertension, Parkinson's disease, amyotrophic lateral sclerosis, cerebral cavernous hemangioma, cardiovascular disease, Alzheimer's disease (AD), glaucoma, multiple sclerosis (MS), corneal lesions, diabetes, chronic and / or neuropathic pain, stroke, ischemia, retinopathy, spinal muscular atrophy (SMA), erectile dysfunction, nephropathy (non-hypertensive), hypertensive nephropathy, hypertension (elevated blood pressure), optic nerve lesions, hepatic fibrosis, lupus, post-transplant liver failure, encephalomyelitis, epilepsy and glioblastoma.
24. 24. The method of claim 22 or 23, wherein the condition or disorder is Huntington's disease.
Citation Information
Patent Citations
Piperazine derivative,medicine containing it,its use and itsproduction
JP1996231509A
Heterocyclic protein kinase inhibitors and uses thereof
JP2007513172A
Selective inhibitor of rock protein kinase and method of use thereof
JP2009536947A
Uses of 4-(4-pyridinyl)-benzamide and ROCK activity regulators
JP2010536925A
